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Abstract 
Ribosome biogenesis is a tightly regulated process that is essential for cell survival. Genetic 
mutations in genes encoding ribosomal proteins or ribosome biogenesis factors lead to the 
development of rare genetic disorders, known as ribosomopathies. The 5S RNP is a ribosome 
assembly intermediate composed of the 5S rRNA, ribosomal protein RPL5 and RPL11. During 
the 5S RNP assembly, the newly transcribed 5S rRNA is stabilized by RPL5 first, before RPL11 
binds. Once it is assembled, the 5S RNP is incorporated into the large ribosomal subunit 
precursor. Ribosome biogenesis defects, which induce ribosomal stress, cause the 
accumulation of the 5S RNP. The accumulated non-ribosomal 5S RNP induces tumour 
suppressor p53, by binding and inhibiting its main negative regulator, MDM2. It has been 
suggested that any factor involved in the 5S RNP assembly and its integration into the 
ribosome will affect p53 signalling.  
I therefore set out to evaluate factors that have been proposed to be connected to the 5S 
RNP. Different proteins, including HEXIM1, Mybbp1a, B23, NML and SRSF1, have been 
suggested to be involved in the 5S RNP-p53 signalling, therefore I aimed to investigate their 
roles in this signalling pathway. Furthermore, I also aimed to investigate the role of RPL11 
phosphorylation in ribosome biogenesis and the 5S RNP-p53 signalling.  
In this work, I present evidence supporting the proposed role of splicing factor SRSF1 in 5S 
RNP assembly. I also demonstrate that SRSF1 could be a part of the 5S RNP complex that is 
essential for p53 activation during ribosomal stress, while protein HEXIM1, Mybbp1a and 
NML are not needed for this pathway. I further provide evidence suggesting the threonine 
73 phosphorylation in RPL11 could control its binding to the 5S RNP, whereas serine 51 
phosphorylation in RPL11 could be important in the 5S RNP incorporation into the large 
ribosomal subunit. Last but not the least, my results also suggest that serine 140 in RPL11 
could be transiently phosphorylated during the ribosomal maturation process.  
In conclusion, this work addresses the important role of the 5S RNP, in both ribosome 
biogenesis and the 5S RNP-p53 signalling.   
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Chapter 1. Introduction  
1.1 The eukaryotic ribosome 
The ribosome is the protein synthesis machinery in both prokaryotic and eukaryotic organisms. It 
translates messenger RNA (mRNA) into polypeptides using amino acids delivered by tRNAs. Even 
though prokaryotic ribosomes are smaller than those in the eukaryotes, ribosomes across all 
living organisms are highly conserved in their structures (Moore and Steitz, 2002). A mature 
eukaryotic ribosome (80S) consists of two subunits, the large ribosomal subunit (60S, LSU) 
and the small ribosomal subunit (40S, SSU). During protein translation, the SSU associates 
with the mRNA and scans the sequence for a start codon. After translation initiation, the LSU 
catalyses condensation reaction joining amino acids to produce polypeptide chains 
(Gamalinda and Woolford, 2015).  
The ribosome is composed of ribosomal proteins (RPs) and ribosomal RNAs (rRNAs). In 
eukaryotes, the LSU is made up of 46 RPs and 3 rRNAs (the 5S, 5.8S and 28S rRNAs). The SSU 
consists of about 33 RPs and the 18S rRNAs (Gamalinda and Woolford, 2015). The ribosome 
is essential for cell survival and the number of ribosomes can dictate the rate of cellular 
growth.  
1.2 Ribosome biogenesis 
It is estimated that there are about five to ten million ribosomes in each mammalian cell, 
which are needed to be synthesized during each round of cell division in an actively 
proliferating mammalian cell (Kenmochi et al., 1998). Because of their large number and the 
crucial role ribosomes play in the cell survival, ribosome biogenesis not only consumes 
substantial amounts of cellular energy, but it is also tightly regulated. For example in yeast, 
approximately 60% of the cellular energy is used in ribosome production (Warner, 1999). 
Furthermore in a growing yeast cell, there are about 2,000 ribosomes produced every 
minute which takes up 60% of the total cellular transcription event (Freed et al., 2010).  
RPs are produced in the cytoplasm whereas the rRNAs are transcribed in the nucleolus, and 
most of the ribosome assembly process takes place in the nucleolus (Kressler et al., 2010). 
There are more than 200 protein co-factors involved in rRNA processing and ribosomal 
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subunit precursor maturation (Henras et al., 2008). Ribosome production is upregulated 
during cell growth, whereas it is supressed during cell differentiation (Warner, 1999; Sulic et 
al., 2005). In addition, ribosome biogenesis is up regulated during tumourigenesis, and 
ribosome production defects have been linked to human diseases (Freed et al., 2010). 
1.2.1 The nucleolus  
Ribosome biogenesis largely takes place in a specific compartment in the nucleus called the 
nucleolus. Using electron-microscopy (EM) it has been revealed that there are three distinct 
regions recognised in the nucleolus, namely the fibrillarin centre (FC), the dense fibrillarin 
component (DFC) and the granular component (GC) (Boisvert et al., 2007; Smirnov et al., 
2016). In humans, the formation of the nucleolus requires the nucleolus organizer regions 
(NORs), chromosomal regions from the short arms of the acrocentric chromosomes 
(chromosomes 13, 14, 15, 21 and 22) (Kenmochi et al., 1998). NORs contain rDNA genes in 
the form of tandem repeats and the nucleolus is formed around these NORs (McStay, 2016). 
rDNA is transcribed by RNA polymerase I (Pol I) into the 47S ribosomal RNA precursor (pre-
rRNA), which contains the sequences of 18S, 5.8S and 28S rRNAs (Cheutin et al., 2002). This 
process takes place at the border which separates the FC and DFC and GC (Boisvert et al., 
2007). The first 47S pre-rRNA cleavage step takes place in the DFC (Derenzini et al., 1989), 
whereas the later rRNA processing events are found happening in the GC, where RPs 
incorporate to the rRNAs (Gerbi and Borovjagin, 1997; Boisvert et al., 2007). 
1.2.2 rDNA transcription and pre-rRNA production 
In yeast, the rDNA gene is flanked by an upstream promoter region and a downstream 
terminator sequence. In humans additional to the promotor, the upstream region of rDNA 
also contains an upstream control element  while multiple termination sequences are 
located downstream to the rDNA (Russell and Zomerdijk, 2005).  
In humans, the upstream binding factor (UBF) binds to the upstream control element of the 
rDNA gene. UBF subsequently recruits the human selectivity factor complex (SL1) to the 
promotor region (Tuan et al., 1999). The SL1 complex is composed of a TATA-binding protein 
(TBP) and three TBP-associated factors (Grummt, 1999). The SL1 complex recruits RNA Pol I 
to the promotor region (Russell and Zomerdijk, 2005). UBF, SL1 and RNA Pol I form the 
transcription preinitiation complex, opening the promotor region and allowing rDNA 
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transcription by RNA Pol I. UBF and SL1 remain on the promotor region in order to recruit 
multiple RNA Pol I to achieve several rounds of transcription (Panov et al., 2001; Russell and 
Zomerdijk, 2005). Once RNA Pol I migrates to the termination sequence, it is stopped by the 
transcription termination factor 1 (TTF-1) which binds on the termination sequence and it is 
released from the gene by the polymerase I and transcription release factor (PTRF) which is  
associated with the TTF-1 (Jansa and Grummt, 1999; Russell and Zomerdijk, 2005).  
The 5S rRNA is transcribed by RNA Pol III separately in the nucleoplasm (Paule and White, 
2000). In human cells, the gene clusters coding for 5S rRNA are located on chromosome 1, 
with a 5’-end flanking region which is important for the RNA Pol III-mediated transcription 
process (Sørensen and Frederiksen, 1991).  
In some eukaryotes, the 5’-end flanking region consists of several elements, such as A-box at 
the 5’-end, the intermediate element (IE) and the C-box at the 3’-end (Cloix et al., 2003). This 
type of upstream promoter region is found in organism such as S. cerevisiae, D. 
melanogaster and X. laevis (Pieler et al., 1987; Sharp and Garcia, 1988; Lee et al., 1995). RNA 
Pol III binds to the upstream promoter region with three transcription initiation factors (TF): 
TFIIIA, TFIIIB and TFIIIC, with TFIIIA regulating 5S rRNA transcription specifically (Pelham and 
Brown, 1980).  
In higher eukaryotes, including humans and mice, the promotor region of the 5S rRNA 
includes an additional upstream element called the D-box (Hallenberg and Frederiksen, 
2001). The D-box is important for the efficient transcription of 5S rRNA. During transcription 
initiation, TFIIIA first associates with the C-box and subsequently recruits TFIIIC. The binding 
of TFIIIA and TFIIIC leads to the assembly of TFIIIB and RNA Pol III to the promoter region 
(Ishiguro et al., 2002). After transcription is initiated, TFIIIC dissociates from the promoter 
while TFIIIB remains bound to the promotor region, allowing multiple rounds of transcription 
initiation to happen (Kassavetis et al., 1998; Kumar et al., 1998). 
1.2.3 rRNA processing in yeast and humans 
Pre-rRNA contains the internal transcribed spacers (ITS1 and ITS2) and the external 
transcribed spacers (5’-ETS and 3’-ETS), which are removed through a series of 
endonucleolytic and exonucleolytic cleavage steps. It eventually produces mature 18S rRNA 
 4 
in the SSU as well as 5.8S and 28S rRNA (25S in yeast) in the LSU. Our current understanding 
of the rRNA processing pathways is largely based on studies in yeast.  
The pre-rRNA maturation starts with the production of pre-rRNA containing the 18S rRNA 
sequence, which involves in the endonucleolytic processing of the 5’-ETS and ITS1. In yeast, 
either full-length 35S pre-rRNA is transcribed or, alternatively, co-transcriptional cleavage 
occurs at the A0, A1 and A2 sites producing the 27S-A2 pre-rRNA (containing sequences of the 
5.8S and 25S) and 20S pre-rRNA (containing sequences of the 18S).  
Although the mechanisms behind these cleavage events are not yet fully clear, it is thought 
that they involve the formation of the SSU processome complex (Phipps et al., 2011) and 
also a number of enzymes and protein cofactors such as different ribosomal proteins 
(O'Donohue et al., 2010), snoRNAs (Fayet-Lebaron et al., 2009), nucleolar ribonucleoprotein 
U14 (Henras et al., 2015) and U3 (Dragon et al., 2002).  
Cleavage at the A2 site located in the ITS1 results in formation of the 20S and 27S-A2 pre-
rRNAs (Henras et al., 2015), and it also leads to the separation of pre-SSU and pre-LSU 
(Kressler et al., 1999). Furthermore, recent studies also revealed that the endonuclease 
Utp24 cleaves at the A2 cleavage site (Wells et al., 2016). After the 5’-ETS removal and A2 
cleavage in ITS1, the 20S pre-SSU rRNA is subsequently exported from the nucleus to the 
cytoplasm, where it undergoes cleavage at site D to produce the mature 18S rRNA. The 
endonuclease Nob1p (Pertschy et al., 2009) is required during this D site cleavage process 
(Kressler et al., 1999). 
There are two pathways in the pre-LSU rRNA maturation process which produce alternative 
versions of the 5.8S rRNA 5’ end. In the first pathway, the 27S-A2 pre-rRNA undergoes 
cleavage at site B1L, producing a long form of the 5.8S rRNA. In the second pathway, A3 
cleavage takes place in the 27S-A2 pre-rRNA by the MRP RNase (Lygerou et al., 1996), 
producing the 27S-A3 pre-rRNA. A number of proteins are important in the A3 site cleavage 
process, such as RNA-binding protein Rrp5p (Venema and Tollervey, 1996) and the nucleolar 
protein Nop4p (Sun and Woolford, 1994). The 27S-A3 pre-rRNA is subsequently processed 
exonucleolyticlly by proteins Rat1p and Rrp17p, producing the short form of the 5.8S rRNA.  
Both long and short forms of the 5.8S-sequence-containing 27S pre-LSU rRNA are 
subsequently cleaved at the C2 site located in the ITS2, producing the 26S (containing the 
 5 
25S rRNA) and 7S (containing the 5.8S rRNA) pre-rRNAs. Recent work showed that the 
endonuclease Las1 preforms this cleavage process (Gasse et al., 2015).  
The 26S LSU pre-rRNA maturation takes place in the nucleus which involves the 5’ end 
exonucleolytic cleavage mediated by the Rai1p protein (El Hage et al., 2008). It produces the 
mature 25S rRNA which is then exported to the cytoplasm.  
The 7S LSU pre-rRNA undergoes the 3’ end exonucleolytic processing in the nucleus, which is 
mediated by the exonuclease Rrp6p (Briggs et al., 1998) and the RNA helicase Mtr4p (Jia et 
al., 2012), producing the 6S LSU pre-rRNA. It is subsequently transported to the cytoplasm 
where the final step of maturation is mediated by the RNA nuclease Ngl2p (Thomson and 
Tollervey, 2010), resulting in the mature 5.8S rRNA.  
In humans the rRNA processing is conserved at a degree to that is seen in yeast, except for a 
few differences. For example, the human 47S pre-rRNA consists of an extra A’ site at the 5’ 
end of its 5’ ETS. Secondly, in human the removal of 5’ ETS takes place after the ITS1 
cleavage (Henras et al., 2015). Finally, there are two distinct pathways involved in separating 
human LSU and SSU pre-rRNAs by cleavage in ITS1, which are known as the major and the 
minor pathways (Mullineux and Lafontaine, 2012; Sloan et al., 2013b).  
In humans rDNA is transcribed into the 47S pre-rRNA and the rRNA processing starts with 
the A’ site cleavage in the 5’ ETS. It is mediated by the UTP-A complex, exonuclease XRN2 
and protein factor MTR4, and this cleavage produces the 45S pre-rRNA (Sloan et al., 2014). 
Subsequently, the 45S pre-rRNA enters either the major or the minor pathway (Henras et al., 
2015). 
During the major pathway, a single cleavage event at the site 2, located in ITS1, produces the 
30S SSU pre-rRNA (containing 18S rRNA sequence) and 32S LSU pre-rRNA (containing 5.8S 
and 28S rRNA sequences). Although the nuclease mediating this cleavage event remains 
unclear, it has been reported that the RNA binding protein RRP5 is important for this process 
(Sloan et al., 2013b). In addition, the RNA binding protein RBM28, the nucleolar protein 
NOL12 and the ribosome biogenesis protein BOP1 are also important for this event (Sloan et 
al., 2013b). The 30S SSU pre-rRNA undergoes A1 and exonuclease processing, producing the 
18SE pre-rRNA, whereas the 32S LSU pre-rRNA undergoes site 4 cleavage separating the 12S 
(containing the 5.8S rRNA sequence) and the pre-28S rRNAs (Henras et al., 2015).  
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During the minor pathway on the other hand, in addition to the site 2 cleavage event, the 
site 2a endonucleolytic cleavage also takes place. It leads to the production of 18SE SSU pre-
rRNA and the 36S LSU pre-rRNA. The endonuclease UTP24 has recently been shown to be 
essential for the site 2a cleavage event (Wells et al., 2016) and the ribosome biogenesis 
protein RRP5 is important for both 2 and 2a cleavage events (Sloan et al., 2013b). The 36S 
LSU pre-rRNA subsequently gives rise to the 12S pre-rRNA and the 28S rRNA (Henras et al., 
2015).  
The 18SE SSU pre-rRNA, produced by either the major or the minor pathway, is exported 
from nucleus to the cytoplasm. It undergoes the site 3 cleavage which is mediated by the 
endonuclease NOB1, and results in the mature 18S rRNA (Henras et al., 2015). For the LSU, 
the 12S pre-rRNA processing which gives rise to the mature 5.8S rRNA, involves a number of 
different proteins in the nucleus (Coute et al., 2008), the exosome associated factors MTR4, 
C1D (Schilders et al., 2007) and the exosome component RRP6 (Tafforeau et al., 2013b). 
After being exported to the cytoplasm, exonuclease ERI1 is also found to be involved in in 
the 5.8S maturation process (Ansel et al., 2008). 
1.2.4 Ribosomal protein production and regulation 
In humans, the ribosomal protein encoding genes are located in all chromosomes (including 
X and Y) except chromosome 7 (Kenmochi et al., 1998) and they are transcribed by RNA Pol 
II. Translation of RPs takes place in the cytoplasm, and the produced RPs are imported into 
the nucleus, and then localize to the nucleolus where they are integrated into the LSU or SSU 
production.  
Ribosomal protein encoding genes are transcribed into 5' TOP mRNAs, a form of mRNAs with 
a 5' terminal oligopyrimidine sequence tract (5’ TOP) attached at their 5’ end (Gentilella et 
al., 2015). The 5’ TOP is a translational regulator sequence starting with a cytidine, following 
by 5 to 15 pyrimidine nucleotides. Other than ribosomal proteins, these regulator sequences 
are also found in mRNAs encoding for translation factors and other ribosome biogenesis 
factors. The translation of these mRNAs is regulated by the mTOR pathway, in response to 
various external stimuli and to ribosomal defects (Levy et al., 1991).  
Protein kinase mTOR (also known as the target of rapamycin), is a member of the 
phosphatidylinositol 3-kinase related kinase family. mTOR is the core protein forming two 
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types of protein complexes, mTOR complex 1 and 2 (mTORC1 and 2) (Gentilella et al., 2015). 
Other than mTOR itself, mTORC1 consists of regulatory-associated protein of mTOR (Raptor) 
(Hara et al., 2002), G protein beta subunit-like (MLST8) (Kim et al., 2003), PRAS40 (Oshiro et 
al., 2007), DEP domain-containing protein 6 (DEPDC6) and Rheb-GTPase RAG (Groenewoud 
and Zwartkruis, 2013). Being essential for metabolism and cell growth, mTORC1 regulates 
protein synthesis in response to various internal and external stimuli, such as nutrient and 
energy status, growth factors and redox levels (Laplante and Sabatini, 2009). A series of 
signalling pathways downstream to mTORC1 play important roles in regulating pyrimidine 
synthesis, which is linked to rDNA transcription, and also mRNA translation initiation and 
elongation (Gentilella et al., 2015).  
1.2.5 The 5S RNP assembly  
The 5S ribonucleoprotein (RNP) is a subcomplex of the LSU which is composed of the 5S 
rRNA and the ribosomal proteins RPL5 and RPL11. The 5S rRNA is 120 nucleotides in length 
and in eukaryotic cells, the 5S rRNA is transcribed by RNA polymerase III in the nucleoplasm. 
Once transcribed, 2-3 nucleotides at the 3’ end of the 5S rRNA precursor are cleaved in order 
to produce the mature 5S rRNA in both human (Sloan et al., 2014) and yeast (van Hoof et al., 
2000). In human this 3’ end processing of the 5S rRNA is dependent on RPL5 binding (Sloan 
et al., 2013a). In yeast, exonucleases Rex1p, Rex2p and Rex3p are required for the 3’ end 
processing of the 5S rRNA (van Hoof et al., 2000).  
The 5S rRNA is the smallest rRNA which the structure is highly conserved throughout most 
organisms and it can be found in all organisms except in the mitochondrial ribosomes from 
fungi and animals (Szymanski et al., 2002; Bhat et al., 2004). However, in Xenopus laevis 
oocytes, the 5S rRNA is found associated with transcription factor TFIIIA and together they 
form the 7S RNP complex (Layat et al., 2013). In humans, after transcription the 5S rRNA is 
bound and stabilised by RPL5 in the nucleoplasm, forming the pre-5S RNP complex. Studies 
have shown that RPL5 binding is required for the maturation of the 5S rRNA (Sloan et al., 
2013a). The level of the stable 5S rRNA is directly related to RPL5 protein levels, as the 
unbound 5S rRNA is unstable and is rapidly turned over. RPL11 subsequently binds to the 
RPL5/5S rRNA complex, forming the mature 5S RNP. Thereafter, the 5S RNP is integrated to 
the pre-60S large ribosomal subunit precursor (Sloan et al., 2013a; Pelava et al., 2016).  
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1.2.6 5S RNP incorporation into the large subunit  
After the 5S RNP is assembled, it is incorporated into the LSU in the nucleolus. The 5S RNP is 
important for the structure and function of the LSU and it is also an essential component for 
the production of a mature ribosome.  
Within the human mature LSU, the 5S rRNA is positioned in the central protuberance (CP), 
closely located to the 28S rRNA (Khatter et al., 2015). During mRNA translation, the 5S rRNA 
is neither associated with tRNAs from at the P or A site of the ribosome nor with any other 
translation factors. However, the region in the ribosome that harbours the 5S rRNA was 
found to be important for associating tRNAs, elongation factors and peptidyltransferase 
centre factor binding (Dinman, 2005). 
In yeast, ribosome biogenesis factors Rrs1 and Rpf2p are important in recruiting the 5S RNP 
into the pre-LSU (Zhang et al., 2007). Firstly, evidence showed that Rpf2p binds to RPL5 and 
RPL11 in yeast two-hybrid studies (Miyoshi et al., 2002; Morita et al., 2002). Secondly, 
structural studies showed that in fungus A. nidulans, the Rrs1-Rpf2p complex interacts not 
only with both the 5S rRNA and RPL5, but also with the ribosome assembly protein 4 (Rsa4) 
(Kharde et al., 2015). From this structure, only Rpf2p, but not Rrs1, has direct contact with 
the 5S rRNA (Kharde et al., 2015). In yeast the homologous Rrs1-Rpf2p complex indeed 
interact with Rpl5, Rsa4 and the 25S rRNA (Madru et al., 2015). 
In humans, ribosome biogenesis factors RRS1 and BXDC1 are the human homologues of Rrs1 
and Rpf2p, respectively. However, there is no evidence showing they bind to non-ribosomal 
5S RNP by pull-down assay, moreover, knockdown of either of them has little effect on 5S 
RNP incorporation into the LSU (Sloan et al., 2013a). Another ribosome biogenesis factor, 
PICT1, was found to be essential for the ribosomal incorporation of the 5S RNP (Sloan et al., 
2013a). The function of human RRS1 and BXDC1 in 5S RNP integration into the ribosomes is 
are not fully clear.   
1.2.7 The 5S RNP remodelling event in the LSU  
In yeast, the 5S RNP undergoes a structural remodelling event during the maturation of pre-
LSU. The 5S RNP-mediated remodelling event of the pre-LSU was recently identified by the 
analysis of a yeast pre-LSU cryo-EM structure (Leidig et al., 2014). Compared to the mature 
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LSU structure, the 5S RNP was rotated approximately 180° in the pre-LSU (Leidig et al., 
2014).   
Interestingly there is growing evidence suggesting the Rrs1-Rpf2p complex, which is 
important for recruiting the 5S RNP into the pre-LSU, together with additional biogenesis 
factors such as Rsa4 and Nog1, are critical in stabilising the pre-rotated state of the 5S RNP 
(Leidig et al., 2014; Madru et al., 2015).  
Recently ATPase and GTPase activities have been shown to be important for driving and 
regulating the remodelling event, such as Nug2 GTPase and, especially, the Rea1-Rix1 
complex (Matsuo et al., 2014; Barrio-Garcia et al., 2016). Rea1 protein is a member of the 
AAA (+) family of ATPases and it was previously found to be important for the late rRNA 
processing, pre-LSU maturation and nuclear export (Galani et al., 2004). In addition, Rsa4 
was identified as a co-substrate of Rea1, and the activity of Rea1 was also linked to the 
removal of ribosome biogenesis factors during pre-LSU processing and maturation (Bassler 
et al., 2010; Bassler et al., 2014).   
Furthermore, mutation of the MIDAS domain (or the ATP-binding domain) of Rea1 was 
found to block the release of Ras4 and Nug2 from the pre-LSU processing complex (Matsuo 
et al., 2014), suggesting its ATPase activity is critical for the pre-LSU maturation. Finally, the 
interaction between Rea1 and Rix1 were found to be essential for pre-LSU maturation.  
In summary, it was proposed that the Rrs1-Rpf2p complex, together with other biogenesis 
factors such as Ras4 and Nog1, provide an interaction platform recruiting and stabilising the 
pre-LSU incorporation of the 5S RNP for the subsequent remodelling event. The activity of 
Rea1-Rix1 complex is proposed to drive the rotation movement of the 5S RNP and the 
conformational change of the pre-LSU, and it also facilitates the release of those associated 
biogenesis factors, enabling the pre-LSU maturation process.  
In human, it was recently reported that AAA ATPase MDN1, the human homologue of Rea1, 
interacts with the pre-LSU processing particle. The MDN1/pre-LSU association was regulated 
by sumolation of PELP1, a MDN1 associated protein (Raman et al., 2016). However, there is 
still lack of evidence explaining ether the mechanics or the functional role of the 5S RNP-
mediated pre-LSU remodelling event in human cells. It is possible that the remodelling event 
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takes place to provide a binding interface for the ribosome biogenesis factors during the LSU 
maturation process.  
1.2.8 Nuclear export of the ribosome 
After pre-LSU and pre-SSU are assembled in the nucleolus, they are exported from nucleus 
to the cytoplasm through the nuclear pore complexes (NPCs). Subsequently, they undergo a 
series of final maturation processes and they gain translation functions in the cytoplasm.  
In yeast although pre-LSU and pre-SSU are translocated independently to the cytoplasm, 
they both require the Crm1/Ran GTPase system (Zemp and Kutay, 2007). Crm1  
(chromosomal maintenance 1, Exportin 1 or XPO1) is involved in the leucine rich nuclear 
export signal (NES)-dependent protein export, and it is found to be essential for the 
cytoplasmic export for both pre-LSU and pre-SSU (Johnson et al., 2002). Apart from Crm1, 
exportin 5 (Exp5) also mediates the export of pre-LSU (Wild et al., 2010)  The GTP-binding 
nuclear protein Ran is a small GTPase which is able to hydrolyse GTP. Functions of Crm1 and 
Exp5 are GTPase-dependent and during the nuclear export process, the small GTPase Ran 
hydrolyses GTP to GDP providing the required energy (Johnson et al., 2002). 
In yeast, the nuclear export of pre-LSU is mediated by Crm1, Nmd3p and other factors 
recognising NES (Hutten and Kehlenbach, 2007). Nmd3p is a shuttling factor associated with 
the late pre-LSU particles, and it acts as an adaptor between the pre-LSU and Crm1 (Zemp 
and Kutay, 2007; Sengupta et al., 2010). Furthermore, ribosome biogenesis factor Arx1 is 
also found to be crucial for the pre-LSU export. It is thought to associate with Nmd3, Crm1 
and the NPC, and depletion of Arx1 results in the accumulation of nuclear pre-LSU (Hung et 
al., 2008).  
In addition, there are other biogenesis factors which are less-well characterized, such as the 
HEAT-repeat protein Rrp12p. This protein interacts with premature ribosomal particles and 
it is involved in their nuclear export (Schafer et al., 2003). Depletion of Rrp12p leads to 
impaired nuclear export of premature ribosomal particles (Oeffinger et al., 2004). 
Furthermore, the protein Mtr2p, known to be important for mRNA export, is also implicated 
as a protein cofactor mediating pre-LSU export. Although it is not involved in the RanGTP-
associated exportin system, Mtr2p is found associated with the late pre-LSU particles in 
proteomic analysis (Nissan et al., 2002).  
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In yeast, Crm1 also mediates nuclear export of the pre-SSU. In contrast to the pre-LSU that 
requires Nmd3p, biogenesis factors Rio2p, Dim2p and Ltv1p are involved in the pre-SSU 
export in yeast, since inhibiting Crm1 leads to the nuclear accumulation of these factors 
(Schafer et al., 2003). However their role in the export process is not yet fully clear since 
there are no clear export defects observed when deleting these proteins (Zemp and Kutay, 
2007). Rrp12p is also thought to mediate pre-SSU export as it is found associated with pre-
SSU particles (Oeffinger et al., 2004).  
In humans, the protein kinase Rio2 (hRio2) has been shown to associate with late pre-SSU 
particles, and its depletion leads to recycling defects of other biogenesis factors and slows 
down pre-SSU maturation (Zemp et al., 2009). Furthermore, depletion of hTsr1 leads to 
nuclear accumulation of pre-SSU particles (Carron et al., 2011).  
1.2.9 Ribosome production quality control  
Ribosome biogenesis is an energy costly process and ribosome biogenesis defects lead to 
serious diseases called ribosomopathies (see Section 1.4). Hence ribosome production is 
tightly regulated and under constant surveillance by a series of quality control systems, 
during or after ribosome production.  
Firstly, when ribosome biogenesis defects occur, pre-rRNAs are not found accumulating 
significantly, suggesting without binding to the correct ribosomal protein or biogenesis 
factor, pre-rRNAs are unstable and being turned over rapidly (Houseley and Tollervey, 2009).  
Secondly, cytoplasmic maturation of pre-SSU is important for the ribosome to acquire 
translation competency and the maturation process needs binding of LSU to complete 
(Lebaron et al., 2012), adding additional quality control mechanisms for ribosome 
biogenesis. In addition, the joining of the LSU and SSU is suppressed by a number of 
ribosome biogenesis factors. For example, the yeast biogenesis factor Rei1 and the adaptor 
protein Nmd3 are found to prevent the two subunits from joining (Greber et al., 2016). 
Furthermore, in yeast, biogenesis factor Tif6p binds to LSU to prevent the LSU association 
with the SSU (Klinge et al., 2011). In humans, the translation initiation factor 6 (eIF6, human 
homologue of Tif6p) has also been found to prevent the joining of pre-LSU and pre-SSU 
(Finch et al., 2011).  
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Finally, for those defective ribosomes escaping the nuclear degradation mechanism and 
reaching the cytoplasm, there are also quality control systems in the cytoplasm. For 
example, cytoplasmic ribosomes carrying critical mutations affecting functionally essential 
structures, such as in the decoding centre of the SSU or the peptidyl transfer centre of the 
LSU, are targeted for the non-functional rRNA decay (NRD) (LaRiviere et al., 2006; Cole et al., 
2009). 
1.3 The tumour suppressor p53 
1.3.1 The p53 protein family  
p53 protein was first described as an antigen involved in cell transformation in multiple 
publications in 1979 (DeLeo et al., 1979; Linzer and Levine, 1979). Ten years later the TP53 
gene which encodes p53 protein was classed as a tumour suppressor gene (Levine, 1989). 
The TP53 gene consists of 11 exons and p53 protein contains five domains, including the N-
terminus transactivational domain (TAD), the proline rich region (PRR), the central DNA-
binding domain (DBD), the tetramerization domain (TET) and the basic C-terminus domain 
(BD) (Figure 1.1) (Joerger and Fersht, 2008).  
The N-terminus transactivational domain (TAD) enables p53 to activate transcription factors 
and allows it to interact with other proteins (Kamada et al., 2016). The proline rich region is 
important for apoptotic activity and is important for the stability of the protein (Green and 
Kroemer, 2009). The central DNA-binding domain is responsible for p53 binding to the DNA 
consensus sequence for p53 binding (McLure and Lee, 1998). The tetramerization domain 
Figure 1.1. Schematic representation of the domain organization in p53, p63 and 
p73.  
The N-terminus transactivational domain (TAD), the proline rich region (PRR), the 
central DNA-binding domain (DBD), the tetramerization domain (TET) and the basic 
C-terminus domain (BD) are indicated. The N-terminus (N’) and C-terminus (C’) are 
indicated above the representation.  
 13 
allows p53 proteins to form tetramers and is important for DNA binding and interactions 
with other proteins (McLure and Lee, 1998; Kamada et al., 2016). The C-terminus regulates 
DBD-DNA interaction (Joerger and Fersht, 2008; Kamada et al., 2016).  
Transcription factors p63 and p73 are members of p53 protein family encoded by individual 
genes, and they share the same structural organization as p53 (Levrero et al., 2000). They 
share similar structures and domains, except p63 and p73 contain a longer C-terminus in 
their tetramerization domains and lack the basic C-terminus domain (Figure 1.1) (Joerger 
and Fersht, 2008). The DNA-binding motifs of p53, p63 and p73 are largely conserved and 
they are able to form heterotetramer complexes, which are involved in gene transcription 
and cell cycle regulation (Brandt et al., 2009). However, p63 and p73 have also been shown 
to regulate non-p53-targed genes and they have non-p53 roles in neuronal or epithelial 
development (Harms et al., 2004).  
1.3.2 p53 regulation: MDM2 and MDMX 
In unstressed cells p53 is normally maintained at a low level. One key negative regulator of 
p53 is the murine double minute 2 protein (MDM2 or HDM2 in human) (Wade et al., 2013). 
MDM2 has domains such as p53 binding domain, acidic domain, zinc finger domain and RING 
(Really Interesting New Gene) -finger domain (Figure 1.2).    
The p53 binding domain of MDM2 recognises the N-terminus transactivational domain (TAD) 
on p53 (Kussie et al., 1996), and its binding to TAD inhibits p53 activity (Momand et al., 
1992). MDM2 mainly functions as an E3 ubiquitin ligase which targets itself and p53 for 
ubiquitination. After the lysine residues located at the C-terminus of p53 are ubiquitinated 
by MDM2, p53 is degraded by the 26S proteasome (Honda and Yasuda, 1999; Michael and 
Oren, 2003). Apart from being involved in proteasome-mediated p53 degradation, MDM2 
also directly inhibits the transcriptional activity of p53. The acidic domain of MDM2 interacts 
and inhibits the DNA binding domain of p53 (Cross et al., 2011).  
It has been shown that multiple forms of MDM2-p53 interactions exist, and that their nature 
is important for MDM2 regulation of p53 stability and activity. Firstly, the central domain of 
MDM2 also interacts with p53 and has shown to be essential for ubiquitination of p53 (Ma 
et al., 2006). Furthermore, the N-terminus of MDM2 also binds to the C terminus of p53 
(Poyurovsky et al., 2010).  
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The interaction between MDM2 and p53 is inhibited by a group of compounds called 
Nutlins. They are cis-imidazoline antagonists discovered in a chemical screen (Vassilev et al., 
2004). Although the molecular mechanism is not fully understood, it has been shown that 
nutlin treatment changes the modification status at the C-terminus of p53 and may inhibit 
MDM-p53 interaction (Poyurovsky et al., 2010).  
In addition, the second intron of MDM2 contains a p53 responsive element, therefore 
MDM2 is also in turn transcriptionally regulated by p53. This creates a negative feedback 
loop between MDM2 and p53 (Wu et al., 1993). Finally, other than p53, MDM2 has also 
been found to suppress transactivation activity of p73 and p63 (Zeng et al., 1999; Kadakia et 
al., 2001).  
Murine double minute X, also known as MDMX or MDM4, also plays an important role in 
negatively regulating p53. MDMX shares 90% homology with MDM2, mainly in its p53-
binding and RING domains (Figure 1.2) (Shvarts et al., 1996). However, in contrast to MDM2, 
MDMX lacks E3 ligase activity, therefore it is not able to target p53 for proteasome-
mediated degradation (Jackson and Berberich, 2000). Furthermore, MDMX lacks the nuclear 
localization signal (NLS) or the nuclear export signal (NES) (Figure 1.2) (Migliorini et al., 
2002). MDMX is also a polyubiquitination target of MDM2 and its levels are regulated by 
MDM2 (Shadfan et al., 2012). 
Through its RING-finger domains, MDMX is able to bind to MDM2 (Tanimura et al., 1999). 
MDM2 and MDMX are able to form heterodimers or homodimers. Despite a lack of E3 ligase 
Figure 1.2. Schematic representation of the domain organization in MDM2 and 
MDMX.  
Protein domains are indicated. The nuclear localization signal (NLS) and nuclear 
export signal (NES) in MDM2 are indicated and coloured in grey. The N-terminus (N’) 
and C-terminus (C’) are indicated above the representation. (Adapted from (Marine 
et al., 2007)) 
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function, MDMX is still able to inhibit p53 activity by binding to the TAD of p53 (Danovi et al., 
2004). The heterodimer of MDM2-MDMX enhances the Mdm2-mediated ubiquitination and 
degradation of p53 (Gu et al., 2002; Linares et al., 2003; Uldrijan et al., 2007; Wade et al., 
2013). Moreover, MDM2-MDMX interaction is important for the nuclear localization of 
MDMX since the latter lacks a nuclear localization signalling peptide (Gu et al., 2002).  
MDM2 and MDMX are both involved in regulating p53, individually or cooperatively. A study 
using a mouse model revealed that MDMX deletion leads to p53-dependent cell cycle arrest 
whereas MDM2 deletion causes apoptosis (Chavez-Reyes et al., 2003). Evidence also shows 
that Nutlin specifically inhibits MDM2-p53 binding but not the MDMX-p53 interaction 
(Joseph et al., 2010).  
1.3.3 p53 post-translational modification and activation 
p53 is induced and activated by several upstream signalling pathways, in response to various 
types of cellular stress, such as DNA damage (induced by UV or ionizing radiation) and 
oncogene expression (Brown et al., 2009; Meek and Anderson, 2009).  
From mass spectrometry studies, p53 was found to be modified extensively at about 50 
residues. These modifications include ubiquitination, phosphorylation, acetylation, 
methylation, glycosylation, neddylation and sumolation (Jimenez et al., 1999; Meek and 
Anderson, 2009). In respond to cellular stresses, p53 is not only stabilized with its half-life 
increasing significantly, but it is also transcriptionally activated, leading to the expression of 
p53-regulated genes. The post-translational modifications on p53, especially 
phosphorylation and acetylation, are important in both its stabilisation and its activation 
(Meek and Anderson, 2009).  
There are several well-studied upstream pathways regulating p53 through its modification. 
In the case of DNA damage, p53 is phosphorylated and activated by two major protein 
kinases: Ataxia telangiectasia mutated (ATM) is a serine/threonine kinase recruited and 
activated in response to DNA double strand break. Serine/threonine kinase ATR, also known 
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as ataxia telangiectasia and Rad3-related protein (ATR) or FRAP-related protein 1 (FRP1), is 
also responsible for phosphorylating serine 15 and serine 37 (Lakin and Jackson, 1999). ATM 
and ATR are the primary kinases responsible for the phosphorylation of serine 15 (Ser15) of 
p53 (Meek and Anderson, 2009), whereas ATM is also thought to modify serines 9, 20 and 
46 (Saito et al., 2002; Loughery et al., 2014).  
Interestingly, ATM-mediated phosphorylation was found to recruit histone/lysine 
acetyltransferases (HAT) such as p300/CBP (Meek and Anderson, 2009). p300/CBP are two 
closely related transcription coactivator proteins which interact with and activate a number 
of transcription factors, including p53. p300/CBP is responsible for the acetylation of seven 
C-terminus lysine residues (Meek and Anderson, 2009), and six of these lysine residues are 
also the targets of MDM2-mediated ubiquitination (Rodriguez et al., 2000). Lysine 
acetylation of p53 is induced in response to several of stresses and leads to p53 stabilisation. 
Because acetylation and ubiquitination of lysine residues are mutually exclusive, acetylation 
helps displacing p53 from MDM2 and interferes with its negative regulation (Tang et al., 
2008; Meek and Anderson, 2009).  
p53 is also activated by the ectopic oncogene expression, such as c-Myc. p14ARF is a tumour 
suppressor protein translated from an alternate reading frame of the CDKN2A locus. p14ARF 
is activated by c-Myc expression and it functions as a negative regulator of MDM2. It binds 
and inhibits MDM2 resulting in stabilisation and activation of p53. Although there is a lack of 
Figure 1.3. p53 is activated in response to DNA damage and oncogene expression.  
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evidence showing the p14ARF pathway promotes p53 phosphorylation, acetylation of p53 has 
been reported (Meek and Anderson, 2009).  
1.3.4 p53 transcriptional activities and the p53-regulated genes 
In response to cellular stress signals, activated p53 drives the expression of a number of 
important genes, promoting cellular responses including DNA damage repair, apoptosis, cell 
cycle arrest and senescence (Purvis et al., 2012).  
1.3.4.1 p53 transcriptional functions in DNA damage repair  
DNA damage is caused by either endogenous sources, such as reactive oxygen species (ROS) 
and replication errors, or exogenous sources, such as UV, x-rays or gamma radiations, toxins, 
mutagenic chemicals and viruses.  
There are different types of DNA damage, such as oxidized base formation and single strand 
breaks which are repaired by the base excision repair (BER) mechanism, or DNA double 
strand breaks which are fixed by homologous recombination (HR) or non-homologous end 
joining (NHEJ). Other types of damage such as insertions, deletions or mismatches induced 
during DNA replication, are repaired by mismatch repair (MMR) mechanism, while the bulk 
of DNA adducts as a result of UV radiation are removed by the nucleotide excision repair 
(NER) mechanism (Sancar et al., 2004; Williams and Schumacher, 2016).  
During NER, activated p53 upregulates the expression of DNA damage binding protein 2 
(DDB2) (Hwang et al., 1999) and XPC protein (Adimoolam and Ford, 2002; Hastak et al., 
2012). DDB2 recruits XPC to the site of DNA damage, enhancing the cell’s ability to target 
DNA damage in response to UV radiation (Williams and Schumacher, 2016). Furthermore, 
p53 also binds to XPC during NER (Wang et al., 1995).  
In addition to NER, the transcriptional activity of p53 is also involved in HR and BER. The 
proliferating cell nuclear antigen protein (PCNA) functions as a DNA clamp which binds to 
DNA forming a complex with GADD45α (Growth arrest and DNA-damage-inducible protein 
alpha) (Hall et al., 1995; Jung et al., 2013). This complex assembles other protein factors 
during homologous recombination (Pfander et al., 2005) and base excision repair (Shivji et 
al., 1992; Jung et al., 2013). Activated p53 also induces the expression of the gene GADD45A, 
which encodes for Gadd45α (Carrier et al., 1999).  
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1.3.4.2 p53 mediated apoptosis pathways 
Apoptosis is a genetically programmed cell death procedure and an important process in 
multicellular organisms. There are two distinctive pathways which p53 transcriptionally 
regulates, namely the extrinsic and intrinsic pathways (Ouyang et al., 2012).  
The extrinsic pathway involves the activation of the tumour necrosis factor receptor (TNFR) 
family and the formation of a death-inducing-signalling-complex (DISC) (Locksley et al., 
2001). This subsequently causes caspase-induced apoptosis. One of the key death receptors 
involved in extrinsic pathway is the cell surface receptor Fas (cell surface first apoptosis 
signal receptor) encoded by gene CD95/Apo-1. In T-cells, Fas interacts with its ligand FasL to 
become activated on the cell surface. Activated p53 functions as a transcription regulator 
and upregulates the transcription of Fas (Muller et al., 1998). The second membrane 
receptor protein being upregulated by p53 is the death receptor-5 (DR5). DR5 levels are 
induced by p53 in response to DNA damage and further promotes cell death via Caspase 8 
(Wu et al., 1997).  
The intrinsic apoptotic pathway mainly involves activation of genes of the Bcl2 family and 
the release of cytochrome-C (CytoC) from the mitochondria (Tsujimoto, 1998). Bcl2 family 
members can be further classed into pro-survival and pro-apoptotic homologs which are 
structurally similar. Cell survival/apoptosis is maintained by the balance between pro-
survival and pro-apoptotic signalling (Ouyang et al., 2012). A subset of Bcl2 genes are 
regulated by transcriptional activation of p53.  
The first member of the Bcl2 family identified to be induced by p53 was BAX (Miyashita and 
Reed, 1995). Activated BAX proteins form a homodimer which leads to the release of CytoC 
from mitochondria. CytoC, apoptotic protease-activating factor-1 (APAF1) and procaspase 9 
subsequently form the apoptosome complex, resulting in cellular apoptosis through a 
cascade of caspase signalling.  
There are other Bcl2 family members induced by the p53, including the p53-upregulated 
modulator of apoptosis (PUMA) and Noxa. In response to DNA damage, the PUMA gene is 
induced directly by p53 and PUMA is essential for the BAX-mediated apoptosis pathway 
(Nakano and Vousden, 2001). Noxa is upregulated by p53 in response to X-ray radiation (Oda 
et al., 2000). Hence in response to DNA damage, there are at least three p53-mediated Bcl2 
family genes induced, shifting the balance towards pro-apoptotic signalling.   
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1.3.4.3 p53 in cell cycle regulation  
In eukaryotic cells, the cell cycle is comprised of interphase, mitotic phase and cytokinesis. 
Interphase is divided into three stages, including G1, S and G2 phase, while the mitotic phase 
contains prophase, metaphase, anaphase and telophase. The cell cycle is essentially 
regulated by the cyclin-dependent serine/thronine kinases (CDKs) and their regulatory 
subunit, the cyclins (Dulic et al., 1992; Schafer, 1998). They form CDK-cyclin complexes which 
activate proteins required for cell cycle progression. For example, Cdk2-cyclin E is required 
for the G1 –S phase transition (Dulic et al., 1992) whereas Cdk4 or the Cdk6-cyclin D complex 
is required for G1 phase progression (Bates et al., 1994).  
Cyclin-dependent kinase inhibitor 1 (p21), encoded by CDKN1A gene, is able to bind to and 
inhibit multiple types of CDK-cyclin complexes, however it primarily inhibits Cdk2 (Harper et 
al., 1993; Xiong et al., 1993). Activated p53 promotes p21 expression which inhibits Cdk2 
and triggers G1 phase arrest (Harper et al., 1993). p21 expression is regulated by p53-
mediated transcriptional activation, therefore p21 expression levels are widely used to 
monitor p53 transcriptional activity. Furthermore, activated p53 promotes expression of 
scaffold protein 14-3-3 sigma which inhibits Cdk1-cyclin B complex and leads to G2 phase cell 
cycle arrest (Laronga et al., 2000).  
1.3.5 The role of ribosomal proteins in p53 and other signalling pathways 
As an energy costly process, ribosome biogenesis is crucial for many cellular activities, 
including cell proliferation. It is important to maintain the integrity of ribosome production 
for cell survival and many studies have linked ribosomal proteins to the regulation of the 
tumour suppressor p53. In the context of ribosome biogenesis defects, ribosomal proteins 
are involved in p53 stabilisation and activation by blocking the p53 regulator, MDM2. 
Misregulated p53 signalling has been found in numerous genetic diseases caused by 
aberrant ribosome biogenesis, which are also known as ribosompopathies.  
A number of different ribosomal proteins interact directly with MDM2, such as RPL5, RPL11, 
RPL23, RPL26, RPL37 from the LSU and RPS3, RPS7, RPS14 from the SSU (Kim et al., 2014) 
and the RP-MDM2 interaction have been linked to p53 activity, such as RPL5, RPL11 (Sloan et 
al., 2013a; Pelava et al., 2016), RPL23 (Dai et al., 2004; Jin et al., 2004), RPL26 (Takagi et al., 
2005; Ofir-Rosenfeld et al., 2008; Chen et al., 2012), RPS7 (Chen et al., 2007; Zhu et al., 2009) 
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and RPS3 (Yadavilli et al., 2009). These reports imply that p53 regulation via ribosomal 
proteins can be influenced by multiple pathways.  
Most interestingly, it has been demonstrated that Actinomycin D (ActD)-induced p53 
activation is neither dependent on RPL23, RPL26 nor RPS7 whilst it is dependent on RPL5 and 
RPL11 (Bursać et al., 2012). ActD is a drug which has been used as an anti-cancer 
chemotherapeutic. A low dose of ActD inhibits transcription elongation of RNA polymerase I 
which abolishes pre-rRNA production and results in ribosomal stress-induced p53 activation 
(Sobell, 1985). This suggests that RPL5, RPL11 and the 5S RNP complex activate p53 via a 
signalling pathway different from other ribosomal proteins.  
1.3.6 The 5S RNP-MDM2 involvement in p53 regulation  
The 5S RNP, which is composed of RPL5, RPL11 and the 5S rRNA, is assembled separately 
from the rest of the LSU. Normally the 5S RNP is integrated into the pre-LSU before the pre-
LSU is processed and becomes mature LSU (Zhang et al., 2007; Sloan et al., 2013a; Pelava et 
al., 2016). Ribosome biogenesis defects cause accumulation of free (non-ribosomal) 5S RNP 
in the nucleoplasm, where it interacts with and inhibits MDM2 mediated ubiquitination of 
p53. This subsequently results in the stabilisation and activation of p53 (Figure 1.4) (Sloan et 
al., 2013a; Pelava et al., 2016). It has been recently identified that all three component of 
the 5S RNP are needed for the 5S RNP-MDM2 interaction, and that MDM2 binds RPL11, 
Figure 1.4. Schematic representation of the 5S RNP-MDM2 mediated p53 
activation. 
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RPL5 and the 5S rRNA (Donati et al., 2013; Sloan et al., 2013a). Structural studies has been 
shown that the RPL11-MDM2 interface largely overlaps with the RPL11-28S rRNA interface 
after 5S RNP integration into the pre-LSU (Khatter et al., 2015; Zheng et al., 2015).  
Large ribosomal subunit production defects cause p53 activation through inhibition of 
MDM2 function by non-ribosomal 5S RNP (Horn and Vousden, 2008; Donati et al., 2013; 
Sloan et al., 2013a). In addition to large ribosomal subunit biogenesis defects, small 
ribosomal subunit production also causes p53 stabilisation and activation through the 
MDM2-5S RNP signalling pathway (Fumagalli et al., 2009; Dutt et al., 2011; Fumagalli et al., 
2012). Fumagalli et al. showed that small ribosomal subunit production defects upregulate 
ribosomal protein production, which causes increased 5S RNP production leading to p53 
stabilisation (Fumagalli et al., 2012).  
The 5S RNP is also involved in other important cellular signalling pathways. For example, 5S 
RNP is important for p14ARF-mediated p53 activation (Sloan et al., 2013a). Furthermore, Liao 
et al. reported that RPL11 and RPL5 recruit the RNA-induced silencing complex (RISC) leading 
to c-Myc inactivation (Liao et al., 2014). Finally, both RPL5 and RPL11 bind to and inhibit 
MDM2 function, causing the activation of p73 (Zhou et al., 2015). 
1.4 Ribosomopathies 
A number of rare genetic diseases arise due to mutations in the genes encoding either 
ribosomal proteins or ribosome biogenesis factors, and they are also known as 
ribosomopathies (Table 1.1) (Freed et al., 2010; Narla and Ebert, 2010). Some well 
characterized ribosomopathies include Diamond Blackfan anaemia (DBA), Treacher-Collins 
(TC) syndrome, and 5q- syndrome, Dyskeratosis Congenita (DSC), and Shwachman-Diamond 
syndrome (Table 1.1). Ribosomopathies are caused by mutations of different genes, 
including genes encoding for large or small ribosomal proteins (Cmejla et al., 2009; Lipton 
and Ellis, 2010), and genes encoding for different ribosome biogenesis factors, including 
TCOF1 (Gonzales et al., 2005) and DKC1 (Angrisani et al., 2014).  
Although the causes of different ribosomopathies vary at the genetic level and the 
mutations affect ribosome biogenesis at different stages, patients with ribosomopathies 
share some similar phenotypes. These phenotypes include anaemia, skeletal development  
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Table 1.1. Summary of ribosomopathies and other diseases in related to gene defects 
and p53 conditions. (Adapted from (Narla and Ebert, 2010)).  
defects and predisposition to cancers, especially to acute myeloid leukaemia (AML) (Table 
1.1) (Narla and Ebert, 2010).  
Although efficient ribosome biogenesis is crucial for all tissue development, ribosome 
biogenesis defects have been shown to cause more severe defects in hematopoietic cells 
during embryogenesis in both ribosomopathies patients and animal models (Yelick and 
Trainor, 2015). In addition, there is increasing evidence from animal models indicating that 
the tumour suppressor p53 is involved in the phenotype development (Amsterdam et al., 
2004; Jones et al., 2008; Pellagatti et al., 2010; Jaako et al., 2015). Since ribosome biogenesis 
defects are directly linked to p53 regulation, investigating the ribosomal stress-induced p53 
signalling pathway could provide greater understanding of the p53 involvement in these 
diseases.  
Ribosomopathy 
Gene 
Defects Clinical features Cancer risk p53 condition 
Diamond Blackfan 
Anemia (DBA) 
Ribosomal 
proteins 
Macrocytic anemia 
Short stature 
Craniofacial defects 
Thumb abnormalities 
osteosarcoma 
MDS 
AML 
Increased levels  
(symptoms 
dependent) 
Treacher Collins 
syndrome 
TCOF1 
POLR1C 
POLR1D 
Craniofacial abnormality  
 
None reported Increased levels 
 
5q-syndrome RPS14 Macrocytic anemia 
Hypolobulated micro-
megakatyocytes 
AML (Low rate); 
MDS 
Increased levels 
deregulated  
Dyskeratosis 
Congenita (DSC) 
DKC1 
NOP10 
NHP2 
TERT 
TERC 
TINF2 
Cytopenias 
Skin hyperpigmentation 
Nail dystrophy 
Oral leukoplakia 
AML 
Head and neck 
tumours 
Regulation 
affected 
Shwachman-
Diamond 
syndrome 
SBDS Neutropenia/ infections 
Pancreatic insufficiency 
Short stature 
MDS and AML Increased levels 
Alopecia, 
neurological 
defects, and 
endocrinopathy 
syndrome 
RBM28 
(Nop4) 
Absence of mature hair 
follicles 
Tooth malplacement 
Mental retardation 
None reported Symptoms 
dependent 
 23 
1.4.1 Diamond Blackfan Anemia 
One of the best characterized ribosomopathies is Diamond Blackfan Anemia (DBA). DBA is a 
rare congenital erythroid hypoplasia and it occurs in 1 : 100,000 to 200,000 births (Narla and 
Ebert, 2010). It is characterized by severe erythroid precursor cell reduction in the bone 
marrow (Narla and Ebert, 2010). DBA patients are also found to be predisposed to cancers, 
such as osteocarcoma, myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) 
(Table 1.1) (Lipton et al., 2001; Narla and Ebert, 2010). Genetically, most of DBA cases are 
caused by mutations in large or small ribosomal subunit proteins (Ellis, 2014). The current 
treatment strategy for DBA involves steroids, blood transfusion or bone marrow 
transplantation (Vlachos et al., 2001; Khanna-Gupta, 2013). 
The most frequently reported gene mutation in DBA is RPS19 which encodes the ribosomal 
protein S19 (Lipton and Ellis, 2010; Horos and von Lindern, 2012). In addition, mutations in 
other ribosomal proteins, such as RPS7, RPS10, RPS17, RPS26, RPS27, RPS28 and RPS29 from 
the small ribosomal subunit, or RPL5, RPL11, RPL15, RPL26 and RPL35A from the large 
ribosomal subunit, have also been identified (Cmejla et al., 2009; Lipton and Ellis, 2010; 
Narla and Ebert, 2010; Delaporta et al., 2014). Interestingly, clinical manifestations vary 
dependent on the genetic defect. For example, patients affected by mutated RPL11 protein 
show thumb abnormalities whereas mutated RPL5 is linked to cleft palate (Gazda et al., 
2008).  
Tumour suppressor p53 has been identified to be involved in DBA pathogenesis using a 
mouse model for DBA, which indicated that certain DBA symptoms are linked to cellular p53 
levels (Jaako et al., 2015). The study further showed that the development of anaemia is 
dependent of the 5S RNP-MDM2 interaction (Jaako et al., 2015).   
1.4.2 Treacher Collins syndrome 
Treacher Collins (TC) syndrome is an autosomal dominant congenital disorder that affects 
approximately 1 in 50,000 births (Posnick and Ruiz, 2000). It was characterized by 
craniofacial defects which can affect breathing, seeing, hearing and brain development of 
the patients (Sakai and Trainor, 2009; Narla and Ebert, 2010).  
Mutations in the gene Treacher-Collins-Franceschetti syndrome 1 (TCOF1) were linked to the 
pathogenesis of the disorder (Dixon et al., 1996). TCOF1 encodes for the nucleolar 
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phosphoprotein treacle, which is involved in rDNA transcription and methylation of the pre-
rRNA (Valdez et al., 2004; Gonzales et al., 2005). Treacle protein associates with the 
upstream binding factor (UPF) and RNA Pol I in the nucleolus (Valdez et al., 2004; Gonzales 
et al., 2005). Furthermore, mutation in the two genes, POLR1C and POLR1D, which encode 
for DNA-directed RNA Pol I and III subunit proteins RPAC1 and RPAC2, were also identified in 
TC patients (Yelick and Trainor, 2015).  
Tumour suppressor p53 was shown to be involved in the development of TC syndrome. 
Studies using mouse embryos showing a TC phenotype revealed that mutated TCOF1 is 
linked to p53 stabilisation and apoptosis of the neuronal crest cells (NCC) which are 
responsible for facial tissue development during embryogenesis (Jones et al., 2008). 
Furthermore, deleting p53 in these embryos inhibits the cyclin G1-driven apoptosis of the 
NCC and rescues the craniofacial abnormality (Jones et al., 2008).  
1.4.3 5q- syndrome 
5q- syndrome, also known as the chromosome 5q deletion syndrome, is an acquired 
hematological disorder which has been classed as a subtype of the myelodysplastic 
syndrome (MDS) (Vardiman et al., 2002; Narla and Ebert, 2010). It is caused by the loss of a 
long arm of chromosome 5 in bone marrow myelocytes (Van den Berghe et al., 1974). This 
syndrome is characterized by macrocytic anemia and compares to patients with other MDSs, 
though 5q- syndrome patients have a lower progression rate to AML (Vardiman et al., 2002; 
Narla and Ebert, 2010). Lenalidomide is able to treat symptoms of the 5q- syndrome and it is 
used as treatment for MDS as it promotes erythroid differentiation (List et al., 2006).  
As a result of the long arm deletion of chromosome 5, haploinsufficiency of the RPS14 gene 
has been identified in 5q- syndrome patients (Ebert et al., 2008; Narla and Ebert, 2010). The 
RPS14 gene encodes the small ribosomal protein RPS14, and the loss of this protein causes 
defects in SSU biogenesis and impaired erythropoiesis (Ebert et al., 2008). Similar to DBA, 
the tumour suppressor p53 is involved in the 5q- syndrome. p53 was reported to be 
activated and deregulated in erythroid progenitor cells in patients with 5q- syndrome 
(Pellagatti et al., 2010; Dutt et al., 2011). Furthermore, it has been reported that 
Lenalidomide leads to p53 degradation by restoring the ubiquitination function of MDM2 
(Wei et al., 2013). 
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1.4.4 Ribosome and cancer 
Since ribosome biogenesis and ribosomal proteins are involved in p53 regulatory signalling, 
it is fair to speculate that misregulation of p53 could play a role in cancer development, with 
or without the involvement of ribosompopathies. Most patients with ribosomopathies 
exhibit an increased risk of developing different types of cancers. For example, DBA, 5q- 
syndrome, Dyskeriatosis Congenita or Shwachman-Diamond syndrome especially result in a 
predisposition for AML (Alter et al., 2009; Narla and Ebert, 2010; Vlachos et al., 2012; 
Khanna-Gupta, 2013). In turn, ribosomal protein mutations are also reported in cancers. For 
example, exome sequencing identified RPL5 and RPL11 mutations in T-cell Acute 
Lymphoblastic Leukaemia (T-ALL) (De Keersmaecker et al., 2013). RPL22 mutations have also 
been reported in T-ALL (Rao et al., 2012).  RPS27a has been identified to be linked to 
leukemia pathogenesis (Wang et al., 2014).  
Furthermore, being the subcellular compartment responsible for ribosome biogenesis, 
evidence has also shown that the nucleolar proteins are involved in disease development. 
For example, mutations of NPM1 gene, encoding protein nucleophosmin, a multifunctional 
protein involved in ribosome biogenesis, was identified in patients affected by AML (Federici 
and Falini, 2013) and MDS (Grisendi et al., 2005). The NPM1 gene mutation occurs in 27% of 
the AML cases (Federici and Falini, 2013). In addition, transcription factor Runx1, which is 
important for ribosome biogenesis, was found involved in AML, MDS and breast cancer 
development (Browne et al., 2015; Behrens et al., 2016). All these reported defects confirm 
that genetic defects in ribosomal proteins and their related biogenesis factors play an 
important role in a broad range of diseases. 
1.5 p53 regulator proteins linked to ribosome 
When ribosome biogenesis defects occur, non-ribosomal 5S RNP accumulates in the 
nucleoplasm where it activates p53. However, the regulation of this 5S RNP-p53 signalling 
pathway, and whether other proteins are involved in this pathway remains unclear. It has 
been suggested that proteins involved in 5S RNP assembly, localization and incorporation 
into the ribosome could be important in regulating p53 through the 5S RNP (Sloan et al., 
2013a).  
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The 5S RNP assembly and its subsequent incorporation into ribosomes is a complicated 
process which has been shown to require the coordination from other protein co-factors. 
Some proteins interacting with RPL11 or RPL5 affect p53 induction, presumably via 5S RNP 
(Donati et al., 2013; Fregoso et al., 2013; Sloan et al., 2013a). Several proteins that are 
involved in either ribosome production (Mybbp1a, NML and B23), mRNA transcription 
(HEXIM1) or splicing (SRSF1) have recently been linked to regulating p53 activity (see below).  
1.5.1 SFSF1 
Serine/Arginine rich Splicing Factor 1 (SRSF1), known as Alternative Splicing Factor 1 
(ASF/SF2) was first identified as an alternative splicing factor protein, which is also involved 
in post-splicing events such as translation initiation (Michlewski et al., 2008), nuclear export 
of mature mRNA and nonsense mediated decay (Long and Caceres, 2009). The SRSF1 gene is 
up regulated in breast cancer and its overexpression was shown to promote transformation 
of mammalian cells (Anczukow et al., 2012; Anczukow et al., 2015).  
Recently it has been reported that SRSF1 interacts with RPL5 (Fregoso et al., 2013). 
Interestingly they also showed that in BJ-TT cells, SRSF1 depletion abolishes ActD-induced 
p53 activation. This suggests that SRSF1 is involved in the 5S RNP-p53 regulatory signalling 
pathway (Fregoso et al., 2013).  
In addition, Loren Gibson, a former member of the Watkins lab, confirmed that SRSF1 not 
only interacts with RPL5, but also the 5S RNP in U2OS cells (unpublished data). Unpublished 
results further demonstrated that the overexpression of SRSF1 stabilises p53, whereas 
depletion of SRSF1 reduces p53 basal activity and counteracts ActD-induced p53 activation 
in U2OS cells. SRSF1 depletion was also shown to reduce 5S RNP recruitment into the 
ribosome (Loren Gibson, unpublished data). Taken together, it was proposed that in normal 
conditions, SRSF1 is involved in the 5S RNP integration into the large subunit. In response to 
nucleolar stress, SRSF1 assists the 5S RNP in inhibiting MDM2. 
Moreover, SRSF1 is highly phosphorylated and its function and cellular localization is 
regulated by its phosphorylation (Ma et al., 2008). One of the kinases involved is the 
serine/arginine-rich protein-specific kinase (SRPK). SRPK phosphorylates specifically multiple 
serine residues located in the arginine/serine rich region (also known as the RS domain) 
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(Giannakouros et al., 2011; Gammons et al., 2013). Therefore, SRSF1 could be an important 
player in both ribosome biogenesis and p53 signalling.  
1.5.2 HEXIM1  
HEXIM1 protein has been well characterized as a positive transcription elongation factor b 
(P-TEFb) inhibitor which associates with RNA Pol II (Yik et al., 2003; Michels et al., 2004). Lew 
et al. recently reported that HEXIM1 positively regulates p53. They first identified the 
interaction between p53 and HEXIM1. They further reported evidence showing that 
overexpression of HEXIM1 leads to stabilised and more active p53, whereas depleting 
HEXIM1 inhibits p53 activation in response to DNA damage and translation blockage stress in 
MCF7 cells (Lew et al., 2012). Since HEXIM1 is a substrate for ubiquitination by MDM2 (Lau 
et al., 2009), it was proposed that HEXIM1 stabilises p53 by antagonizing the MDM2 
ubiquitination function upon p53 (Lew et al., 2012; Lew et al., 2013).  
Lew et al. also showed that ActD treatment, which blocks ribosome biogenesis, increased 
association between HEXIM1 and p53 in MCF7 cells (Lew et al., 2012), suggesting HEXIM1 
could be a potential protein factor involved in the 5S RNP-p53 regulatory signalling pathway. 
Nevertheless, how HEXIM1 is related to ribosomal stress-inducing p53 activation remains 
unclear. 
1.5.3 Mybbp1a  
Myb-binding protein 1a (Mybbp1a) was originally identified as a binding protein for the 
proto-oncogene c-Myb and since then, increasing evidence connects its involvement in rRNA 
production and in p53 acetylation and regulation, suggesting its association with ribosome 
biogenesis and p53 regulation.  
Mybbp1a is a nucleolar protein that is associated with RNA Pol I in HeLa cells, and the 
expression of Mybbp1a represses rRNA transcription (Hochstatter et al., 2012). They also 
showed that Mybbp1a is linked to rRNA processing. Furthermore, they demonstrated that 
Mybbp1a depletion delays the proliferation of HeLa cells, suggesting that it is also needed 
for cell cycle regulation (Hochstatter et al., 2012).  
Under ribosomal stress, Mybbp1a is translocated from the nucleolus to the nucleoplasm and 
induces p53 acetylation via the transcription coactivator P300, which leads to the 
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tetramerization of p53 (Kuroda et al., 2011; Ono et al., 2013). However, more intriguingly, 
ActD treatment promotes p53-K382 acetylation and increases protein levels of p21 in MCF7 
cells, whereas depleting Mybbp1a counteracts such effects caused by the ActD treatment 
(Kuroda et al., 2011).  
1.5.4 NML  
Nucleomethylin (NML; also known as RRP8) was identified as a component of the energy-
dependent nucleolar silencing complex (eNoSC). This complex includes two other protein 
components, sirtuin 1 (SIRT1) and Histone-lysine N-methyltransferase (SUV39H1). NML helps 
to recruit SIRT1 and SUV39H1, resulting in methylation and deacetylation of histone H3K9 
which inhibits rDNA transcription when cells are in low glucose conditions (Vaquero et al., 
2007; Murayama et al., 2008; Yang et al., 2013).  
NML is an RNA binding protein associating with 5S, 5.8S and 28S rRNA. The NML-SIRT1 
protein interaction is inhibited by the rRNA binding. During nutrient starvation, reduced 
rRNA production which promotes eNoSC recruitment via NML, results in a positive feedback 
loop further inhibiting the production of rRNAs. It was proposed that the NML-SIRT1 
interaction couples nutrient levels to ribosome biogenesis (Yang et al., 2013). 
NML is also a methyltransferase which is essential for the N1-methyladenosine (m1A) 
modification in the human and mouse 28S rRNA (Waku et al., 2016). In addition, Oie et al. 
reported evidence showing NML protein is also linked to fatty acid metabolism in a mouse 
model. NML-null mice showed reduced lipid accumulation in liver cells and after feeding 
these mice with a high fat diet, their weight gain and fat accumulation were lower than their 
wild type counterparts fed with the same diet (Oie et al., 2014). Kumazawa et al. provided 
evidence showing that in response to the glucose starvation Mybbp1a translocates to the 
nucleoplasm where it promotes p53 acetylation and activation. They also showed that 
Mybbp1a depletion reduces p53 activation in response to glucose starvation (Kumazawa et 
al., 2011).  
1.5.5 B23 
Nucleophosmin, also known as phosphoprotein B23, NPM1 or numatrin, is a multifunctional 
protein which is involved in multiple stages of ribosome biogenesis (Lindström, 2011). Wild 
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type B23 is predominantly localized in the nucleolus, whereas the NPMc+, a mutated form of 
B23 caused by chromosomal aberrations, is found mislocated in the cytoplasm in acute 
myeloid leukaemia (AML) cells (Wang et al., 1993). There are approximately 35% of AML 
patients that have NPMc+ mutations (Federici and Falini, 2013).  
The interaction between B23 and MDM2 was confirmed biochemically in SaOS-2 cells and 
UV radiation increases B23/MDM2 complex formation (Kurki et al., 2004). Knockdown of 
B23 protein reduces p53 stability and activity in response to radiation treatment (Colombo 
et al., 2002; Kurki et al., 2004). It was proposed that B23 inactivates MDM2 and 
subsequently stabilising p53 in response to DNA damage stress.  
Furthermore, evidence also suggests that B23 itself is able to associate with p53 (Kurki et al., 
2004; Lambert and Buckle, 2006). In addition, B23 interacts with both RPL5 and the 5S rRNA 
(Yu et al., 2006). B23 translocating from nucleoli to the nucleoplasm was shown to be caused 
by ActD treatment (Huang et al., 2005; Yao et al., 2010; Brodská et al., 2016) and UV 
radiation (Colombo et al., 2002; Kurki et al., 2004).  
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1.6 Aims and objectives 
Ribosome biogenesis is a tightly regulated process that is essential for cell survival. 
Mutations in genes encoding ribosomal proteins or ribosome biogenesis factors lead to a 
group of rare genetic disorders called ribosomopathies, and upregulated ribosome 
biogenesis is often found in various cancers. Large ribosomal subunit component 5S RNP is 
composed of the 5S rRNA, ribosomal protein RPL5 and RPL11. This small ribonucleoprotein 
complex is assembled independently, later being incorporated into the large subunit 
precursor. When ribosome biogenesis defects occur, non-ribosomal 5S RNP accumulates and 
inhibits the ubiquitination function of MDM2, leading to stabilisation and activation of p53. 
The 5S RNP-MDM2 pathway is essential for p53 homeostasis in the cell for responding to 
oncogene overexpression and to defects in ribosome biogenesis. Ribosome biogenesis is also 
targeted for anti-cancer therapeutic treatment, showing its significance in cancer 
development and treatment.  
A number of proteins linked to either translation regulation (HEXIM1), mRNA splicing (SRSF1) 
or ribosome biogenesis (Mybbp1a, B23 and NML) have recently been identified as p53 
regulators. Evidence from the literature suggests that they regulate p53 via the 5S RNP-
MDM2 signalling pathway. However, their role in relation to the 5S RNP remains unclear. 
The Splicing factor SRSF1 has recently been established as a p53 regulator and interacts with 
RPL5 (Fregoso et al., 2013). Loren Gibson, a past member from the Watkins lab proposed 
that SRSF1 functions as a chaperone during 5S RNP assembly. Nonetheless, whether the 
function of SRSF1 is directly related to 5S RNP-p53 signalling is not yet clear.  
Ribosomal protein RPL11 is important not only for 5S RNP assembly but also the 5S RNP 
incorporation into the large ribosomal subunit precursor. On the other hand, RPL11 binds to 
MDM2 and recent structural analyses highlight that the RPL11-MDM2 interface significantly 
colocalizes with the RPL11-28S rRNA interaction in the mature ribosome (Khatter et al., 
2015; Zheng et al., 2015), suggesting that the RPL11 interaction is likely to be important in 
both ribosome biogenesis and p53 signalling. Since proteomic study revealed that RPL11 is 
phosphorylated at multiple residues, it is possible that the phosphorylation of RPL11 is 
involved in both regulating ribosome biogenesis and MDM2-p53 signalling.  
Therefore, the aims and objectives in this PhD research project are,  
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Evaluate the role of protein cofactors HEXIM1, Mybbp1a, NML, B23 and SRSF1 in the 5S 
RNP-p53 regulatory signalling pathway.  
Investigate the role of RPL11 phosphorylation in both ribosomal biogenesis and the 5S RNP-
mediated p53 regulatory signalling.  
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Chapter 2. Materials and Methods 
2.1 Molecular cloning and DNA analysis 
2.1.1 Plasmid DNA amplification using E. coli  
E. coli DH5α ultra-competent cells were prepared according to the Inoue Method 
(Sambrook and Russell, 2006). Approximately 100 ng of plasmid DNA was added to 100 
µl of DH5α cells followed by a 30 minutes incubation on ice. Thereafter, a 90 second 
heat shock at 42 °C was given to the mixture, followed by an immediate return of the 
mixture back on ice. Then, 1 ml of Luria Broth (LB) medium was added to the mixture 
and incubated at 37 °C shaking for one hour. The cells were inoculated on a selective 
LB agar plate and incubated overnight at 37 °C for transformants selection.   
2.1.2 Plasmid DNA extraction from E. coli 
A single colony of E. coli cells acquired the plasmid DNA transformant was inoculated 
in 6 ml LB medium containing suitable antibiotic (100 μg/ml of Ampicillin and/or 10 
μg/ml of Chloramphenicol dependent on the plasmid backbone) and incubated 
overnight at 37 °C. The plasmid DNA was extracted the next day from the overnight 
culture using the GeneJet Plasmid Miniprep Kit (ThermoFisher Scientific) according to 
the protocol provided.  
2.1.3 DNA sequencing  
Plasmid DNA sequencing was performed using Sanger sequencing service provided by 
Source Biosciences to analyze the plasmid construct. Primers (provided by Source 
Biosciences) targeted DNA sequences either upstream or downstream of the open 
reading frame. 
2.1.4 Site-directed mutagenesis PCR 
PCR with designed primers (listed in Table 2.1) was performed to introduce mutations 
into the FLAG-tagged RPL11 cDNA sequence cloned within a pcDNA5/FRT/TO plasmid 
backbone, a plasmid which was previously constructed in the Watkins lab. 
Approximately 200 ng of plasmid DNA was subjected to the PCR reaction, with 2.5 
 33 
units of Pfu Turbo DNA polymerase (Agilent Technologies 600254), 1x Pfu Turbo 
buffer, 100 ng of each primer (mixture of forward and reverse, Table 2.1) and 200 nM 
dNTPs. PCR cycle conditions were used according protocols provided by the 
manufacturer.  
The PCR products were treated with DpnI restriction enzyme (Promega) at 37 °C for 60 
minutes to remove the methylated template, before transformation of DH5α E. coli 
competent cells. Site-directed mutations were confirmed by Sanger sequencing 
(methods are described in previous sections).  
Gene Mutation Primer direction 5' to 3' Sequence 
RPL11 
S29A Forward CATCTGTGTTGGGGAGGCTGGAGACAGACTGACGC 
Reverse GCGTCAGTCTGTCTCCAGCCTCCCCAACACAGATG 
S29D Forward CATCTGTGTTGGGGAGGATGGAGACAGACTGACGC 
Reverse GCGTCAGTCTGTCTCCATCCTCCCCAACACAGATG 
T47V Forward GCTCACAGGGCAGGTCCCTGTGTTTTCCAAAGC 
Reverse GCTTTGGAAAACACAGGGACCTGCCCTGTGAGC 
T47E Forward GCTCACAGGGCAGGAGCCTGTGTTTTCCAAAGC 
Reverse GCTTTGGAAAACACAGGCTCCTGCCCTGTGAGC 
S51A Forward GGCAGACCCCTGTGTTTGCCAAAGCTAGATACACTG 
Reverse CAGTGTATCTAGCTTTGGCAAACACAGGGGTCTGCC 
S51D Forward GGCAGACCCCTGTGTTTGACAAAGCTAGATACACTG 
Reverse CAGTGTATCTAGCTTTGTCAAACACAGGGGTCTGCC 
T73V Forward GCTGTCCACTGCGTAGTTCGAGGGGCC 
Reverse GGCCCCTCGAACTACGCAGTGGACAGC 
T73E Forward GCTGTCCACTGCGAAGTTCGAGGGGCC 
Reverse GGCCCCTCGAACTTCGCAGTGGACAGC 
S140A Forward GGTAGGCCAGGTTTCGCCATCGCAGACAAGAAGC 
Reverse GCTTCTTGTCTGCGATGGCGAAACCTGGCCTACC 
S140D Forward GGTAGGCCAGGTTTCGACATCGCAGACAAGAAGC 
Reverse GCTTCTTGTCTGCGATGTCGAAACCTGGCCTACC 
Table 2.1. Primers for RPL11 site-directed mutagenesis PCR. 
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2.1.5 E. coli transformation and plasmids for recombinant protein 
expression  
recombinant protein plasmid backbone Source 
GST-RPL5 
pGEX6P1 Dr. Loren Gibson GST-RPL11 
GST-Tip48 
His-SRS1 unknown gift from Prof. Reinhard Lührmann 
Table 2.2. List of plasmid construct used in recombinant protein expression.  
 
Plasmids were transformed into E. coli Strain: BL21 Rosetta™ (Novagen). Expressed 
proteins were purified by Glutathione or Nickel resin. To examine protein yields and 
qualities, purified product was separated by SDS-PAGE and visualized by coomassie 
blue staining. 
Freshly plated E. coli cells were resuspended thoroughly to 120 μl of 50mM CaCl2. 
Then, 1 μl of recombinant plasmid was added to the cells and the mixture was 
incubated on ice for 15 minutes. This was followed by a heat shock for 90 seconds at 
42 °C, before incubation on ice for another 5 minutes. 700 μl of LB media was then 
added and the cells were incubated at 37 °C for 30 minutes. The cells were retrieved 
by centrifugation and plated on ampicillin chloramphenicol double selective plates and 
incubated at 37 °C overnight for transformant selection. 
2.2 RNA extraction, detection and analysis  
2.2.1 RNA extraction 
RNA was extracted from cells harvested after experimental treatment using Tri-
Reagent (Ambion) according to the protocol provided by the manufacturer.  
2.2.2  Agarose-glyoxal gel electrophoresis and Northern blotting  
The extracted RNA was dissolved in 1x glyoxal loading buffer (61.2 % DMSO (v/v), 
20.4 % glyoxal (v/v), 12.2 % 1x BPTE buffer (28.7 mM Bis-Tris, 9.9 mM PIPES, 1 mM 
EDTA) (v/v), 4.8 % glycerol (v/v), and 0.02 mg/ml ethidium bromide) and incubated at 
55 °C for 60 minutes. RNA samples were separated on a glyoxal-agarose gel (1.2 % 
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Agarose (Melford) dissolved in 1x BPTE (30 mM Bis-Tris free acid pH 7.0, 10 mM PIPES 
free acid, 1 mM EDTA) by electrophoresis at 185V in 1x BPTE buffer. The gel was 
washed with 75 mM NaOH for 20 minutes (room temperature), then washed twice 
with Tris-Salt pH 7.4 (0.5 mM Tris-HCl pH 7.4, 1.5 M NaCl) for 15 minutes at room 
temperature, followed by washing the gel with 6x SSC buffer (1 M NaCl, 0.1 M Sodium 
citrate) for 20 minutes at room temperature. The separated RNA was transferred to a 
Hybond-N nylon membrane (GE Healthcare) using the capillary action method, before 
UV cross-linking using a Stratalinker UV Crosslinker (Stratagene).  
For detecting RNA using the 5’ 32P-labelled oligo RNA probes, the Hybond-N nylon 
membrane was pre-hybridized with SESI buffer (0.5 M sodium phosphate pH 7.2, 7 % 
SDS (w/v), 1 mM EDTA) for 30 minutes at 37 °C. Then, it was incubated with the probe 
for overnight to 2 days at 37 °C. After the probing, the membrane was washed twice 
with 1x SSC/0.1 % SDS solution for 20 minutes at 37 °C. The membrane was exposed to 
a phosphorimager screen and the radioactive signal was scanned by a Typhoon 
Phosphorimager (Life Technologies).  
For detecting RNA using the random-prime 32P-labelled probes, the membrane was 
incubated with the hybridization (Pre-Hyb) buffer (25 mM NaPO4 pH 6.5, 6x SSC, 5x 
Denhardts, 0.5 % SDS (w/v), 50 % deionised formamide, 100 μg/ml denatured salmon 
sperm DNA) for two hours at 42 °C. Then, it was incubated with the probe for 
overnight to 2 days at 37 °C. After the probing, the membrane was washed twice with 
the 2x SSC/0.5 %SDS for 5 minutes at 42 °C, before being washed with 2x SSC/0.1 % SDS 
for 20 minutes at 50 °C. Detection was performed as above using a Typhoon 
Phosphorimager. 
  
 36 
2.2.3 Nucleic Acid labelling using 32P isotope for Northern blotting  
Oligo probes (Table 2.3) were purchased from Sigma Aldrich and subsequently labelled 
with 32P γ-ATP (Perkin Elmer) in the lab. 1 μl of 10 μM oligo probe was used in a 20 μl 
reaction containing 1 μl of T4 Polynucleotide Kinase (1 U/1 μl, NEB), 2 μl of 10x 
Polynucleotide Kinase Buffer (NEB) and 4 μl of 32P labelled γ-ATP and incubated at 
37 °C for 45 minutes.  
At the end of the reaction, reaction volume was adjusted to 50 μl followed by G50 
column purification (GE Healthcare). The unbound isotope was removed by 
centrifugation of the column at 0.9 g for 2 minutes. The labelled probes were retrieved 
from the column according to the manufacturer’s instructions. Probes were incubated 
at 95 °C for 2 minutes and then added to SES1 buffer for the hybridization process.  
Target Sequence 5' to 3' 
5S rRNA CCGAGATCAGACGAGATCGGGCGCGTTCAGGGTGGTATGG 
5.8S rRNA CAATGTGTCCTGCAATTCAC 
Table 2.3. A list of 32P-labelled probes used in northern blotting. 
 
2.3 Protein related assays 
2.3.1 Recombinant protein expression  
A single colony of the transformed E. coli BL21 Rosetta cells was incubated overnight at 
37 °C in a 10 ml starter culture. The next day it was diluted 1 : 100 in 1 L of 2x YT 
medium (Sigma Aldrich) containing 100 μg/ml of Ampicillin and 10 μg/ml of 
Chloramphenicol. The culture was incubated at 37 °C until the beginning of 
exponential growth, then 1 mM of IPTG was added to the culture to induce protein 
expression. The culture was then incubated at 18 °C overnight, before the cells were 
harvested for recombinant proteins purification.  
2.3.2 His-tagged and GST-tagged protein purification 
At the end of incubation, the culture was centrifuged in a Beckman J6-HC rotor at 
4,000 rpm for 30 minutes at 4 °C to pellet the cells. Cells were resuspended in ice cold 
GST buffer (20 mM Tris-HCl at pH8, 5 mM MgCl2, 300 mM KCl, 0.1% Tween and 10% 
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Glycerol). After repeated washing with the GST buffer, the cells were lysed by 
sonication (3 minutes/5 cycles/90% power). Insoluble cellular material was removed by 
high speed centrifugation in the JA20 rotor at 18,500 rpm for 45 minutes at 4 °C while 
the supernatant was recovered.  
Glutathione Sepharose beads (Glutathione Sepharose 4 Fast Flow, GE Healthcare Life 
Sciences) were added to the supernatant to capture the GST-tagged proteins according 
to the manufacturer’s protocol. The beads were recovered, washed and the bound 
GST-tagged protein was eluted using the GST buffer containing 50mM of glutathione. 
For His-tagged proteins, Ni Sepharose beads (Ni Sepharose 6 Fast Flow, GE Healthcare 
Life Sciences) were used to capture the recombinant protein. Beads were washed with 
binding buffer (20 mM sodium phosphate, 0.5 M NaCl, 20 to 40 mM imidazole, pH 7.4) 
and the bound protein was eluted with elution buffer (20 mM sodium phosphate, 0.5 
M NaCl, 500 mM imidazole, pH 7.4). 
2.3.3 Protein dialysis and concentration  
The purified recombinant proteins were dialyzed in order to remove glutathione or 
imidazole. Protein solutions were placed into the size exclusion semipermeable 
membrane, the Snakeskin Dialysis Tube (Thermofisher Scientific). The sealed 
membrane was then placed into a large volume of PBS buffer for sufficient time to let 
buffers exchange. If necessary, the protein solution was concentrated in 500 ml PBS 
containing 30% PEG8000 (Sigma-Aldrich) at 4 °C for 5-10 hours until the protein 
solution was reduced to the desired volume.  
2.3.4 Protein separation by SDS-PAGE and Coomassie staining 
Protein separation was performed using 12% SDS-PAGE, casted using liquid 
polyacrylamide solution and the Mini-PROTEAN® Tetra Handcast Systems (Bio-Rad). 
The separation section of the SDS-PAGE consisted of 12% polyacrylamide, 375 mM 
Tris/HCl pH 8.8 and 2% SDS in water, and the mixture was solidified by 0.1% 
ammonium persulfate (APS) and 0.2% TEMED.  
Gel electrophoresis was run in a Bio-Rad Western Electrophoresis tank, filled with 1x 
Protein Running Buffer (25 mM Tris-HCl pH 8.3, 250 mM glycine, 0.1 % SDS (w/v)) at 
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200 V for 40 minutes. The separated proteins were then analyzed by Coomassie 
staining and/or for Western blotting dependent on the experiment design. 
For Coomassie staining a ten-fold dilution of Coomassie stain in 1.0 % in ethanol in a 
fixation solution (10 % methanol, 10 % acetic acid, 10 % isopropanol and 5 % glycerol) 
was prepared. After soaking the gel in the stain for approximately one hour, the gel 
was destained by washes in the fixation solution until the protein signals were visible 
and the background colour stain was minimised. The image of the stained protein gel 
was then digitalized as 300dpi images using a HP professional high definition scanner.  
2.3.5 Western blotting and antibodies  
For Western blotting, protein samples were first separated on SDS-PAGE using 
conditions stated in the previous section, before being transferred onto a 
nitrocellulose membrane (Amersham Protran Premium 0.2 NC, GE Healthcare), which 
was achieved using a Bio-Rad Western Transfer tank containing the Western Transfer 
buffer (25 mM Tris-HCl pH 8.3, 150 mM glycine, 10 % methanol).  
The protein transfer was performed at 65 V for 1.5 hour at room temperature, or at 
16V overnight at 4 °C. The transfer quality was examined using a quick one to five 
minute staining with Ponceau S Solution (Sigma).  
The stained membrane was washed by PBS (Phosphate Buffered Saline) containing 
0.1 % Triton (PBST), and then blocked  in 2 % skimmed milk (Marvel) dissolved in PBST 
at room temperature for one to two hours.  
Primary antibody solution was prepared as indicated in  and added to the membrane 
for an overnight incubation at 4 °C. Membranes were then washed for three 5 - 10 
minutes in PBST followed by a secondary antibody solution incubation at room 
temperature for one to two hours. The secondary antibody solution was prepared 
according to . The membranes probed with secondary antibody were washed again for 
3 times 5 - 10 minutes in PBST.  
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2.3.6 Visualization and digitalization of Western blots  
This work involved two types of signals for visualizing proteins, chemiluminescence 
(HRP congregated secondary antibody, ECL substrate) or fluorescence (fluorophore 
congregated secondary antibody) and three different detection methods were used, 
including X-ray films, chemiluminescence biomolecular imager and fluorescence 
scanner.  
For blots probed with secondary antibodies conjugated with Horseradish Peroxidase 
(HRP), the membranes were developed by adding ECL substrate (Clarity™ ECL Western 
Blotting Substrate, Bio-Rad) and the signals were captured on X-ray films (Amersham 
Hyperfilm ECL, GE Healthcare). The film was processed using an automatic film 
developer. The developed X-ray films were scanned and digitalized at 300dpi 
resolution using a HP professional high definition scanner. Alternatively, the 
chemiluminescence signal was captured and digitalized by an ImageQuant™ LAS 4000 
mini biomolecular imager (GE Healthcare Life Sciences).  
For those membranes blotted with fluorescently labelled secondary antibodies, the 
antibody signals were visualised by using the Odyssey-LICOR system (LICOR). 
Digitalized western blot images generated using either methods were analysed using 
the ImageQuant™ TL software (GE Healthcare Life Sciences). The same software was 
used to quantify unsaturated protein signals.  
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Table 2.4. List of antibodies used in western blotting. Antibodies were diluted in PBST 
or TBST containing blocking agent recommended by the manufacturer.  
 
2.3.7 Luciferase assay  
U2OS cells stably expressing firefly luciferase controlled by the p53-regulated 
promoter sequence were cultured in  24-well plates (conditions as stated in section 
Cell culturing, the cells were kindly provided by Professor Neil Perkins, Newcastle 
University). After experimental treatments the cells were washed with PBS and 
harvested using 1x Passive Lysis Buffer (Promega) according to manufacturer's 
protocol. Luciferase reaction substrate (Luciferase Assay System, Promega) was 
prepared according to manufacturer's protocol. The luciferase assay was performed 
 Antibody Animal 
origin 
Dilution  Source 
Primary antibody α-HEXIM1 Rabbit 1 in 5,000 Bethyl A303-113A 
α-Mybbp1a Rabbit 1 in 1,000 Bethyl A301-327A 
α-NML (RRP8) Rabbit 1 in 2,000 Bethyl A304-201A 
α-B23 (NPM1) Mouse 1 in 1,000 Santa Cruz sc-
32256 
α-MDMX Rabbit 1 in 2,000 Bethyl A300-287A 
α-p53 Rabbit 1 in 1,000 Santa Cruz- (FL-
393) 
α-p21 Rabbit 1 in 1,000 Santa Cruz- sc-397 
α-FLAG Rabbit 1 in 
10,000 
Sigma Aldrich- 
F725 
α-RPL7 Rabbit 1 in 2,000 Abcam- ab72550 
α-Poly His Mouse 1 in 2,000 Santa Cruz H-3 
Loading control α-Fibrillarin Mouse 1 in 200 Santa Cruz G2808 
α-Karyopherin Rabbit 1 in 500 Santa Cruz (H-300) 
α-Tubulin Mouse 1 in 
10,000 
Cell Signalling 
(DM1A) 
Secondary 
antibody 
α-Mouse HRP 
conjugated 
Donkey 1 in 
10,000 
Santa Cruz- sc-
2314 
α-Rabbit HRP 
conjugated 
Donkey 1 in 
10,000 
Santa Cruz- sc-
2313 
α-Rabbit IRDye® 
800CW 
Donkey 1 in 
10,000 
LICOR 926-60073 
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according to the protocol provided by Promega and the luciferase intensity was 
measured using a Lumat 100 luminometer (Berthold).  
Cell lysate samples were also subjected to a Bradford assay in order to determine the 
total protein concentration (Bio-Rad) according to the manufacturer’s protocol. 
Luciferase intensity was normalized against the protein centration.  
2.3.8 Bradford assay  
Protein concentrations were measured using the Bradford protein assay kit (Bio-Rad) 
according to the protocol provided by the manufacturer. The optical density (OD) of 
the samples were measured at 595 nm wavelength using a spectrophotometer 
(Ultrospec 2000, Pharmacia Biotech).  
2.4 In vitro assays 
2.4.1 Protein pull-down assay 
Purified GST-tagged proteins were incubated with His-SRSF1 for 1 hour at 4 °C 
(incubation buffer: 20 mM Tris-HCl at pH 8, 5 mM MgCl2, 150 mM KCl, 0.1% Tween and 
10% Glycerol). Glutathione sepharose beads were subsequently used to extract GST-
tagged protein by one hour incubation and retrieved by centrifugation. Beads were 
washed with incubation buffer followed by analysis of the bound material using 
western blotting with anti-His antibody. 
To investigate the interaction between SRSF1 and the 5S RNP in vitro, equal amount of 
GST-tagged RPL5, RPL11 or Tip48 were incubated individually with same amount of 
His-SRSF1 at 4 °C for 5 hours before purification with glutathione sepharose resin. The 
resins was subsequently washed and the bound material was denatured and separated 
by SDS-PAGE. To confirm the interaction, an anti-His tag antibody was used in western 
blotting. 50% of His-SRSF1 input were processed in parallel and used as a positive 
control.  
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2.5 Cell culturing and in vivo assays 
2.5.1 Cell culturing and Human tissue cell line 
U2OS human osteosarcoma cells were maintained in DMEM (Dulbecco's Modified 
Eagle Medium, Sigma) with 10% fetal bovine serum and 2% penicillin-streptomycin 
solution. Cells were incubated at 37 °C with 5% CO2. 
2.5.2 RNA interference 
7 μl of 20 mM of siRNA stock were used to transfect cells at 50% confluence with 5 μl 
of Lipofectamine RNAiMAX (Invitrogen) in 2 ml of optiMEM solution. Cells were 
incubated in antibiotic-free DMEM. The cells were harvested and prepared into 
samples 48 hours after the siRNA transfection. The siRNA effect of protein knockdown 
was subsequently determined by Western Blotting.  
 
siRNA Sequence 5' to 3' Source Reference 
GL2 CGTACGCGGAATACTTCGATT Eurofins MWG (Sloan et al., 
2013a) 
HEXIM1 SMARTpool ThermoFisher 
SCIENTIFIC 
(Lew et al., 
2013) 
Mybbp1a UGGAUCAUCUUUCGAUUGG Eurofins MWG (Hochstatter 
et al., 2012) 
NML UUCUCCGAACGUGUCACGUTT Eurofins MWG (Grummt 
and 
Ladurner, 
2008) 
B23 UGAUGAAAAUGAGCACCAG Eurofins MWG (Colombo et 
al., 2002) 
MDMX AGAUUCAGCUGGUUAUUAAATT Eurofins MWG (Gilkes et al., 
2006) 
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Table 2.5. List of siRNAs used in this work.  
2.5.3 Stable inducible cell lines creation 
Stable inducible cell lines were created using the Flp-In™ system. pcDNA5/FRT/TO 
plasmid carrying the target gene insert and the pOG44 plasmid were co-transfected 
into U2OS Flp-In cells grown in 6-well plates using FuGene 6 Transfection Reagent 
(Promega) according to the protocol provided by the manufacturer. Cells were 
transferred to T75 flask from 6-well plates and left to grow for 72 hours before 
selection of the stable transformants using 100 µg/ml hygromycin B and 10 µ g/ml 
Blasticidin S.   
2.5.4 Drug treatments 
Human cells were subjected to chemical or drug treatments listed in Table 2.6, before 
harvested and analyzed as described.  
Drug Dose Solvent Treatment length 
ActD 5 nM ethanol 18 hours 
Nutlin 3a 5 µM DMSO 18 hours 
SRPIN340 10 µM DMSO 12 hours 
Table 2.6. List of drugs or chemicals used in cell culture. 
2.5.5 Immunofluorescence and microscopy  
Cells were seeded and grown on glass coverslips in 24-well plates. At the end of the 
experimental treatment, the coverslips were washed with PBS, before incubation in 
200 µl of PBS/0.1 % Triton for 15 minutes, followed by three PBS washes.  
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The blocking reagent was made up of 0.1 % Triton and 10 % Fetal Calf Serum (FCS) in 
PBS. After the PBS washes the coverslips were treated with the blocking reagent for 
approximately one to two hours at room temperature, before transferring the cells to 
a fresh 24-well plate where they were probed with primary antibody for one to two 
hours at room temperature. The primary antibody solution was prepared by diluting 
the antibody in the blocking reagent.  
Then, the coverslips were washed with PBS for three times, followed by a 10 minutes 
PBS soaking step. This was followed by a one to two hours secondary antibody 
incubation in the dark. The secondary antibody solution was prepared as the primary 
antibody solution. At the end, the coverslips were washed with PBS in the dark three 
times, followed by a 10 minutes PBS soaking step. Then, PBS containing 0.01 ng/ml 
DAPI (Sigma) was used to wash the coverslips for three times, following by an 
additional 10 minutes PBS soaking step in the dark.  
Finally, the samples were soaked in deionized water followed by ethanol for five times. 
Coverslips were air-dried and mounted on glass slides with Moviol. Samples were 
visualized using a Zeiss Axiovert 200M inverted microscope with a Plan-Apochromat 
100x / 1.40 oil DIC x / 0.17 objective lens. The digital images were captured with an 
AxioCam HRm camera, and they were analyzed using the AxioVision software (Zeiss). 
2.5.6 Glycerol gradient for ribosomal material separation 
4 ml 10-40 % glycerol gradients(v/v) were prepared by combining 2 ml of 40% glycerol 
solution (bottom; 40 % Glycerol, 0.15 M KCl, 20 mM HEPES pH 8, 1.5 mM MgCl2, 1 mM 
DTT, 0.2 % Triton X-100) and 2 ml of 10% glycerol solution (top; 10 % Glycerol, 0.15 M 
Antibody Animal 
origin 
Dilution in 
PBS/10% 
FBS/0.2% Triton 
Source 
ANTI-FLAG® antibody, 
polyclonal 
Rabbit 1/500 SIGMA-ALDRICH (MERCK) 
anti-Rabbit IgG 
Secondary Antibody, 
Alexa Fluor 555 
Donkey 1/500 ThermoFisher SCIENTIFIC 
Table 2.7. List of antibodies used in immunofluorescence. 
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KCl, 20 mM HEPES pH 8, 1.5 mM MgCl2, 1 mM DTT, 0.2 % Triton X-100) in a thin wall 
Ultra-Clear Centrifuge Tube (Beckman Coulter), mixed with a BioComp Gradient 
master (BioComp) rotating at a 83° angle for 70 seconds at 22rpm, before storing at 
4 °C for 1 hour.  
Gradient samples were prepared from 5 - 7x106 cells. They were first sonicated in 0.5 
ml of ice cold Gradient Buffer E (20 mM HEPES pH 8, 150 mM KCl, 0.5 mM EDTA, 0.1 
mM DTT, 5 % Glycerol) with twice a 15 second pulse, with a 30 second interval at 20 % 
/0.3 second amplitude. 0.2 % Triton-X 100 was added to the sample and the insoluble 
material was removed by centrifugation at 13,000 rpm for 10 minutes at 4 °C.  
0.4 ml of solution was removed from the top of the gradient and replaced with the 
same volume of sample, before centrifuging in a SWTi60 rotor (Beckman L7-80) at 
52,000rpm for 90 minutes at 4 °C with no brakes and slow acceleration. 40 μl of the 
remaining sample were stored and used later as 10% total input control during sample 
analysis. Each gradient was fractionated into 20 200 μl fractions from top to bottom and 
snap frozen in liquid nitrogen prior to storage at -80 °C.  
2.5.7 Pulse trace labeling experiments for ribosome biogenesis study 
Cells were seeded and grown in a 6-well plate for the experimental treatment. Prior to 
the labelling, cellular phosphate was depleted by incubating the cells in phosphate-
free medium (Life Technologies) at 37 °C/5 % CO2 for one hour. Then, the cells were 
incubated with phosphate-free medium containing inorganic 32P-orthophosphate (0.5 
μl/ml) at 37 °C/5 % CO2 for another hour. After that cells were cultured with normal 
DMEM media (Sigma Aldrich) for an additional three hours. Cellular total RNA was 
extracted using Tri-reagent and separated on a glyoxal-agarose gel, before the being 
transferred onto a Hybond-N nylon membrane (GE Healthcare). A phosphorimager 
screen was used to expose the radioactivity and the radiolabeled RNA signals were 
visualized using a Typhoon Phosphorimager (Life Technologies).  
2.6 Software and statistical analysis 
Pymol software was used to present protein-RNA molecular structures. Software 
ImageQuant™ TL (GE Healthcare Life Sciences) are used to perform signal quantitation 
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from images acquired from western blotting or northern blotting analysis. AxioVision 
software (Zeiss) was used to analyse the immunofluorescence images. 
Statistical analysis was performed in Microsoft Excel, using the ‘t-test: Two-Sample 
Assuming Equal Variances’ function from the data analysis toolkit.  
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Chapter 3. Characterisation of Co-factors Involved in the 5S RNP-
p53 signaling 
3.1 Introduction 
Ribosome biogenesis is an energy-consuming process. It involves over 200 proteins and an 
equivalent number of non-coding RNAs in human cells. This complicated process requires 
coordinated expression of genes, transcription by RNA Pol I (for 18S, 5.8S and 28S rRNAs), 
RNA Pol II (for ribosomal proteins and biogenesis factors) and RNA Pol III (for the 5S rRNA). 
Ribosome biogenesis starts within a specific region in the nucleus called the nucleolus, 
where 18S, 5.8S and 28S rRNAs are transcribed by RNA Pol I as a single precursor transcript, 
called the 47S pre-rRNA. The 47S pre-rRNA is subsequently processed to become the three 
mature rRNAs through a series of endonucleolytic and exonucleolytic cleavage events. 
During these events, pre-rRNAs incorporate ribosomal proteins, forming ribosomal 
precursors throughout the biogenesis process. During the early stage of the process, the 90S 
pre-ribosome is formed around the 47S pre-rRNA, which later splits into pre-60S and pre-40S 
ribosomal subunits. While the majority of these processing steps take place in the nucleolus, 
some late ribosome maturation events take place in the cytoplasm where pre-ribosomes 
become mature ribosomal subunits.  
In contrast to other rRNAs, the 5S rRNA is transcribed by RNA polymerase III which takes 
place in the nucleoplasm. The 5S rRNA is 120 nucleotides in length and it is found in all 
organisms, except in the mitochondrial ribosome from fungi and animals. The 5S rRNA, 
together with ribosomal proteins RPL5 and RPL11, forms a subcomplex of the large 
ribosomal subunit called the 5S RNP. In human cells, RPL5 binds and stabilises the 5S rRNA in 
the nucleoplasm, which is required for the maturation of 5S rRNA. After that the RPL5/5S 
rRNA complex is transported into the nucleolus, where it recruits RPL11. The 5S RNP is 
subsequently integrated into the pre-LSU. 
Misregulated ribosomal biogenesis, also known as nucleolar stress, causes accumulation of 
non-ribosomal (free) 5S RNP which promotes p53 activation (Figure 3.1). The tumour 
suppressor p53, also known as the ‘guardian of the genome’, monitors genome integrity and 
regulates the cell cycle. It is activated by different types of cellular stress such as DNA 
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damage, oxidative stress, oncogene expression and nucleolar stress. In response to these                                                                                             
stresses, p53 is stabilised and activated by post translational modifications such as 
phosphorylation and acetylation. It has been shown that p53 acetylation is linked to 
apoptosis (Reed and Quelle, 2015).  
Being a transcription factor, the activated p53 drives the expression of different p53-
regulated genes, resulting in cellular responses such as cell cycle arrest, DNA damage repair, 
senescence and apoptosis. Being one of the most important downstream factors, the 
transcription of CDKN1A gene, which encodes protein p21, is controlled by the transcription 
activity of p53 (Figure 3.1). p21, also known as cyclin-dependent kinase (CDK) inhibitor 1, 
interacts and inhibits CDK complexes which regulate cell cycle at G1 to S phase. 
Overexpression of p21 results in cell growth arrest and senescence (Xu et al., 2014).  
Cellular p53 is maintained at a low level in non-stressed cells. One of the most important 
negative p53 regulators is MDM2. MDM2 functions as an E3 ubiquitin ligase regulating both 
the stability and the activity of p53. MDM2 interacts with p53 through its N-terminal binding 
site, inducing the polyubiquitination of p53 which targets p53 for proteasome-mediated 
degradation. Furthermore, the binding of MDM2 to p53 inhibits the transcriptional activity 
of p53. However, being one of the p53 transcriptional target, MDM2 expression is promoted 
Figure 3.1. Schematic representation of the 5S RNP -p53 signalling pathway.  
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by p53 activation and it therefore forms a negative feedback loop to regulate p53 (Barak et 
al., 1993). 
Murine double minute X, also known as MDMX or MDM4 protein, also plays an important 
role negatively regulating p53. MDMX shares 90% homology with MDM2 mainly in its p53-
binding domain and the RING domains (Shvarts et al., 1996). However, in contrast to MDM2, 
MDMX does not have the E3 ligase activity and it lacks the nuclear localisation/export 
sequence (Biderman et al., 2012). In non-stressed cells, MDMX interacts with MDM2 
through its RING domain and they function as one complex in regulating p53. The MDMX 
association to MDM2 stabilises MDM2 enhancing the MDM2 ubiquitination function of p53. 
Nevertheless, MDMX is also a polyubiquitination target of MDM2 (Shadfan et al., 2012). In 
response to ribosomal stress, Gilkes et al. found that MDMX degradation was required for 
ribosomal stress-mediated p53 activation in an MDM2-dependent manner. They also 
demonstrated that overexpression of MDMX increases cellular resistance to ribosomal stress 
induced by 5-Fluorouracil (Gilkes et al., 2006).  
Recent studies have linked nucleolar stress, caused by defects in ribosome biogenesis, to p53 
activation through the inactivation of MDM2. Ribosome biogenesis is affected in almost all 
stress conditions causing accumulation of free 5S RNP which is not integrated into the LSU. 
The accumulated non-ribosomal 5S RNP binds to, and inhibits the MDM2 ubiquitination 
function causing p53 activation (Horn and Vousden, 2008; Chakraborty et al., 2011; Donati et 
al., 2013; Sloan et al., 2013a; Pelava et al., 2016). Furthermore, the C305F mutation in 
MDM2 which was originally identified in cancer cells, has been shown to block the 
interaction between the 5S RNP and MDM2 (Macias et al., 2010). This mutation causes mice 
to become insensitive to certain anti-cancer chemotherapeutics and being prone to c-Myc 
driven cancers (Macias et al., 2010). It has also been shown that p53 is activated through the 
5S RNP in response to different cellular stresses, including nucleolar stress, oxidative stress, 
replicative stress, oncogene overexpression and nutrient starvations (Orsolic et al., 2015). 
The 5S RNP not only activates p53 during nucleolar stress, but was also found to be involved 
in regulating p53 homeostasis (Sloan et al., 2013a).  
Ribosome biogenesis is a tightly regulated and complicated process requiring the 
coordination of a large number of protein factors. It was therefore proposed that proteins 
involved in 5S RNP production, localisation and its integration into the ribosome could be 
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important in the 5S RNP-p53 regulation (Sloan et al., 2013a). For example, it has been 
demonstrated that the tumour suppressor PICT1, which is involved in the 5S RNP complex 
integration into the ribosome, determines free 5S RNP abundance and controls cellular p53 
levels (Sloan et al., 2013a). In addition to PICT1, there are several other protein factors have 
been proposed to be involved in p53 regulation via the 5S RNP.   
The splicing factor SRSF1 is involved in mRNA splicing, translation initiation, mature mRNA 
export and nonsense mediated decay (Michlewski et al., 2008; Long and Caceres, 2009). A 
recent publication showed that SRSF1 binds to RPL5 and that this is essential for the ActD-
induced p53 activation (Fregoso et al., 2013). Loren Gibson, a former member of the 
Watkins lab, further demonstrated the molecular interaction between SRSF1 and the 5S RNP 
components (unpublished data). Furthermore, it has also been demonstrated that 
overexpressing SRSF1 promotes p53 stabilisation. Hence it was proposed that SRSF1 assists 
5S RNP in p53 activation in response to ribosomal stress.  
The positive transcription elongation factor b (P-TEFb) inhibitor, HEXIM1 protein, is involved 
in translation (Yik et al., 2003; Michels et al., 2004). It was reported that HEXIM1 is not only a 
p53 binding protein, but also a positive p53 regulator (Lew et al., 2012). They further 
demonstrated that ActD treatment in MCF7 cells increases the association between HEXIM1 
and p53, suggesting regulation of p53 via 5S RNP.  
Mybbp1a protein is a ribosome biogenesis factor involved in pre-rRNA transcription 
(Hochstatter et al., 2012). It has been demonstrated that when ribosomal stress occurs, 
Mybbp1a translocates from the nucleolus to nucleoplasm where it induces p53 acetylation 
via the transcription coactivator P300. This results in the tetramerisation of p53 (Kuroda et 
al., 2011; Ono et al., 2013). Furthermore, ActD treatment in MCF7 cells promotes p53 
acetylation resulting in p53 activation (Kuroda et al., 2011), suggesting Mybbp1a could be 
involved in the 5S RNP-p53 signalling.  
NML protein (Nucleomethylin) is a component of the energy-dependent nucleolar silencing 
complex (eNoSC) which inhibits rDNA transcription when cells are in low glucose conditions 
(Murayama et al., 2008). NML is also a methyltransferase which is essential for the N1-
methyladenosine (m1A) modification in the human and mouse 28S rRNAs (Waku et al., 
2016). NML is also important in the glucose starvation-induced p53 activation (Kumazawa et 
al., 2011).  
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Protein B23 (Nucleophosmin) is a nucleolar protein involved in ribosome biogenesis. It is 
translocated from the nucleoli to the nucleoplasm in response to ActD treatment (Huang et 
al., 2005; Yao et al., 2010; Brodská et al., 2016) or UV radiation (Colombo et al., 2002; Kurki 
et al., 2004). Furthermore, studies showed that it is able to interact with MDM2 and p53 
(Kurki et al., 2004; Lambert and Buckle, 2006). It has also been shown to interact with both 
RPL5 and the 5S rRNA (Yu et al., 2006), therefore it is possible that B23 is involved in 5S RNP-
p53 signalling.   
Although these protein candidates, HEXIM1, Mybbp1a, NML and B23, are linked to p53 
regulation, their involvement in 5S RNP-p53 signalling remains unclear. Hence in this 
chapter, I aim to investigate how these reported p53 regulators, and SRSF1, are involved in 
the 5S RNP-p53 regulatory pathway. I first use a siRNA mediated protein depletion approach 
to validate whether they are essential for the nucleolar stress-induced p53 activation in 
U2OS cells. I further characterise the importance of SRSF1 function in regulating p53 activity, 
using the kinase inhibitor compound SRPIN340. Eventually I report evidence showing SRSF1 
function is related to p53 activation via the 5S RNP.  
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3.2 Results 
3.2.1 HEXIM1, Mybbp1a, B23 and NML protein levels were depleted by siRNA 
treatment in U2OS cells  
I first validated the effect of siRNAs on depleting cellular protein levels of HEXIM1, Mybbp1a, 
B23 and NML human osteosarcoma (U2OS) cells. Actinomycin D (ActD) was applied to cells 
to block ribosome biogenesis and to induce 5S RNP accumulation. ActD is an anti-cancer 
compound that has been widely used in research. High doses (30 nM or above) of ActD in 
human tissue culture inhibit RNA Pol II and Pol I function and induce DNA double strand 
breaks promoting transcription blockage. Low doses (below 30 nM) of ActD specifically 
inhibit RNA Pol I activity and do not induce DNA damage (Sobell, 1985). RNA Pol I inhibition 
caused by a low dose of ActD abolishes pre-rRNA transcription, disrupting small and large 
ribosomal subunit production which results in non-ribosomal (free) 5S RNP accumulation 
(Donati et al., 2013; Sloan et al., 2013a). Low dose ActD treatment has been commonly used 
in tissue culture to study the 5S RNP-p53 signalling pathway.   
siRNAs targeting the mRNA of each protein of interest (siHEXIM1, siMybbp1a, siNML and 
siB23) were transfected to U2OS cells for 48 hours, in the presence or absence of 5 nM of 
ActD during the last 18 hours of culturing. To validate the efficiency of the siRNA on protein 
knockdown, whole cell lysates were separated by SDS-PAGE and the targeted proteins were 
probed by western blotting using protein-specific antibodies. An siRNA targeting firefly 
luciferase protein (siLuc) was used as a control. 
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Result showed that HEXIM1 and Mybbp1a protein levels became undetectable as a result of 
the siRNA treatment (Figure 3.2A and B). A fourfold reduction in B23 levels was also 
observed (Figure 3.2D). Compared to the control, the siRNA targeting NML caused a 
threefold reduction in NML protein levels (Figure 3.2C). The presence of ActD did not affect 
the protein levels of HEXIM1, NML and B23 (Figure 3.2A, C and D). However, ActD resulted in 
a fourfold reduction in Mybbp1a levels (Figure 3.2B).  
3.2.2 B23 protein depletion caused rRNA processing defects in U2OS cells 
Since defects in ribosome biogenesis promote p53 activation, it is important to confirm 
whether these protein candidates are involved in ribosome biogenesis before investigating 
their roles in the 5S RNP-p53 signalling. I therefore used pulse chase labelling to investigate 
whether knocking down any of these proteins affects rRNA processing.  
HEXIM1 and Mybbp1a knockdown and pulse labelling experiments were previously 
performed by Loren Gibson, a former member in the Watkins lab. The results showed that 
Figure 3.2. Protein levels were efficiently depleted using siRNA. 
(A-D) Western blots showing protein levels in U2OS cells that had been treated with 
siRNAs targeting protein candidates (siHEXIM1, siMybbp1a, siNML and siB23), in the 
presence or absence of ActD, as indicated above each lane. siRNAs were transfected for 
48 hours with addition of 5 nM ActD treatment to the cells during the final 18 hours. An 
siRNA targeting firefly luciferase mRNA (siLuc) was used as control. Whole cell lysates 
were separated on SDS-PAGE and proteins were detected by western blotting using 
indicated antibodies. Signals were detected using HRP/chemiluminescent method 
exposed on X-ray films. Karyopherin or fibrillarin protein levels were used as loading 
controls. 
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while HEXIM1 depletion did not affect rRNA production, Mybbp1a protein knockdown 
resulted in increased 47/45S and 32S RNA levels and relative reductions in 28S and 18S RNA 
levels, indicating Mybbp1a is involved in rRNA production (data not shown). Consistent with 
these findings, Hochstatter et al. reported that Mybbp1a is involved in pre-rRNA 
transcription and also RNA processing (Hochstatter et al., 2012).  
To investigate the role of NML and B23 in rRNA processing, U2OS cells were first transfected 
with control siRNA (siLuc) or siRNAs targeting mRNAs of protein candidates (siNML and 
siB23) for 48 hours. Next, cellular phosphate was depleted by culturing cells in phosphate-
free media for one hour. Cells were then cultured for one hour in media containing inorganic 
32P radioactive phosphate. Finally, cells were incubated in normal growth media for a further 
three hours to allow the production of radiolabelled newly synthesised rRNAs. The extracted 
cellular RNAs were separated on an agarose gel before being transferred onto a nylon 
membrane. The signal of the radiolabelled RNAs was visualised using a phosphor imager 
(Figure 3.3B). Total 28S and 18S rRNA levels were analysed by ethidium bromide (EtBr) 
staining and used as loading control. The radioactive RNAs were quantified and normalised 
to the levels of the initial 47/45S precursor RNA (Figure 3.3C-D).  
Compared to the control, NML depletion resulted in a slight increase in newly synthesised 
32S pre-rRNA, 28S and 18S rRNA levels (Figure 3.3C). However, there was no change in the 
relative levels of the mature rRNAs and pre-rRNAs. Since NML binds to histone H3 and 
functions as an rDNA transcription suppressor (Murayama et al., 2008), the increased rRNA 
levels could be due to increased pre-rRNA when NML was knocked down.  
Compared to the control, B23 depletion resulted in a 30% reduction in newly synthesised 
32S pre-rRNA levels. However, there was no change in newly synthesised 28S rRNA levels 
after knocking down B23. Furthermore, there was also a slight reduction in the newly 
synthesised 18S rRNA levels (Figure 3.3D). My results suggest that knocking down B23 
affects 28S rRNA processing because it causes a reduction in 32S pre-rRNA levels  but has no 
effect on 28S rRNA levels, indicating B23 may be involved in 28S rRNA processing.   
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Figure 3.3. B23 depletion resulted in a reduction in 32S pre-rRNA levels in U2OS cells 
whereas NML protein depletion did not change rRNA processing. 
(A) Schematic representation of the human rRNA processing pathway adopted from 
Sloan et al., 2013a. (B) siRNAs targeting the mRNA of NML (siNML) or B23 (siB23) were 
transfected into U2OS cells. siRNA targeting the mRNA of firefly luciferase (siLuc) was 
used as control. 48 hours later, cells were first incubated with phosphate-free media for 
one hour followed by one additional hour incubation with 32P containing media. Cells 
were subsequently grown under normal growth conditions for 3 hours before RNA was 
extracted and separated on a glyoxal-agarose gel and transferred to Hybond-N nylon 
membrane. The 32P radioactive bands were visualised using a phosphoimager (upper 
panel). The total 18S rRNA levels on the membrane were detected with ethidium 
bromide (EtBr) staining (visualised by UV) and used as loading control (lower panel). 
siRNAs used are indicated above each lane, pre-rRNA and rRNA species are indicated on 
the right. (C-D) 32P-labelled pre rRNA levels were quantified using ImageQuant software 
and normalised against the radioactive 47/45S RNA levels. The signal intensity of the 
detected radioactivity from each lane in (B) are quantitated, plotted in a chart and 
presented as fold change relative to the radioactive 47/45S RNA levels.  
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3.2.3 HEXIM1 depletion causes increased p53 activity responding to nucleolar 
stress in U2OS cells.  
HEXIM1 protein is best known as positive transcription elongation factor b (P-TEFb) inhibitor 
which associates with RNA Pol II (Yik et al., 2003; Michels et al., 2004). A study showed that 
HEXIM1 physically interacts with p53 and functions as a positive regulator. HEXIM1 
knockdown was shown to inhibit p53 stabilisation and activation in response to DNA damage 
in MCF7 cells (Lew et al., 2012). They also showed that ActD treatment, which blocks 
ribosome biogenesis, increased association between HEXIM1 and p53 in MCF7 cells (Lew et 
al., 2012). Furthermore, it was also shown that HEXIM1 interacts with MDM2 and is also a 
substrate for ubiquitination by MDM2 (Lau et al., 2009). Since HEXIM1 depletion does not 
affect rRNA processing suggesting it is not involved in ribosome biogenesis (Section 3.2.2), I 
next investigated if HEXIM1 is essential for 5S RNP-p53 signalling.  
To investigate this, I depleted HEXIM1 in U2OS cells and analysed the cellular response to 
ActD-induced p53 activation. U2OS cells were transfected with control siRNA (siLuc) or siRNA 
targeting HEXIM1 (siHEXIM1) for 48 hours before they were treated with ActD during the 
final 18 hours. To evaluate the p53 protein levels and p53 activity, whole cell lysates were 
separated using SDS-PAGE before p53 and p21 protein levels were analysed by western 
blotting. Since ActD treatment had been shown to stabilise and activate p53 through the 5S 
RNP (Sloan 2013), based on the observations of Lew et al. (2012), I hypothesised that 
knocking down HEXIM1 should abolish the ActD-induced p53 activation.  
My result showed that p53 and p21 levels were basically undetectable in control cells or cells 
treated with siRNA targeting HEXIM1 (siHEXIM1, Figure 3.4A). In the presence of ActD, p53 
and p21 levels were significantly increased in control cells (Figure 3.4A-C). Knocking down 
HEXIM1 resulted in a significant reduction in the ActD-induced p53 levels (Figure 3.4B). 
Moreover, compared to the control, HEXIM1 depletion promoted a threefold increase in the 
ActD-induced p21 levels (Figure 3.4C). 
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Since p21 is a downstream transcription target of p53, higher p21 protein levels indicate p53 
is more active. Therefore, the increased p21 levels but reduced p53 levels suggest an overall 
increase in p53 activity as a result of knocking down HEXIM1 protein. Hence, my result 
suggest that HEXIM1 functions as a p53 activity repressor, which contradicts the previously 
reported role as a positive p53 regulator (Lew et al., 2012). This difference could be due to 
cell line variations between MCF7 and U2OS cells (see Section 3.3.1).    
Figure 3.4. HEXIM1 depletion results in p53 reduction and p21 induction. 
SiRNAs were transfected to U2OS cells for 48 hours in the presence or absence of 5 nM 
ActD treatment during the final 18 hours. (A) Whole cell lysates were separated on SDS-
PAGE and proteins were detected by western blotting using the indicated antibodies. 
Signals were visualised by X-ray films. Karyopherin protein levels were used as loading 
control. (B-C) Protein levels were quantified using ImageQuant software (GE Healthcare) 
and normalised against the loading control (α-Karyopherin). Graphs are presented as fold 
change relative to the indicated protein levels (siLuc Act+). Values are presented as 
mean±standard error of three independent experiments (*p<0.05; student’s t-test). 
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3.2.4 Mybbp1a protein depletion does not affect p53 stability but results in 
more active p53  
Mybbp1a is a nucleolar protein that is involved in ribosome biogenesis and is associated with 
RNA Pol I (Hochstatter et al., 2012). A recent study showed that it is necessary for p53 
activation through p53 acetylation during nucleolar stress (Kuroda et al., 2011; Ono et al., 
2013). Since Mybbp1a is involved in ribosome biogenesis and also p53 signalling, I was 
interested to determine whether the protein is important for p53 regulation via the 5S RNP.  
To investigate this question, siRNA was used to knockdown Mybbp1a in U2OS cells for 48 
hours. To block ribosome biogenesis, ActD was added to the cells for the final 18 hours. To 
evaluate the p53 protein levels and p53 activity, whole cell lysates were separated by SDS-
PAGE and p53 and p21 protein levels were analysed by western blotting. Fibrillarin protein 
levels were used as loading control.  
The levels of p53 in the untreated control cells were basically undetectable (Figure 3.5A), 
while ActD treatment resulted in a significant induction in p53 levels (Figure 3.5B). The same 
difference in p53 levels was observed in cells with depleted Mybbp1a (Figure 3.5A and B). 
This suggests that Mybbp1a depletion does not affects ActD-induced p53 stabilisation.  
The p21 protein was also undetectable in control cells, and ActD treatment caused a 
significant increase in p21 levels (Figure 3.5A and C). In the absence of ActD, knocking down 
Mybbp1a resulted in a noticeable increase in p21 levels compared to the control (Figure 
3.5C). In the presence of ActD, Mybbp1a depletion caused a three-fold induction in p21 
levels compared to the ActD treated control (Figure 3.5C). Mybbp1a knockdown resulted in 
increased p21 levels in the presence or absence of ActD treatment (Figure 3.5C), indicating 
Mybbp1a depletion increases overall p53 activity.  
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My results showed that Mybbp1a depletion did not stabilise p53, but p21 levels were 
increased in the presence or absence of ActD (Figure 3.5A-C), hence I conclude that 
Mybbp1a depletion results in more active p53. My results, however, contradict the 
published data (Kuroda et al., 2011; Ono et al., 2014) which previously demonstrated that 
Mybbp1a depletion counteracts the ActD-induced p21 level induction in MCF7 cells (Kuroda 
et al., 2011). This could be due to cell line variation between U2OS to MCF7 cells or to the 
different ActD treatment length (8 hours compared to 18 hours) (Kuroda et al., 2011; Ono et 
al., 2014).  
Figure 3.5. Mybbp1a depletion alters p53 activity but not stability. 
SiRNAs were transfected to U2OS cells for 48 hours in the presence or absence of 5 nM 
ActD treatment during the final 18 hours. (A) Whole cell lysates were separated on SDS-
PAGE and proteins were detected by western blotting using the indicated antibodies. 
Signals were visualised by X-ray films. Fibrillarin protein levels were used as loading 
control. (B-C) Protein levels were quantified using ImageQuant software (GE Healthcare) 
and normalised against the loading control levels (α- Fibrillarin). Graphs are presented as 
fold change relative to the indicated protein levels (siLuc Act+). Values are presented as 
mean±standard error of four independent experiments (**p<0.01; Mann-Whitney U test).  
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3.2.5 NML depletion results in higher p53 activity  
Nucleomethylin (NML; also known as RRP8) was identified as a component of the energy-
dependent nucleolar silencing complex (eNoSC). As a methyltransferase, it methylates RNAs 
and it is also found to be involved in histone remodelling and suppressing rDNA transcription 
under glucose starvation (Murayama et al., 2008). A recent study showed that NML is 
involved in p53 activation during glucose starvation-induced nucleolar stress (Kumazawa et 
al., 2011; Yang et al., 2013). I was therefore interested to find out whether NML is linked to 
p53 activation through the 5S RNP-p53 pathway in response to nucleolar stress.  
SiRNA targeting NML mRNA was used to knockdown NML protein levels in U2OS cells for 48 
hours. To block ribosome biogenesis ActD was added for the final 18 hours. To evaluate the 
p53 protein levels and p53 activity, whole cell lysates were separated by SDS-PAGE and p53 
as well as p21 protein levels were analysed by western blotting using protein-specific 
antibodies. Fibrillarin protein levels were used as loading control. 
The p53 protein levels were barely detectable and ActD treatment caused a significant 
induction of p53 levels (Figure 3.6A). p21 protein was also undetectable in control cells and 
ActD treatment resulted in a significant induction of p21 levels (Figure 3.6A). In the absence 
of ActD, knocking down NML caused no change in p53 levels, while promoting a fourfold 
increase in p21 levels compared to the ActD-free control (Figure 3.6A-C).  
In the presence of ActD, NML depletion resulted in inconsistent p53 levels, ranging from 30% 
lower to 40% higher than the ActD+ control (observed from two repeated experiments), 
hence more repeat experiments are needed to elucidate the effect of NML depletion on p53 
stability. However, in the presence of ActD, NML depletion resulted in a reproducible 
increase in p21 levels compared to the control (Figure 3.6C), suggesting NML depletion 
promotes p53 activity.  
A recent study reported that NML depletion in HCT116 cells resulted in p53 stabilisation and 
increased p21 levels (Waku et al., 2016). My results indeed showed increased p21 levels 
after NML depletion in U2OS cells which is consistent with the previous study (Kumazawa et 
al., 2011) (Figure 3.6C). However, my work requires further repeat experiments to clarify 
how NML depletion affects p53 stability (Figure 3.6B).  
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Based on previous a study showing that NML is involved in p53 activation in response to 
glucose starvation-induced nucleolar stress (Kumazawa et al., 2011; Yang et al., 2013), I 
hypothesised that NML is involved in p53 activation via 5S RNP. However, my results showed 
that NML depletion causes p21 level induction in the present of ActD. Since p21 protein 
levels indicate the transcription activity of p53, my results suggest that NML depletion 
causes higher p53 activity in response to ActD treatment. If NML was essential for p53 
activation through 5S RNP, NML depletion could counteract the ActD-induced p53 
activation. My result therefore implies that NML is not involved in the 5S RNP-p53 signalling 
pathway.  
Figure 3.6. NML depletion increases p53 activity. 
SiRNAs were transfected into U2OS cells for 48 hours in the presence or absence of 5 nM 
ActD treatment during the final 18 hours. (A) Whole cell lysates were separated on SDS-
PAGE and proteins were detected by western blotting using indicated antibodies. Signals 
were visualised by X-ray films. Fibrillarin protein levels were used as loading control. (B) 
Quantitation of the p53 levels shown in (A). Protein levels were quantified using 
ImageQuant software (GE Healthcare) and normalised against the loading control (α- 
Fibrillarin). Graphs are presented as fold change relative to the indicated protein levels 
(siLuc Act+). Due to inconsistent results, data from a single experiment are presented. 
Refer to result section for further details. (C) p21 levels were quantified as in (B), values 
are presented as mean from two independent experiments.  
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3.2.6 B23 protein depletion caused inconsistent p53 and p21 levels.  
Nucleolar phosphoprotein B23 is a multifunctional protein involved in multiple steps during 
ribosome biogenesis (Lindström, 2011). Mutated B23 mislocates to the cytoplasm in acute 
myeloid leukaemia (AML) cells (Federici and Falini, 2013). B23 has been shown to interact 
with p53 and is involved in p53 stabilisation and activation in response to DNA damage 
stress (Colombo et al., 2002).  
In order to investigate whether B23 is involved in the 5S RNP-p53 signalling pathway, 
knockdown experiments using siRNA targeting B23 protein and ActD treatment were 
performed as described above. However multiple independent experiments showed 
inconsistent results for p53 and p21 protein levels. Due to time constraints I abandoned 
these experiments.  
3.2.7 Knockdown of HEXIM1, Mybbp1a, NML and B23 results in loss of MDMX.  
HEXIM1 and Mybbp1a depletion caused higher p53 activity i.e. increased p21 levels in the 
presence of ActD (Figure 3.4C; Figure 3.5C) and NML depletion also resulted in increased p21 
levels in the presence of ActD (Figure 3.6C). These results are all unexpected and reject my 
hypothesis. To explain the unexpected results, I investigated whether MDMX is involved in 
the increased p53 activity. MDMX is a p53 regulator that forms a dimer with MDM2. 
Although MDM2, is responsible for p53 ubiquitination and degradation, Gilkes et al., 
reported that the p53 response to nucleolar stress requires the degradation of MDMX 
(Gilkes et al., 2006). Therefore, I decided to investigate the effect of depleting HEXIM1, 
Mybbp1a, NML and B23 on cellular MDMX levels.  
siRNAs were transfected into U2OS cells followed by  ActD treatment as described above. 
Whole cell lysates were separated by SDS-PAGE and MDMX protein levels were analysed by 
western blotting.  
Knockdown of HEXIM1, Mybbp1a, NML or B23 resulted in a notable reduction in MDMX 
levels, ranged from 60% to 80%, compared to the siLuc transfected controls (Figure 3.7). 
ActD treatment caused a notable reduction in MDMX levels in the control as well as in cells 
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with depleted proteins (Figure 3.7A and B). Quantitation analysis showed that, comparted to 
the ActD untreated control, ActD treated cells resulted in further MDMX reduction in all 
protein knockdown samples. This suggests that ActD treatment causes a greater reduction in 
MDMX levels than the knock down of these proteins. To investigate whether MDMX 
reduction is linked to the increased p53 activity, I next investigate how MDMX depletion 
affects p53 stability and activity.   
  
Figure 3.7. Depleting HEXIM1, Mybbp1a, NML and B23 causes a reduction in MDMX 
protein levels. 
siHEXIM1, siMybbp1a, siNML and siB23 were used to deplete their targeted proteins. 
These siRNAs were transfected to cells for 48 hours in presence or absence of 5 nM ActD 
treatment during the final 18 hours. Whole cell lysates were separated on SDS-PAGE. 
Proteins were detected using indicated protein-specific antibodies. Fibrillarin protein levels 
were used as loading control. MDMX protein levels were quantified using ImageQuant 
software (GE Healthcare) and normalised against the loading control (α-Fibrillarin). 
Quantitation are presented from the mean of the two independent experiments. Graphs 
are presented as fold change relative to the indicated protein levels. (A) Protein bands 
were visualised using X-ray films and digitalised with an hp professional high-resolution 
scanner. (B) Protein bands were visualised and digitalised using the ImageQuant bioimager 
(CCD camera, GE Healthcare). Independent experiments were repeated twice and the 
average of the consistent results are presented.    
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3.2.8 MDMX depletion causes both p53 stabilisation and activation 
SiRNA targeting MDMX mRNA was used to knockdown MDMX in U2OS cells for 48 hours. 
Half of the cells were treated with ActD during the final 18 hours. Whole cell lysates were 
separated by SDS-PAGE. MDMX, p53 and p21 protein levels were analysed by western 
blotting. MDMX siRNA treatment to U2OS cells resulted in a significant reduction in MDMX 
levels compared to cells treated with the control siRNA (Figure 3.8A). Additionally, in the 
presence of ActD, MDMX levels also became undetectable (Figure 3.8A). p53 protein was 
barely detectable in the untreated control cells (Figure 3.8A).   
In control cells, addition of ActD caused a significant induction in p53 levels (siLuc ActD+, 
Figure 3.8B). In the ActD untreated cells, MDMX depletion also promotes significant increase 
in p53 levels (MDMX siRNA ActD-, Figure 3.8B), but the p53 level is only half the level caused 
by ActD treatment (siLuc ActD+, Figure 3.8B).  
In cells with MDMX depletion ActD treatment resulted in a threefold increase of p53 levels 
compared to untreated controls (MDMX siRNA ActD+, Figure 3.8B). The observed  level is 
about 1.5 times higher than the one seen in the ActD treated control cells (siLuc ActD+, 
Figure 3.8B). My results showed that p53 stabilisation is promoted by either MDMX 
depletion or ActD treatment, however, ActD results in higher p53 levels than MDMX 
depletion. My results therefore suggest that MDMX depletion is not the only factor causing 
ActD-induced p53 stabilisation in U2OS cells.  
p21 protein was basically undetectable in control cells (Figure 3.8A). In these cells, the 
addition of ActD resulted in a noticable increase in p21 levels (siLuc ActD+, Figure 3.8C).  
After depleting MDMX there was also a significant increase in p21 levels (MDMX siRNA 
ActD-, Figure 3.8A), which is comparable to the increase seen in the ActD treated control 
cells (siLuc ActD+, Figure 3.8A). Moreover ActD treatment of the MDMX depleted cells 
resulted in a twofold increase in p21 levels, compared to the ActD treated control cells 
(MDMX siRNA ActD+, Figure 3.8C). However, this change in p21 levels was not significant 
compared to ActD untreated cells with MDMX depleted (MDMX siRNA ActD-, Figure 3.8A). 
MDMX depletion resulted in increased p21 levels regardless of the presence of ActD, 
suggesting MDMX depletion indeed activates p53. 
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It had been reported that MDMX degradation was caused by ActD treatment in U2OS cells 
(Gilkes et al., 2006). Gilks et al. also showed that MDMX degradation is essential for p53 
activation in response to ActD. My result showed that MDMX depletion increases ActD-
induced p53 activation, which is consistent with the published findings. Additionally, from 
my result also indicate that a loss of MDMX also enhances p53 stability. In conclusion, my 
result showed that MDMX depletion causes both p53 stabilisation and activation.  
I hypothesised that HEXIM1, Mybbp1a and NML protein were involved in the 5S RNP-p53 
signalling pathway. However, my results do not support my initial hypothesis,  some of them 
even contradict published findings (REF). Consequently, it is more likely that the investigated 
Figure 3.8. MDMX depletion enhances p53 stabilisation and increases p53 activity. 
(A) MDMX siRNAs were transfected into U2OS cells for 48 hours in presence or absence of 
5 nM ActD treatment during the final 18 hours as indicated above each lane. Whole cell 
lysates were separated on SDS-PAGE. Proteins were detected using the indicated protein-
specific antibodies,  as indicated. Proteins were visualised using X-ray films. The 
karyopherin protein levels were used as loading control. (B-C) p53 and p21 protein levels 
were quantified using ImageQuant software (GE Healthcare) and normalised against the 
loading control (α-Karyopherin). Graphs are presented as fold change and normalised to 
the siLuc ActD+ sample. Values are presented as mean ± standard error of three 
independent experiments (*p<0.05, **p<0.01; Student's T test). 
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proteins are involved in p53 regulatory pathways that are independent of 5S RNP (see 
discussion Section 3.3.1). I therefore decided to focus on investigatingprotein factor SRSF1.  
3.2.9 Recombinant SRSF1 binds to both RPL11 and RPL5 in vitro 
It was previously shown that SRSF1 interacts with RPL5 and stabilises p53 via RPL5 in 
response to nucleolar stress (Fregoso et al., 2013). Unpublished data from the Watkins lab 
further demonstrated that SRSF1 depletion counteracts ActD- induced p53 activation (Loren 
Gibson, unpublished data). Furthermore, SRSF1 depletion resulted in free 5S RNP 
accumulation and affected the localisation of 5S RNP components. Lauren Gibson proposed 
a model that SRSF1 protein functions as a chaperone during the 5S RNP assembly and is 
essential in 5S RNP-p53 signalling in response to nucleolar stress.  
To further characterise SRSF1, I first investigated the interaction between SRSF1, RPL5 and 
RPL11 using recombinant proteins. Compared to the wild type, the recombinant His-tagged 
SRSF1 construct lacks the RS domain, since E. coli lacks human kinase that phosphorylates 
the RS domain leading to insoluble protein products (Figure 3.10A) (Gallego et al., 1997). The 
protein Tip48, an ATPase and a pre-snoRNP complexes component, does not bind RNA as 
previously shown in the lab. Tip48 was therefore used as a negative control in these 
experiments.  
Recombinant proteins, either GST-tagged (RPL5, RPL11 and Tip48) or His-tagged (SRSF1), 
were over-expressed in E. coli and purified, before being analysed by coomassie stained SDS-
PAGE. The intensity of the stained protein bands was quantified and used as a loading 
control for the pull-down experiments (Figure 3.10B). To investigate the interaction between 
SRSF1 and the 5S RNP in vitro, equal amounts of GST-tagged RPL5, RPL11 or Tip48 were 
incubated individually with an equal amount of His-SRSF1 at 4 °C for 5 hours before 
purification with glutathione sepharose resin. Resins were subsequently washed and the 
bound material was denatured and separated by SDS-PAGE and analysed by western 
blotting. Bound SRSF1 was revealed using anti-polyHis antibody. 50% of His-SRSF1 input 
levels were used as a positive control. 
 67 
In the pull- down experiment results, His-SRSF1 was detected in the bound material from 
both GST-tagged RPL5 and RPL11 (Figure 3.10C). The levels of His-SRSF1 bound to RPL11 was 
noticeably higher than to RPL5. There were barely detectable His-SRSF1 levels interacting 
with the control protein Tip48, suggesting the interaction is non-specific (Figure 3.10C). 
These results suggest that SRSF1 interacts with both ribosomal proteins and may have a 
higher affinity to RPL11 than RPL5 in vitro. This evidence provides support to the ‘chaperone’ 
model previously proposed by Loren Gibson suggesting that SRSF1 is involved in the 5S RNP 
assembly (see Section 3.3.2).  
Figure 3.9. SRSF1 interacts with RPL11 and RPL5 in vitro. 
(A) Schematic representation of the domain composition of wild type and recombinant 
His-SRSF1. (B) Affinity-tagged proteins expressed in E. coli BL21 strains were purified using 
GST or Ni resin. Yield and quality of the eluted product were analysed by SDS-PAGE and 
stained with coomassie. The molecular weight for these recombinant proteins are: GST-
RPL5 (60 kDa), GST-RPL11 (46 kDa), His-SRSF1 (28 kDA) and GST-Tip48 (77 kDa). (C) GST-
tagged RPL5, RPL11 and Tip48 were incubated with His-SRSF1 in vitro before pull- down 
by glutathione sepharose resin. The eluate was separated by SDS-PAGE before western 
blotting using an anti-PolyHis antibody to confirm the interaction with His-SRSF1. Tip48 
protein was used as a negative control. 
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3.2.10 Splicing inhibitor SRPIN340 reduces ActD-induced p53 activation in a 
dose dependent manner 
I next investigated how SRSF1 function is involved in 5S RNP-p53 signalling. It has been 
reported that SRSF1 is highly phosphorylated which controls the function and localisation of 
SRSF1 (Gonçalves et al., 2015). The serine/arginine-rich protein-specific kinase (SRPK) is one 
of the kinases responsible for the phosphorylation of SRSF1, and SRPK phosphorylates SRSF1 
specifically on multiple serine residues located in the RS domain (also known as the 
arginine/serine rich region) of the protein (Ma et al., 2008; Giannakouros et al., 2011).  
SRPIN340 is a specific chemical inhibitor of SRPK. Inhibition of SRPK blocks phosphorylation 
of SRSF1 and subsequently affects SRSF1 function (Gammons et al., 2013). Therefore, I 
decided to use SRPIN340 to further investigate how SRSF1 function links to the 5S RNP-p53 
signalling via phosphorylation of the protein.  
In order to investigate how different doses of SRPIN340 affect the ActD-induced p53 activity, 
U2OS cells stably expressing a p53-driven firefly luciferase reporter were treated with 5 nM 
ActD in combination with different concentrations of SRPIN340 (0 to 20 µM). Subsequently, 
p53 activity was analysed by measuring luciferase levels in the whole cell lysate using a 
luminometer. Total protein concentration in each sample was determined by Bradford assay 
and used as an input control.  
First, cells treated with 5 nM ActD only (0 µM SRPIN340) were referred as 100% (control). As 
SRPIN340 dose increased, the luciferase levels decreased linearly in the ActD treated cells 
(Figure 3.11). A SRPIN340 dose of 5 µM resulted in 20% reduction of cellular luciferase levels 
compared to cells treated with only ActD. 10 µM SRPIN340 caused 50% luciferase reduction 
compared to the control. 20 µM SRPIN340 resulted in luciferase levels lower than 10% 
compared to the control.  
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My result showed that the ActD-induced p53 activation was inhibited by the SRPIN340 
treatment in a dose dependent manner in U2OS cells. Since SRPIN340 prevents SRSF1 
phosphorylation by SRPK, it implies that SRSF1 phosphorylation is important in p53 
activation in response to nucleolar stress. Moreover, SRPIN340 had a significant effect on 
cell survival. I therefore used 10 µM SRPIN340 in later experiments to reduce the impact of 
SRPIN340 on cell survival.  
  
Figure 3.11. ActD-induced p53 activity is inhibited by SRPIN340 in a dose dependent 
manner. 
U2OS cells expressing a p53-driven firefly luciferase reporter was treated with 5 nM ActD 
and a range of SRPIN340 concentrations (0 to 20 µM) for 12 hours. Luciferase levels in the 
whole cell lysate were measured by the single-tube luminometer with supplement of 
luciferase assay substrate (Promega). The signal was normalised to total protein 
concentration of the sample measured using Bradford assay. Cells treated with 5 nM ActD 
was referred as 100% control and experimental data (mean from two repeated 
experiments) was plotted relative to these control levels. A linear trend line was generated 
from the experimental data using Microsoft Excel. 
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3.2.11 SRPIN340 inhibits ActD-induced p53 activation and stabilisation 
Since blocking SRSF1 phosphorylation with SRPIN340 inhibits p53 activation in response to 
ActD treatment in a dose dependent manner, I next decided to investigate whether this 
effect observed was specific to 5S RNP-mediated activation of p53. I also investigated 
whether SRPIN340 affects p53 stability.   
Nutlin-3a (Nut3a) which inhibits the interaction between MDM2 and p53 was used as a 
control to ActD treatment, allowing me to determine if SRPIN340 affects p53 specifically via 
5S RNP. Nut3a causes p53 stabilisation by counteracting negative p53 regulation by 
inhibition of MDM2. Hence, in contrast to ActD, MDM2 activates p53 in a 5S RNP-
independent manner. 
U2OS cells stably expressing p53-driven luciferase were used. They were treated with 2.5 
µM Nut3a or 5 nM ActD for 12 hours, in the presence or absence of 10 µM SRPIN340. 
Luciferase levels were measured using a luminometer by supplying whole cell lysates with 
luciferase substrate. The signal was normalised to total protein concentration measured by 
the Bradford assay.  
Treating cells with SRPIN340, in the absence of ActD or Nut3a, had no effect on luciferase 
levels and therefore, no change in p53 activity (Figure 3.12A). Addition of ActD resulted in an 
eight-fold increase in luciferase levels. This increase was not seen in cells treated with 
SRPIN340 (Figure 3.12A).  
Similarly, addition of Nut3a to these cells resulted in a fivefold increase in luciferase levels. 
However, compared to cells treated with SRPIN340 alone, the Nut3a treatment-induced 
luciferase change was not statistically significant (Figure 3.12A). The high variation in 
luciferase levels in the cells treated with a combination of Nut3a and SRPIN340 meant these 
result are unconclusive and repeated experiments are needed. In conclusion, my results 
show that SRPIN340 inhibits ActD-induced p53 activation, however more experiments are 
needed to elucidate whether this effect is ActD specific.  
I also investigated p53 and p21 levels in these cells, to test if SRPIN340 affects p53 stability. 
To evaluate p53 protein levels and p53 activity, whole cell lysates prepared from U2OS cells 
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stably expressing p53-driven luciferase reporter were separated by SDS-PAGE and p53 and 
p21 protein levels were analysed by western blotting. Karyopherin protein levels were 
Figure 3.12. SRPIN340 inhibits ActD-induced p53 activation 
U2OS cells expressing p53-driven luciferase reporter were incubated in media containing 
2.5 µM Nut3a or 5 nM ActD, in the presence or absence of 10 µM SRPIN340 for 12 hours. 
(A) Luciferase levels in the whole cell lysate were measured using the single-tube 
luminometer with supplement of luciferase substrate (Promega). The signal was 
normalised to the total protein concentration of the sample measured using Bradford 
assay. The graph is presented as fold change relative to the control treatment level. Values 
are presented as mean ± standard error of three independent experiments. *p<0.05, 
**p<0.01; Student's T test. Non-significant difference is indicated as n.c. (B) p53 and p21 
protein levels were analysed using western blotting. Whole cell lysates were separated on 
SDS-PAGE. Proteins were detected using indicated protein-specific antibodies. Protein 
were visualised using ECL methods and the ImageQuant bioimager (CCD camera, GE 
Healthcare). Karyopherin protein levels were used as loading control. (C-D) p53 and p21 
protein levels were quantified using ImageQuant software (GE Healthcare) and normalised 
against the loading control (α-Karyopherin). Graphs are presented as fold change relative 
to the indicated protein levels. Results are consistent in repeated experiments. Presented 
quantitation is from one representative experiment. 
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analysed likewise and used as loading control. However, due to toxicity of the combination 
treatment of Nut3a and SRPIN340, cell numbers were greatly reduced. As a consequence, 
there was insufficient protein material to allow  conclusive results to be observed from these 
samples. Therefore, the Nut3a treated samples were excluded from this section.  
The SRPIN340 only treatment of the cells did not stabilise p53 compared to the control, but 
it caused a two to three-fold increase in p21 levels (Figure 3.12 C, D). The combination of 
ActD and SRPIN340 treatment resulted in a five-fold reduction in p53 levels compared to the 
ActD only treatment (Figure 3.12C), whereas it only caused slight reduction in p21 levels 
(Figure 3.12D).  
Taken together, I conclude that SRPIN340 inhibits both ActD-induced p53 activation and 
stabilisation. However, as the combination treatment of these drugs affects cell survival, it 
causes protein levels to be insufficient for protein analysis in the samples. Hence in the 
further experiment, method development should focus on use less dose of drug and 
improve the protein detection in order to generate more reliable data. 
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3.3 Discussion and future work   
3.3.1 HEXIM1, Mybbp1a and NML are not required for the 5S RNP-
mediated p53 signalling in U2OS cells  
In this chapter, I aimed to characterise protein factors HEXIM1, Mybbp1a and NML, 
and their involvement in the 5S RNP mediated-p53 regulatory signalling. Previously 
they all have been reported in the literature to be important in activating p53 in 
response to DNA damage (HEXIM1; (Lew et al., 2013)), ActD treatment (Mybbp1a; 
(Kuroda et al., 2011)) or glucose starvation (NML; (Kumazawa et al., 2011)). Based on 
their published data, I hypothesised that they are important in 5S RNP-induced p53 
activation.  
Using siRNA mediated-protein depletion, I tested if their depletion in U2OS cells affects 
the p53 activation in response to ActD treatment. However unexpectedly, I observed 
that knocking down any of these proteins in U2OS cells results in upregulated p21 
protein levels in response to ActD treatment. 
Low doses of ActD treatment promote p53 activation specifically through 
accumulation of the non-ribosomal 5S RNP (Donati et al., 2013; Sloan et al., 2013a). 
p53 stabilisation is mainly achieved by inhibiting the MDM2 ubiquitination function on 
p53 which targets p53 for proteasome-mediated degradation. Non-ribosomal 5S RNP 
interacts with the acidic domain of MDM2, which inhibits its E3 ubiquitin ligase activity 
(Golomb et al., 2014). This results in p53 stabilisation and activation as a transcription 
promoter, binding to p53 responsive elements in the DNA. p21 protein is encoded by 
the CDKN1A gene, which is controlled by the transcriptional activation of p53 (Section 
3.1). As one of the most important downstream factors, the cellular protein levels of 
p21 is commonly used as a read-out of p53 activity. Therefore, the increased p21 levels 
in my results suggest that depletion of HEXIM1, Mybbp1a or NML in U2OS cells 
resulted in higher p53 activity in response to ActD treatment.  
Since depletion of essential protein factors in the 5S RNP-mediated p53 pathway 
would counteract the ActD effect on p53 activation, I concluded that these proteins 
are not needed in the 5S RNP-mediated p53 signalling pathway, which does not 
support my hypothesis.   
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HEXIM1 
(regulates transcription) 
Mybbp1a 
(repress rRNA transcription) 
NML 
(regulates pre-rRNA 
transcription) 
published data 
 
30 nM ActD on MCF7 cells: 
⬆ HEXIM1/p53 association 
KD in MCF7 cells: 
⬇ p53 activation upon ActD 
KD in WI-38 cells: 
⬇p53 ⬇p21 upon glucose 
starvation 
 
KD in MCF7 cells: 
⬇p53 activity on DNA 
damage 
reference 
(Lew et al., 2012) (Kuroda et al., 2011) (Kumazawa et al., 2011) 
experimental result 
U2OS p53 p21 p53 p21 p53 p21 
KD 
ActD- 
N/A N/A n.c. ⬆10x n.c. ⬆3x 
KD ActD+ ⬇1/3 ⬆3x n.c. ⬆3x ⬇1/4 ⬆20% 
MDMX  ⬇ ⬇ ⬇ 
Table 3.1. Summary of the published data and my experimental result for HEXIM1, 
Mybbp1a and NML. 
 (N/A: not detectable level; n.c.: no change; ⬆ increased in level; ⬇ reduced in level) 
Lew et al. (2012) demonstrated that treatment with 30 nM ActD promotes p53-
HEXIM1 interaction in MCF7 cells. They also showed that knockdown HEXIM1 
counteracts the doxorubicin or flavopiridol-induced p53 stabilisation and activation 
(Lew et al., 2012). My result showed that HEXIM1 depletion results in 40% less of 
stable p53 in response to ActD treatment but three times more p21 (Figure 3.4), 
suggesting HEXIM1 is needed to stabilise p53 during nucleolar stress, which is 
consistent with previous Lew’s findings. However, I could not show HEXIM1 depletion 
counteracts the ActD-induced p53 activation as predicted, which suggests HEXIM1 
could be selectively involved in DNA damage response signalling.  
Doxorubicin is a DNA damage inducing compound and flavopiridol inhibits P-TEFb 
function promoting mRNA transcription blockage. On the other hand, ActD induces 
nucleolar stress. My results in conjunction with the published studies suggest that 
HEXIM1 is involved in p53 activation specifically induced by DNA damage, but not by 
nucleolar stress. It also implies that p53 activity may be differentially regulated in a 
stress-dependent manner.  
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p53 activity is determined by its modification status, such as acetylation and 
phosphorylation, and it has been demonstrated that in response to DNA damage 
signals, phosphorylation of serine 15 and serine 20 regulate p53 by affecting the 
MDM2/p53 interaction (Lakin and Jackson, 1999). Unfortunately, the modifications of 
p53 directly linked to a response to nucleolar stress remain unknown. Therefore, it is 
possible that HEXIM1 mediated p53 regulation depends on modifications triggered in 
response to a DNA damage signal but not to a nucleolar stress signal.  
Kuroda et al. (2011) demonstrated that Mybbp1a depletion counteracts the ActD-
promoted p21 induction in MCF7 cells (Kuroda et al., 2011), suggesting the protein is 
needed for p53 activation in response to ActD in these cells. However, I could not 
reproduce the result previously demonstrated by Kuroda using U2OS cells. In contrary, 
my result showed that Mybbp1a depletion caused an opposite effect on p21 levels. 
Since Kuroda et al. (2011) have only tested HEXIM1 in MCF7 cells whereas U2OS cells 
were used in my work, the difference in results could also be due to the different cell 
types.  
Although both U2OS and MCF7 cells express wild type p53, both cell lines have highly 
altered chromosomes with hypertriploid to hypotetraploidy range chromosome counts 
(ATCC database). These uncontrollable differences may cause them to respond 
differently to particular drugs. Hence ActD treatment in MCF7 cells should be used to 
clarify the discrepancy in future investigations.  
My result also showed that in the absence of ActD, depleting Mybbp1a or NML in 
U2OS cells caused p21 level induction, tenfold or threefold respectively, without 
causing p53 stabilisation. This suggests that these proteins could mediate p53 activity 
but may not be involved in regulating p53 stability. In order to understand the 
unexpected results better, I further investigated the involvement of MDMX, one of the 
p53 negative regulator, in the ActD-induced p53 activation.  
My subsequent results demonstrated that depleting Mybbp1a or NML promotes 
MDMX reduction (Section 3.2.7), and I also demonstrated that MDMX depletion 
results in p53 stabilisation and activation in U2OS cells (Section 3.2.8). MDMX 
functions as a negative p53 regulator which inhibits p53 activity by directly blocking its 
transactivation domain. It also dimerises to MDM2 which enhances the MDM2-
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mediated ubiquitination and degradation of p53 (Section 1.3.2, Chapter 1). Therefore, 
it is possible that Mybbp1a or NML depletion promotes p53 activation via reducing 
MDMX levels.  
However, the association between Mybbp1a or NML depletion and MDMX level 
reduction remains unclear. Both these co-factor proteins are nucleolar proteins linked 
to rDNA transcription repression. Mybbp1a associates with RNA Pol I and it represses 
rDNA transcription (Section 1.5.3, Chapter 1) and NML helps recruiting other protein 
factors resulting in histone methylation and deacetylation which inhibits rDNA 
transcription (Section 1.5.4, Chapter 1). Hence, it is possible that knocking down either 
of the protein results in misregulated rDNA transcription, which causes a stress signal 
resulting in p53 activation and p21 level induction.  
3.3.2 SRSF1 could facilitate RPL11 recruitment during 5S RNP assembly  
Given that the results could not establish a link between HEXIM1, MYBBP1A and NML 
and p53 signalling through 5S RNP, I subsequently focused on characterising the 
involvement of splicing factor SRSF1 in both 5S RNP assembly and 5S RNP-p53 
signalling.  
SRSF1 has been previously shown to interact with the 5S rRNA in BJ-TT cells (Fregoso et 
al., 2013). Loren Gibson, a past member of the Watkins Lab, further confirmed that 
SRSF1 interacts with RPL5 and the 5S rRNA in U2OS cells (data unpublished). It was 
also demonstrated that SRSF1 depletion reduced RPL11 levels in the cytoplasm and 
decreased RPL5 levels in the nucleolus in U2OS cells, suggesting SRSF1 is required for 
5S RNP assembly (Gibson, data unpublished). Dr Gibson therefore proposed that SRSF1 
is involved in 5S RNP assembly functioning as a chaperone, facilitating the recruitment 
of RPL11 to the 5S rRNA/RPL5 complex during the 5S RNP assembly process.  
In this work I demonstrated that recombinant SRSF1 interacts with both RPL11 and 
RPL5 in vitro (Figure 3.10C). My result confirmed the association between SRSF1 and 
RPL11, supporting the proposed role of SRSF1 in 5S RNP assembly. Since it showed that 
noticeably more RPL11 is pulled down by SRSF1 than RPL5, my result suggests that 
SRSF1 could have a higher affinity to RPL11 than that to RPL5. It is not yet clear why 
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SRSF1 has higher affinity for RPL11 than RPL5. One explanation could be that SRSF1 
functions as a chaperone which binds to and stabilises RPL11 during the 5S RNP 
assembly.  
Since RPL11 is produced in excess and the unbound molecules are degraded by the 
proteasome (Lam et al., 2007), high SRSF1 binding affinity to RPL11 could help 
stabilising RPL11. It was also shown that RPL11 recruitment to the 5S RNP is a rate 
limiting step during the LSU production (Sloan et al., 2013a), therefore SRSF1 may also 
facilitate the recruitment of RPL11 to the 5S rRNA/RPL5 complex, ensuring the 
efficiency of the 5S RNP assembly. In addition, since the recombinant His-tagged SRSF1 
protein lacks the RS domain, my result further suggests this domain is not required for 
the interaction between SRSF1 and these 5S RNP components.  
3.3.3 SPRIN430 affects p53 stability and p53 activity in response to ActD 
and Nutlin 3 treatment.  
SRSF1 is a highly phosphorylated protein and its phosphorylation determines its 
functions (Gonçalves et al., 2015). SRPK is one of the kinases responsible for the 
phosphorylation of SRSF1 and SRPIN340 is a kinase inhibitor specifically targeting 
SRPK. It has been proposed that SRSF1 is also important in p53 activation via the 5S 
RNP (Fregoso et al., 2013), I therefore investigated, using the kinase inhibitor 
SRPIN340, whether SRSF1 function is involved in the 5S RNP-p53 signalling pathway.  
SRPIN340 is a selective inhibitor only specific to SRPK1 and SRPK2, but not to Clk1 and 
Clk4 (database: Selleckchem; caymanchem). Its specificity for inhibiting SRPK2 is found 
to be 10-fold less than that for SRPK1 (Fukuhara et al., 2006). SRPK1 targets selectively 
on SR protein family which includes SRSF1 (Ghosh and Adams, 2011). Compared to 
SRSF1, the SRPK1 function on other members in SR family is less understood. Hence 
SRPIN340 affects selectively to SRSF1 via specifically inhibiting SRPK1. 
I first showed that in U2OS cells, blocking SRSF1 phosphorylation by SRPIN340 
treatment inhibits p53 activation in response to ActD treatment in a dose dependent 
manner, suggesting SRSF1 phosphorylation could be important in the 5S RNP-p53 
signalling pathway (Figure 3.11).   
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My result also showed that SRPIN340 treatment significantly reduces ActD-induced 
p53 activation, whereas it does not affect p53 activity in response to Nutlin3a 
treatment (Figure 3.12). Because Nutlin3a treatment stabilises and activates p53 via 
dissociating the MDM2/p53 interaction, my results imply that the SRPIN340 effect on 
counteracting p53 activation could be specific to nucleolar stress. I also demonstrated 
that ActD-induced p53 stabilisation was inhibited by SRPIN340 treatment in these cells 
(Figure 3.12). However, more future repeats of these experiments are required to fully 
address the SRPIN340 effect on p53 stability.  
It has been shown that the SRPK1-mediated phosphorylation of the RS domain of 
SRSF1 is essential for its nuclear localisation (Lai et al., 2001; Cazalla et al., 2002). 
Therefore, it is likely that SRPIN340 keeps SRSF1 in a non-phosphorylated state, which 
cannot be translocated into the nucleus and accumulates in the cytoplasm. 
Accordingly, in my experiments, SRPIN340 may have caused depletion of nuclear 
SRSF1 in U2OS cells. In support of these results, it has been demonstrated that 
SRPIN340 blocks the insulin-like growth factor 1 (IGF-1) induced-nuclear localisation of 
SRSF1 in epithelial cells (Nowak et al., 2010).  
SRSF1 has been proposed to be important for the 5S RNP-p53 signalling. If SRPIN340 
results in nuclear depletion of SRSF1, my results imply that a physical interaction 
between SRSF1 and the 5S RNP may be required for activating p53 in the nucleus. The 
requirement for a physical interaction between SRSF1 and the 5S RNP may also 
provide an explanation for the loss of stable p53 when treating cells with SRPIN340 
and ActD (see Chapter 5). Therefore, in the future investigations, immunofluorescence 
could be used to confirm the SRPIN340 effect on the cellular localisation of SRSF1.  
3.3.4 Future work   
In this chapter I provided evidence showing HEXIM1, Mybbp1a and NML are not 
essential for the 5S RNP-mediated p53 signalling pathway. I also aimed to characterise 
the involvement of nucleolar protein B23 in this pathway, however due to inconsistent 
data no conclusive results could be shown. Because evidence suggested that B23 is 
important for p53 stabilisation and activation in response to cellular stress (Section 
1.5.5), future investigation in its involvement in the 5S RNP-p53 pathway would be of 
interest. This could include repeating the experiment of B23 depletion and test how it 
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affects Actinomycin D-induced p53 and p21 levels in U2OS cells. Furthermore, the 
same workflow could be applied on U2OS cells expressing the p53-driven luciferase 
reporter to measure the p53 activity directly.  
Moreover, this work also provided evidence supporting the ‘chaperone’ role of SRSF1 
in the 5S RNP assembly, which was previously proposed by Loren Gibson in the 
Watkins Lab (Section 3.3.2). My results also suggested that phosphorylation of SRSF1 is 
important in regulating p53 activity in response to ribosomal stress. However, the dose 
of SRPIN430 and/or treatment time on U2OS cells should be reduced in future 
experiments, in order to minimise cell loss during the experiment (Section 3.2.11).  
Future investigations should also focus on characterising the effect of splicing inhibitor 
SPRIN430 on SRSF1. For example, immunofluorescence could be used to confirm 
whether SPRIN430 treatment affects cellular localisation of SRSF1. 
Finally, further studies should be carried out using SPRIN430 in optimised experiments, 
to elucidate whether SRSF1 phosphorylation affects specifically the 5S RNP-p53 
signalling pathway (see Chapter 5).  
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Chapter 4. Understanding the Role of RPL11 Phosphorylation 
in Regulating Large Ribosomal Subunit Biogenesis and p53 
Signalling 
4.1 Introduction  
4.1.1 The 5S RNP is important in ribosome biogenesis and p53 signalling  
In eukaryotic cells, the mature ribosome consists of the small ribosomal subunit (SSU; 
40S) and the large ribosomal subunit (LSU; 60S). The eukaryotic SSU contains the 18S 
rRNA and about 30 ribosomal proteins (RPs) whereas the eukaryotic LSU contains 28S, 
5.8S, 5S rRNAs and 45 RPs (Gamalinda and Woolford, 2015).  
In humans, ribosome biogenesis starts in the nucleolus, a membrane-less subcellular 
compartment within the nucleus, where rDNA is transcribed into the 47S pre-rRNA by 
RNA Pol I (Mullineux and Lafontaine, 2012). The 47S pre-rRNA undergoes multiple 
cleavage and modification processes. After incorporating to RPs it eventually becomes 
28S and 5.8S rRNA in the LSU, and the 18S rRNA in the SSU (Figure 4.1) (Tafforeau et 
al., 2013a).  
The 5S rRNA, which is 120 nucleotides in length, is transcribed by RNA Pol III in the 
nucleoplasm. Once being produced, it is stabilised by binding to the ribosomal protein 
RPL5, before the RPL5/5S rRNA complex recruits RPL11. The 5S rRNA, RPL5 and RPL11 
together form the 5S RNP which is subsequently integrated into the pre-LSU. The pre-
LSU subsequently undergoes a series of maturation processes becoming the mature 
LSU (Figure 4.1) (Bursać et al., 2012).  
Ribosome biogenesis is linked to the stability and activation of the tumour suppressor 
p53 through the 5S RNP and MDM2 (Chakraborty et al., 2011; Sloan et al., 2013a). In 
response to different cellular stresses, p53 is activated and promotes the expression of 
its downstream regulated genes. Depending on severity and stress type, it leads to 
different cellular responses such as cell cycle arrest, DNA damage repair, apoptosis and 
senescence (Vousden and Prives, 2009). For example, one of the p53-regulated genes 
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is CDKN1A which translates to p21 protein, and p21 expression promotes cell cycle 
arrest (Vousden and Prives, 2009).  
Normally p53 protein is tightly regulated and maintained at a low level in human cells 
by the proteins MDM2 and MDMX (Shadfan et al., 2012). MDM2 functions as an E3 
ubiquitin ligase polyubiquitinating p53 for proteasome mediated degradation (Figure 
4.1). MDM2 and MDMX are highly conserved in their p53 binding domain located at 
the N-terminal and the RING domain located at the C-terminal (Zhang et al., 2011). 
They bind to each other through the RING domain and function as a complex when 
regulating p53 (Chavez-Reyes et al., 2003).  
Figure 4.1. Schematic representation of how the 5S RNP is involved in ribosome 
biogenesis and MDM2-p53 regulatory signalling.  
The pathway of the small and large ribosomal subunit biogenesis is shown on the 
left. 5S RNP biogenesis and integration pathway is shown in the middle. p53 
stabilisation via the 5S RNP-MDM2 pathway was shown on the right. 
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In the event of a ribosome biogenesis defect, free 5S RNP accumulates in nucleoplasm 
where it binds to and inhibits MDM2, causing p53 to be stabilised and activated (Figure 
4.1) (Chakraborty et al., 2011; Sloan et al., 2013a; Pelava et al., 2016).  
4.1.2 RPL11 is important in ribosome biogenesis and 5S RNP-MDM2 
binding  
Ribosomal protein RPL11 plays a vital role in 5S RNP assembly and 5S RNP integration 
into the ribosome. The interaction between RPL11 and the 5S rRNA is important during  
the 5S RNP assembly. It was reported that the R75Q mutation in RPL11 inhibits RPL11-
5S rRNA binding, blocking RPL11 recruitment to the 5S RNP (Horn and Vousden, 2008). 
In addition, RPL11 binding to the RPL5/5S rRNA complex was shown not only to be 
crucial for 5S RNP integration into the ribosome, but also for being a rate limiting step 
during LSU maturation (Sloan et al., 2013a).  
On the other hand, there is emerging evidence to suggest that RPL11 also plays an 
important role in p53 signalling, likely through the interaction between RPL11 and 
MDM2. Firstly, all three 5S RNP components, RPL5, RPL11 and the 5S rRNA interact 
with MDM2, and they are all required for the 5S RNP-p53 signalling (Sun et al., 2010; 
Bursać et al., 2012; Fumagalli et al., 2012; Donati et al., 2013; Sloan et al., 2013a).  
Secondly, mutated MDM2 abolishes 5S RNP-p53 signalling by inhibiting RPL11-MDM2 
interaction. Interactions between RPL11 and MDM2 were first biochemically 
demonstrated in 2003 (Zhang et al., 2003). Since then, the zinc finger domain in MDM2 
has been shown to be crucial for the RPL11-MDM2 interaction. The C305F mutation in 
MDM2, located in the zinc finger domain (Figure 4.2A), was subsequently 
demonstrated to inhibit the interaction between MDM2 and RPL11 (Macias et al., 
2010). Furthermore, the disruption of RPL11-MDM2 interaction caused by this 
mutation also blocks p53 activation in response to nucleolar stress in a mouse model 
(Macias et al., 2010), indicating the importance of RPL11-MDM2 binding in p53 
regulation.  
In addition, amino acid residues in RPL11 are important for the RPL11/MDM2 
interaction. It has been reported that certain basic residues in RPL11, including K52, 
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R54 and R136, are important for RPL11 binding to MDM2 and also inhibit MDM2 
activity (Zhang et al., 2011).  
4.1.3 Binding sites for MDM2 and the 28S rRNA colocalise in RPL11  
A most recent piece of evidence supporting the important role that RPL11 plays in 
both ribosome biogenesis and p53 signalling, was reported by Zheng et al. in 2015. The 
structure of the human RPL11 associated with a short peptide fragment of human 
MDM2 (E293 to K334) has been resolved at 2.4 Å (Zheng et al., 2015). Firstly, this work 
revealed that binding to RPL11 causes a conformational change in MDM2. In addition, 
the structural comparison of the MDM2 peptide bound on RPL11 with the 28S rRNA 
structures from T. thermophiles (PDB ID: 4W2E), S. cerevisiae (PDB ID: 4V88) and D. 
melanogaster, revealed a high degree of structural similarity between the bound 
MDM2 peptide and the 28S rRNA structure (Zheng et al., 2015). This finding implies 
that MDM2 competes for the RPL11 binding site with the 28S rRNA which further 
suggests that RPL11 could be important controlling the 5S RNP-p53 signalling via 
MDM2 when ribosome biogenesis defect occurs.  
To further validate this, I first analysed the structural similarity between Zheng’s 
MDM2 peptide-RPL11 structure and the RPL11 that associates the 28S rRNA in the 
human ribosome. The Human 80S ribosome structure was resolved at 3.6 Å and 
published by Khatter et al. in 2015 (PDB ID: EMD-2938). To conduct the structural 
comparison, RPL11 and its associated 28S rRNA structure was isolated from the human 
ribosome (Figure 4.2C). The MDM2 E293-K334 peptide (PDB: 4xxb; Zheng et al., 2015) 
was also isolated and overlaid on the 28S rRNA binding site of human RPL11 structure 
(Figure 4.2B).  
The structural comparison showed a high degree of similarity between the MDM2 
peptide and the 28S rRNA when binding to RPL11 in the ribosome (Figure 4.2B and C). 
In addition, 28S rRNA and MDM2 share the same RPL11 binding interface, except a 
small region of the Zinc finger domain in MDM2 (sticks in blue, Figure 4.2B). This 
suggests that RPL11 could be an important factor determining the 5S RNP integration 
into the LSU, or stabilising and activating p53 through binding to MDM2.  
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RPL11 mutations have also been linked to ribosomopathies. Ribosomopathies are a 
group of genetic disorders associated with impaired ribosome production and 
function, such as Diamond-blackfan anaemia (DBA), 5q syndrome, and Treacher-Collins 
Syndrome (Narla and Ebert, 2010) (see Chapter One for details). DBA, one of the best 
Figure 4.2. MDM2 interacts with RPL11 through its zinc finger domain; MDM2 and 
the 28S rRNA share the same binding interface on RPL11 in the ribosome.  
(A) Schematic representation of protein domains in MDM2. The number of amino 
acid residues are indicated below the representation. p53 binding domain and RING 
finger domains (RING) are shown in grey. Acidic domain and the zinc finger domain 
(Zn) are coloured in cyan and blue respectively. Cysteine 305 (C305) is indicated in 
red. The peptide E293-K334 resolved in the MDM2-RPL11 crystal structure by Zheng 
et al. is indicated with an asterix. (B) Structure of RPL11 (pink, molecular surface, PDB 
ID: EMD-2938, Khatter et al., 2015) bound to MDM2 short peptide E293 to K334 
(represented in sticks), with the acidic domain in cyan and the zinc finger domain 
(Zn) in blue (PDB ID: 4XXB, Zheng et al., 2015). Cystine 305 (C305) is coloured in red 
whereas the Zn ion is coloured in yellow. (C) Structure of RPL11 (pink, molecular 
surface, PDB ID: EMD-2938, Khatter et al., 2015) bound to 28S rRNA (C4237 to C334, 
in blue, shown in sticks, PDB ID: EMD-2938, Khatter et al., 2015). The molecular 
structures were generated using PyMOL.  
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studied ribosomopathies, is a form of inherited congenital bone marrow failure 
syndrome. It is characterised by macrocytic or normocytic anaemia with absence or 
insufficient erythroid precursors in the bone marrow (Gazda et al., 2008; Narla and 
Ebert, 2010; Jaako et al., 2015). In one recent study, DBA was associated to 
abnormalities in nine different ribosomal protein genes in approximately 53% of total 
96 patients. Among them, RPL11 and RPL5 gene mutations were identified in 4.8% and 
6.6% of total patients respectively (Gazda et al., 2008). Furthermore, studies using a 
DBA mouse model suggested that the development of anaemia symptom was 
dependent on the 5S RNP-MDM2 interaction (Jaako et al., 2015). These evidence once 
again implies the importance of 5S RNP-MDM2 interaction in connection with p53 
regulatory signalling.  
4.1.4 Aims and objectives  
Although a number of studies have demonstrated the importance of RPL11 in relation 
to both ribosome biogenesis and the p53 regulation via MDM2, the involvement of 
post translational modification (PTM) in RPL11 function has not been described. There 
are numerous reports identifying RPL11 PTMs, including phosphorylation, acetylation, 
ubiquitination, methylation, neddylation and sumoylation according to the database 
PhosphoSitePlus® (see Section 4.2.1). Given the different functions of RPL11, such as 
binding to and stabilising the RPL5/5S rRNA complex during the 5S RNP assembly, 
associating with 28S rRNA to form the pre-60 large ribosomal subunit and interacting 
with MDM2 to stabilise p53, PTM could play a vital role in these functions.  
In this chapter, I therefore aimed to establish the importance of RPL11 
phosphorylation in ribosome biogenesis and 5S RNP/p53 signalling. I first validate the 
reported phosphorylated residues in RPL11. Thereafter, human cell lines expressing 
RPL11 phospho-mutants are created, and they are used to investigate whether the 
mutant protein affects ribosome biogenesis and the p53 signalling pathway.  
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4.2 Results  
4.2.1 Reported phosphorylated sites in RPL11 are highly conserved 
To start with my investigation, I first focused on the reported RPL11 phosphorylation 
sites in the database PhosphoSitePlus®. Up to the date of writing this thesis, a total of 
eight phosphorylated residues have been in reported in the literature using proteomic 
discovery-mode mass spectrometry (Table 4.1).  
According to the database, the residue which scored the highest number of reports is 
threonine 47 (T47, 29 reports, Table 4.1). One of the recent studies reported the 
phosphorylation on both serine 29 (S29) and serine 51 (S51) using mass-spectrometry-
based proteomic and phosphoproteomic analysis (Mertins et al., 2016). In addition, 
serine 140 (S140) phosphorylation was reported twice (Rigbolt et al., 2011; Luerman et 
al., 2014).  
Site Number of reports 
S29 6 
T44 2 
T47 29 
S51 3 
T73 1 
Y119 1 
S140 2 
Y170 2 
 Table 4.1. Number of reports of each phosphorylated residue in Human RPL11 
identified using proteomic discovery mass spectrometry. (PhosphoSitePlus® 
database, March 2018)  
 
I further aligned RPL11 protein sequences from different eukaryotes, including human, 
mouse, zebrafish, fruit fly, yeast, Tetrahymena and mouse-ear cress, to analyse 
whether these reported phosphorylation sites are conserved in different species. The 
alignment showed that among these eukaryotic RPL11 sequences, S29, S51 and T73 
are highly conserved (Figure 4.3). S140 however, is also conserved but interestingly 
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only among vertebra RPL11 sequences (Human, mouse and zebrafish). In yeast, 
Tetrahymena and plant RPL11, there is an arginine instead of a serine, whereas in fruit 
fly there is an asparagine (Figure 4.3).   
Figure 4.3.Reported phosphorylated sites on RPL11 are highly conserved. 
Multiple sequence alignment of RPL11 protein sequences from different species. 
Serine and threonine residues are highlighted in cyan. Phospho-sites of interest (S29, 
S51, T73 and S140) are indicated above the sequence alignment in bold.   
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4.2.2 Serine 51 interacts with 28S rRNA while threonine 73 and serine 140 
locate close to the 5S rRNA in the ribosome structure  
In mature ribosomes, RPL11 associates with the 5S rRNA of the 5S RNP and it also 
contacts the 28S rRNA from the LSU (see Chapter 1). In addition, Zheng et al. provided 
evidence suggesting MDM2 competes with the 28S rRNA for the same RPL11 binding 
site (Zheng et al., 2015). I therefore decided to investigate whether these 
phosphorylated residues locate to the rRNA binding sites in RPL11.  
I mapped the reported phosphorylated residues on RPL11 using the 60S ribosome 
structure resolved by Khatter et al. (Figure 4.4). Zheng et al. compared the RPL11 
structure with a hand indicating the ‘thumb’, ‘palm’ and ‘fingertips’ (Figure 4.4) (Zheng 
et al., 2015). Firstly, S29 is located in the RPL11 ‘thumb’ region whereas S51 is located 
in the ‘palm’ region (Figure 4.4A). The ‘palm’ region was also reported to be the shared 
interface for RPL11/28S rRNA or RPL11/MDM2 binding (Zheng et al., 2015). In the 
magnified view, the side chain of S51 is in close proximity to the backbone from 
cytosines 4258 and 4259 of the 28S rRNA (Figure 4.4B). Furthermore, T73 and S140 are 
located in the RPL11 ‘fingertip’ region, where the 5S rRNA binds to RPL11 (Figure 4.4A). 
Interestingly, a magnified view locates T73 adjacent to the R75 and a previous study 
showed that a R75Q mutation abolishes RPL11/RPL5 interaction (Horn and Vousden, 
2008). The sidechain of both R75 and T73 share an interaction interface with the base 
of the 5S rRNA (Figure 4.4C). Finally, the magnified view also revealed that the 
sidechain of S140 is in close proximity to the phosphate backbone of the 5S rRNA 
(Figure 4.4D).  
As these highly conserved phospho-sites S29, S51, T73 and S140 are located on key 
regions in RPL11, it is likely that they are involved in ribosome biogenesis and/or 
MDM2-p53 signalling. I therefore decided to investigate how phosphorylation of these 
residues affects both processes.  
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Figure 4.4. Threonine 73 and serine 140 are located close to the 5S rRNA whereas 
serine 51 is located close to the 28S rRNA in the ribosome. 
(A) Reported phosphorylated sites are mapped in the region of RPL11/5S rRNA/28S 
rRNA within the ribosome (PDB ID: EMD-2938; Khatter et al., 2015). RPL11 (in pink) is 
shown as a molecular surface view, with the phospho-sites of interest highlighted in 
yellow. 28S rRNA (blue) and 5S rRNA (white) are shown as sticks. The ‘thumb’, ‘palm’ 
and ‘fingertips’ descriptions are adopted from Zheng et al. (2015). (B-D) Magnified 
view from (A) showing a tight molecular interface (represented in dots) between 
RPL11 (pink) and 28S (blue) or 5S rRNAs (white). The side chain of the 
phosphorylated sites (S51, T73 and S140 in yellow) are represented as sticks. R75 is 
coloured in red. The molecular structures were generated using PyMOL.  
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4.2.3 Creation of inducible U2OS stable cell lines expressing FLAG-tagged 
RPL11 wild type and mutants 
I first created U2OS cell lines stably expressing FLAG-tagged RPL11 wild type (WT) or 
RPL11 mutants in which the phosphorylated amino acid residues were mutated. I 
mutated the RPL11 encoding sequence such that serine (at 29, 51 and 140) was 
changed to an aspartic acid (D) as a negatively charged residue in order to mimic the 
phosphorylated serine side chain. At the same sites, I also replaced the serine to an 
alanine (A) so that the side chain cannot be phosphorylated (denoted phospho-null 
mutant). With the same idea and approach, I mutated the threonine (at 73) into a 
glutamic acid (E) which contains a negatively charged side chain, or to a valine (V) as a 
phospho-null mutant. 
The pcDNA5 plasmid containing the RPL11 cDNA was used as the vector for these 
mutagenesis experiments as it enables the creation of stable mammalian cell lines 
expressing the RPL11 mutants in an inducible manner. A pcDNA5 plasmid containing 
an insert of FLAG-tagged wild type RPL11 has been previously constructed in the lab, 
and it is used as a template for site-directed mutagenesis to create vectors containing 
RPL11 mutants using mutagenesis PCR. The detail of this method is described in 
Section 2.1.4.  
Eight pcDNA5 plasmids containing FLAG-tagged RPL11 mutants S29A, S29D, S51A, 
S51D, T73V, T73E, S140A and S140D were successfully created. I also aimed to create 
phospho-mutants at T47 in RPL11 because the phosphorylation of this threonine 
residue has been reported 29 times in database PhosphoSitePlus®. Unfortunately, 
despite significant time and effort spent, the site-directed mutagenesis PCR did not 
produce plasmids containing the desired sequence.  
U2OS Flp-In™ cells were subsequently used and these plasmids were transfected to 
create inducible U2OS stable cell lines. An induction test was performed with the 
transfected cells by treating them with tetracycline for 48 hours. Cells were then 
harvested and whole cell lysates were separated using SDS-PAGE. FLAG-tagged protein 
levels were analysed by western blotting using the anti-FLAG antibody. U2OS cells 
transfected with the empty pcDNA5 plasmid were used as a control. 
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FLAG-tagged proteins with the expected size were observed in all cell lines created, 
whereas FLAG levels were undetectable in the cells that contain the empty pcDNA5 
control plasmid (Figure 4.5). In cells expressing S51A, S29A and S29D RPL11 mutants, 
FLAG-tagged protein levels were similar to those in WT cells. In contrast, the rest of 
mutant cells showed significantly less FLAG-tagged RPL11 protein, especially for T73V 
(Figure 4.5). This suggests that these mutant proteins may be less stable than their WT 
counterparts.   
Figure 4.5.FLAG-tagged RPL11 mutants were detected in U2OS stable cell lines at 
different levels. 
FLAG-tagged RPL11 wild type or mutant protein levels in U2OS stable cell lines 
were determined by western blotting. U2OS stable cell lines transfected with 
plasmid encoding FLAG-tagged RPL11 wild type or mutants (indicated above the 
panel) were treated with 1 μg/ml tetracycline for 48 hours. Whole cell lysates were 
separated using SDS-PAGE and analysed by western blotting using specific 
antibodies. U2OS cells transfected with empty plasmid were used as control. 
Tubulin levels were determined and used as loading reference. Antibodies used are 
indicated to the left of each panel.  
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4.2.4 FLAG-tagged RPL11 mutants associate with the 5S and 5.8S rRNAs  
As shown previously, S51, T73 and S140, are located close to either the 5S or 5.8S rRNA 
in the LSU (Figure 4.4). Therefore, it is important to evaluate whether the point 
mutations introduced to RPL11 affect the protein’s ability to associate with the 5S and 
5.8S rRNAs.  
To analyse this question, U2OS cells were treated with tetracycline for 48 hours in 
order to express WT or mutant FLAG-tagged RPL11 before whole cell lysates were 
prepared. Anti-FLAG affinity agarose beads were then incubated with the whole cell 
lysates. The unbound material was removed and the beads were washed. RNA was 
subsequently extracted from the bound material and analysed by Northern blotting 
using 32P labelled probes specific to the 5S and 5.8S rRNAs. FLAG-tagged protein levels 
bound to the beads were also detected by western blotting using anti-FLAG antibody. 
U2OS cells transfected with empty pcDNA5 plasmid were analysed as control.  
For reasons that we could not explain 5S and 5.8S rRNAs were not reliably detected 
from both T73 mutants, therefore their results were left out from this analysis (Figure 
4.6),. A possibility could be the low protein levels of T73E and T73V, which was 
observed previously (Figure 4.5), which resulted in too little protein for 
immunoprecipitation.  
When analysing 10% of the total input, FLAG-tagged proteins were detected in all 
samples except in the control (Figure 4.6). Among all samples, the protein levels of 
FLAG-tagged RPL11 S51D and S140D bound to the beads were noticeably lower than 
the other mutants (Figure 4.6), in agreement with cellular protein levels from previous 
results (Figure 4.5). This suggests that the FLAG-tagged S51D and S140D mutant 
proteins may be less stable than other mutant proteins.   
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The FLAG IP showed background levels of the 5.8S and 5S rRNAs that were co-purified 
in the control sample (Figure 4.6). It also showed that in all mutant samples, the both 
5S and 5.8S rRNAs were detected in the FLAG-IP material.  
These results confirm the association between the mutant proteins and the 5S and 
5.8S rRNAs. In conclusion, except for the T73 site, RPL11 mutant proteins are able to 
bind to the 5S and 5.8S rRNAs, and the cells are able to utilise the mutated FLAG-
tagged RPL11 proteins to produce ribosomes.  
  
Figure 4.6. The 5S and 5.8S rRNAs associate with some of the RPL11 mutants. 
U2OS cells stably expressing RPL11 WT or mutants (indicated above the panels) 
were induced for 48 hours. Anti-FLAG affinity agarose beads were used to capture 
the FLAG-tagged protein and the associated rRNAs. After removal of the unbound 
material, the rRNAs associated to the FLAG-tagged protein were detected by 
Northern blotting using specific probes (indicated on the left). 10% of the total IP 
input material was also analysed and used as a positive control. U2OS cells 
transfected with empty plasmid were used as negative control. FLAG-tagged protein 
levels were determined by western blotting with anti-FLAG antibody. Independent 
experiments were repeated twice and a representative result is presented. 
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4.2.5 The 5S RNP incorporation of FLAG-RPL11 wild type is less efficient 
than seen with the endogenous RPL11  
I next investigated whether the reported phosphorylated amino acid residues in RPL11 
are involved in the ribosome biogenesis. The idea is to analyse whether the expression 
of RPL11 phospho-mutant proteins affect the ribosome production in U2OS cells as 
compared to the WT protein.  
Glycerol gradient centrifugation was used to separate the free 5S RNP from the mature 
and the pre-ribosomes, before determining the distribution of FLAG-tagged protein 
found in both free and ribosomal complexes. I also analysed ribosomal protein RPL7 
which provides a marker for the ribosomal complexes. Ribosomal protein RPL7 is a 
large subunit protein component which exists in pre-60S and the mature 60S 
ribosomal subunits (Russo et al., 1997). RPL7 protein distribution was measured in 
each gradient experiment for two reasons: Firstly, RPL7 distribution indicates those 
fractions containing ribosomes and pre-ribosomes. Secondly, it also serves as an 
internal control between different gradient runs.  
Stable U2OS cell lines were treated with tetracycline for 48 hours in order to express 
FLAG-tagged RPL11 WT or mutant proteins. The cells were then harvested and whole 
cell lysates were prepared. The extracts were subsequently separated in a 10-40% 
glycerol gradient using ultracentrifugation. The gradient was subsequently fractionated 
into 20 samples (labelled as 1-20, from top to bottom, Figure 4.7A). Proteins in each 
fraction were separated by SDS-PAGE followed by western blotting using anti-FLAG 
and anti-RPL7 antibodies. The probed proteins were visualised using either ECL or 
fluorescence detection. A quantitative distribution analysis was perform based on the 
western signals, by first quantitating the protein signal (FLAG-tagged RPL11 or RPL7) 
detected in each fraction. The protein signal intensity in each fraction was then 
converted into a percentage of total, before data from all fractions were presented in a 
histogram which represents the protein distribution from free and ribosomal 
complexes (protein level percentage over gradient fraction, Figure 4.7B). Finally, the 
FLAG-tagged RPL11 distribution in free and ribosomal complexes are calculated by 
combining the percentage number in free (fraction #1-6) or ribosomal fractions 
(fraction #8-20) (Figure 4.7C).  
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Before focusing on the mutant proteins, I first analysed gradient samples from cells 
expressing the FLAT-tagged RPL11 WT protein. In these cells, RPL7 protein was 
detected in the fractions #8 – 20 which coincides with the distribution of ribosomal 
complexes in the gradient (Figure 4.7A). The signal quantitation showed a primary 
peak in fractions #9 – 11, followed by a relative smaller ‘shoulder peak’ in fractions #13 
– 16 where the RPL7 distribution declined gradually (Figure 4.7B).  
The quantitative distribution analysis also showed that about 30% of the total FLAG-
RPL11 was present in free fractions whereas about 70% was detected in the ribosomal 
Figure 4.7. One third of FLAG-RPL11 wild type protein was found in the ‘free’ 
fractions in U2OS cells overexpressing the protein. 
(A)Extracts from stable U2OS cells expressing FLAG-RPL11 wild type were analysed 
using glycerol gradient centrifugation followed by western blotting. The glycerol 
gradient was fractionated into 20 samples (indicated above the panel). Fractions #1-
6 and #8-19 are indicated as ‘free’ and ‘ribosomal’, respectively. Antibodies used are 
indicated to the left of each panel. (B)Protein levels detected in each gradient 
fraction was quantitated. Protein distributions are presented as the percentage of 
total protein levels (sum of all fractions #1-20). (C) FLAG-RPL11 levels in ‘free’ or 
‘ribosomal’ fractions are presented. FLAG levels from fractions #1-6 in (B) were 
combined and indicated as ‘free’, fractions #8-19 is indicated as ‘ribosomal’. Multiple 
independent experiments were performed and a representative result is presented.  
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counterparts (Figure 4.7C). Among the non-ribosome associated fractions, #3 
contained the highest percentage of FLAG-RPL11 protein and the percentage declined 
gradually from #4 to #7 (Figure 4.7B). In ribosomal fractions, FLAG-RPL11 distributed in 
a similar way compared to RPL7. They were both distributed from fractions #8 to #20, 
with a peak at fractions #9-11 (Figure 4.7A-B).  
Previous study had shown that the free, or non-ribosomal, 5S RNP is distributed in the 
‘free’ fractions (Sloan et al., 2013a). Sloan et al. also reported that in HEK293 cells 
there was almost no endogenous RPL11 found in the free complexes but primarily 
detected in the ribosomal complexes (Sloan et al., 2013a). The FLAG-tagged RPL11 is 
primarily found in ribosomal complexes in my result, which is largely consistent with 
what has been previously reported by Sloan et al. However, the increased levels of 
FLAG-RPL11 in the ‘free’ fractions may suggests that the FLAG-tagged protein is not 
being incorporated into the ribosome as well as the endogenous form. This could be 
due to the charged nature of the FLAG tag which may affect the recruitment of 5S RNP 
into the LSU.  
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4.2.6 Threonine 73 mutations in RPL11 cause accumulation in free 5S RNP in 
U2OS cells 
Having characterised the wild type RPL11, I next analysed RPL11 mutations T73V and 
T73E. In U2OS cells expressing the FLAG-RPL11 T73V mutant, more than 60% of the 
total FLAG-tagged protein was detected in the free fractions (#1-6), significantly more 
than that observed from WT protein (Figure 4.8B). In free fractions, the FLAG-RPL11 
T73V mutant showed a similar distribution to the WT protein (#1-6, Figure 4.8B). In the 
ribosomal fractions (#8-18), FLAG levels from fractions #10 to #15 were slightly lower 
than from the WT protein (Figure 4.8B). Taken these results together, they suggest 
that 5S RNP containing the RPL11 T73V mutation incorporates less efficiently into the 
large subunit precursor than the RPL11 WT.   
In U2OS cells expressing the FLAG-RPL11 T73E mutant protein, the majority of T73E 
protein was detected in free fractions whereas the protein was present only at low 
levels in the ribosomal fractions (Figure 4.8A). Over 80% of total T73E protein was 
present in free fractions, approximately three fold as much as seen with the WT 
protein (Figure 4.8D).  
The majority of the FLAG-RPL11 T73E mutant was detected in fraction #2. In the ‘free’ 
fractions the T73E mutant was accumulated in fractions #1-3, resulting a relatively 
narrower peak, whereas the WT protein distributed broadly in fractions #1-6 (Figure 
4.8C). This ‘shifted’ peak seen in the ‘free’ fractions suggests that the RPL11 containing 
T73E mutation is not being assembled efficiently into the 5S RNP.  
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Figure 4.8. T73 RPL11 mutants are defective at integration into ribosomes. 
(A) Extracts from U2OS cells overexpressing FLAG-RPL11 T73V (T73V) or T73E 
(T73E) were analysed using glycerol gradient centrifugation followed by western 
blotting. The gradient fractions are indicated above the panel. Antibodies used are 
indicated to the left of each panel. (B-C) FLAG-tagged RPL11 levels detected in each 
gradient fraction from U2OS cells expressing RPL11 T73V or T73E mutants were 
quantitated. FLAG-tagged RPL11 distributions are presented as percentage of total 
protein levels (sum of fractions #1-20). Extracts from U2OS cells expressing RPL11 
wild type were analysed likewise and FLAG-RPL11 wild type levels were used as 
control (indicated as WT). (D) FLAG-tagged RPL11 levels distributed in ‘free’ or 
‘ribosomal’ fractions were presented as percentage of the total FLAG levels. FLAG 
levels from fractions #1-6 (in B or C) were compiled and presented as ‘free’, 
fractions #8-19 are presented as ‘ribosomal’. Independent experiments were 
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4.2.7 Serine 51 mutations in RPL11 affect 5S RNP integration into the 
ribosome  
In stable U2OS cells expressing the S51A RPL11 mutant, there was almost 50% of the 
total FLAG-RPL11 S51A mutant protein accumulated in the ‘free’ fractions which was a 
noticeable increase compared to the WT protein (Figure 4.9D). When looking at FLAG-
RPL11 distributions in the ‘free’ fractions (#1-6), the mutated protein predominantly 
located in fractions #2 to #4 and was almost enriched two fold as compared to the WT 
protein (Figure 4.9B). Furthermore, in the ribosomal fractions, the FLAG-RPL11 S51A 
protein peak was shifted slightly compared to the WT protein peak (Figure 4.9B). 
However, when comparing the RPL7 distribution between S51A and WT cell extracts, 
the RPL7 peak was shifted similar to the altered distribution seen with FLAG-RPL11. 
Therefore, the FLAG peak difference between S51A and WT extracts was likely due to 
fractionation inconsistency. The accumulated FLAG-RPL11 S51A mutant in ‘free’ 
fractions suggest that this mutation leads to a less efficient 5S RNP incorporation into 
the ribosome.  
In U2OS cells expressing the S51D RPL11 mutant, the majority of the protein was 
detected in the ‘free’ fractions and made up almost 70% of the total mutant protein, 
more than the double of the WT protein (Figure 4.9D). In contrast, the FLAG-RPL11 
mutant protein was almost undetectable in the ribosomal fractions (fractions #8-18, 
Figure 4.9A).  
When analysing the gradient fractions, most of the S51D mutant protein appeared 
accumulated in fractions #2-4, whereas the distribution of the mutant in the following 
fractions #5-7 was similar to the WT protein (Figure 4.9C). Comparable to the cells 
expressing the S51A RPL11 mutant, the S51D mutant accumulated in fractions #2-4 
whereas fractions #3-7 contained similar levels compared to the WT protein (Figure 
4.9B and C). In the ‘ribosomal’ fractions, the S51D mutant distributed similarly to the 
WT protein, in which the peak of FLAG-tagged protein locates to fraction #10 (Figure 
4.9 C).  
The accumulation of the S51D mutant in ‘free’ fractions suggest that this mutation 
blocks 5S RNP incorporation into the ribosome. In summary, these result suggest that 
serine 51 is important for 5S RNP incorporation into the ribosome.  
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Figure 4.9. Serine 51 mutations promote increased RPL11 in ‘free’ fractions. 
(A) Extracts from U2OS cells overexpressing FLAG-RPL11 S51A (S51A) or S51D (S51D) 
were analysed using glycerol gradient centrifugation followed by western blotting. 
The gradient fractions are indicated above the panel. Antibodies used are indicated to 
the left of each panel. (B-C) FLAG-tagged RPL11 levels detected in each gradient 
fraction from U2OS cells expressing RPL11 S51A or S51D mutants were quantitated. 
The FLAG distribution is presented as the percentage of total protein levels (sum of 
fractions #1-20). Extracts from U2OS cells expressing RPL11 wild type were analysed 
in parallel and FLAG-RPL11 wild type distributions were used as control (indicated as 
WT). (D) The level of FLAG-tagged RPL11 distributed in ‘free’ or ‘ribosomal’ fractions 
are presented in percentage of the total FLAG levels. FLAG levels from fractions #1-6 
(in B or C) were compiled and presented as ‘free’, fractions #8-19 are presented as 
‘ribosomal’. (E) The distribution of RPL7 was determined by quantitating RPL7 levels 
decribed in (A). Data are presented in percentage of the total RPL7 levels. U2OS cells 
expressing RPL11 wild type were analysed in parallel and the corresponding RPL7 
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4.2.8 Serine 140 mutations in RPL11 affect ribosome maturation  
When analysing the protein distribution in extracts harvested from U2OS cells 
expressing S140A or S140D FLAG-RPL11 mutants, both of the FLAG-tagged proteins 
were detected predominantly in the ‘ribosomal’ fractions (Figure 4.10A). In general, 
the overall FLAG-RPL11 distributions between ‘free’ and ‘ribosomal’ fractions were 
very similar among the S140A, S140D mutants and the WT protein (Figure 4.10D).  
In the ‘ribosomal’ fractions, S140D RPL11 mutant distributed in two peaks in fractions 
#9 and #11, which was distinctively different from the single peak seen for the WT 
RPL11 in fraction #10 (Figure 4.10C). Referencing to the RPL7 distribution, as RPL7 in 
WT cell extracts is primarily detected in fractions #9 and #10 and RPL7 marks fractions 
containing mature ribosomes, those two peaks seen with the S140D RPL11 mutant 
suggest that this mutation results in pre-60S accumulation and less mature ribosomes. 
However, the defect seen with the S140D mutants was less pronounced with the 
S140A mutants. This implies that serine 140 phosphorylation could be important for 
ribosome biogenesis (see Section 4.3 Discussion).  
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Figure 4.10. Serine 140 mutations promote accumulation of pre-60S ribosomes. 
(A) Extracts from U2OS cells overexpressing FLAG-RPL11 S140A (S140A) or S140D 
(S140D) were analysed using glycerol gradient centrifugation followed by western 
blotting. The gradient fractions are indicated above the panel. Antibodies used are 
indicated to the left of each panel. (B-C) FLAG-tagged RPL11 levels detected in each 
gradient fraction from U2OS cells expressing RPL11 S140A or S140D mutants were 
quantitated. The FLAG distribution is presented in the percentage of total protein 
levels (sum of fractions #1-20). Extracts from U2OS cells expressing RPL11 wild 
type were analysed in parallel and FLAG-RPL11 wild type distributions were used as 
control (indicated as WT). (D) The level of FLAG-tagged RPL11 distributed in ‘free’ 
or ‘ribosomal’ fractions are presented in percentage of the total FLAG levels. FLAG 
levels from fractions #1-6 (in B or C) were compiled and presented as ‘free’, 
fractions #8-19 are presented as ‘ribosomal’. (E) The distribution of RPL7 was 
determined by quantitating RPL7 levels detected in (A). The RPL7 distribution is 
presented in percentage of the total RPL7 levels. U2OS cells expressing RPL11 wild 
type were analysed in parallel and its RPL7 distribution was used as control 
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4.2.9 RPL11 S29D mutant causes accumulation of pre-LSU complexes in 
U2OS cells  
I next analysed the FLAG-RPL11 mutant distribution in ‘free’ and ‘ribosomal’ fractions 
in U2OS cells expressing S29A mutants. Approximately 40% of the total FLAG-tagged 
RPL11 mutants were present in the free fractions (Figure 4.11A and D). This was 
slightly higher than the WT protein (Figure 4.11D). Compared to the WT, despite the 
slight quantitative increase, the distribution of FLAG-RPL11 S29A in the ‘free’ fractions 
was comparable to the WT protein (Figure 4.11B).  
When looking at the ribosomal fractions (#8-18, Figure 4.11B), fraction #11 contained 
the highest amount of S29A mutant protein. Compared to the WT, this ‘ribosomal’ 
peak was slightly shifted (Figure 4.11B). Furthermore, RPL7 distribution in the 
ribosomal fractions of cells expressing RPL11 S29A was also shifted compared to the 
WT (Figure 4.11E). Hence the shifted FLAG peak of the mutants are likely due to 
gradient or fractionation inconsistencies. 
In cells expressing the S29D mutant, there were barely detectable levels of FLAG-RPL11 
mutants in the ‘free’ fractions, whereas the majority was detected in the ‘ribosomal’ 
fractions #10 to #15 (Figure 4.11A). Overall, there was only less than 10% of total 
FLAG-RPL11 mutant protein present in ‘free’ fractions, which was noticeably less than 
in WT or RPL11 S29A expressing cells (Figure 4.11D). In the ‘ribosomal’ fractions, the 
FLAG-RPL11 S29D mutant peak was broader and shifted compared to the WT protein 
(Figure 4.11C). When comparing the RPL7 distribution in WT and RPL11 S29D extracts, 
a similar broader and shifted peak could also be observed (Figure 4.11E). The shifted 
RPL7 peak from RPL11 S29D cell extracts indicated that the observed shifted FLAG-
RPL11 S29D peak was likely due to inconsistent gradient fractionation. However, both 
the FLAG-RPL11 mutant and RPL7 proteins from the RPL11 S29D extract distributed 
differently to the control.  
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Figure 4.11. S29A and S29D RPL11 mutations cause different FLAG-RPL11 distributions. 
(A) Extracts from U2OS cells overexpressing FLAG-RPL11 S29A (S29A) or S29D (S29D) were 
analysed using glycerol gradient centrifugation followed by western blotting. The gradient 
fractions are indicated above the panel. Antibodies used are indicated to the left of each 
panel. (B-C) FLAG-tagged RPL11 levels detected in each gradient fraction from U2OS cells 
expressing RPL11 S29A or S29D mutants were quantitated. FLAG-tagged RPL11 
distributions are presented as the percentage of total protein levels (sum of fractions #1-
20). Extracts from U2OS cells expressing RPL11 wild type were analysed in parallel and 
FLAG-RPL11 wild type distributions were used as control (indicated as WT). (C) The level of 
FLAG-tagged RPL11 distributed in ‘free’ or ‘ribosomal’ fractions are presented as 
percentage of the total FLAG levels. FLAG levels from fractions #1-6 (in B or C) are 
compiled and presented as ‘free’, and fractions #8-19 are presented as ‘ribosomal’. (E) The 
distribution of RPL7 was determined by quantitating RPL7 levels detected in (A). Data is 
presented in percentage of the total RPL7 levels. U2OS cells expressing RPL11 wild type 
were analysed in parallel and the RPL7 distribution was used as control (indicated as WT). 
Independent experiments were repeated three times and a representative result is 
presented. 
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The disappearance of the FLAG-RPL11 S29D peak in the ‘free’ fractions, suggests that 
5S RNP containing this mutant RPL11 is incorporated into the large ribosomal subunit 
more efficiently than the WT protein. Furthermore, the broader ‘ribosomal’ FLAG and 
RPL7 peak from the S29D extracts suggests that, relative to the mature 60S, the 
mutation resulted in accumulated pre-60S ribosomes. Taken together, serine 29 
phosphorylation and/or dephosphorylation could be important to both 5S RNP 
integration and large ribosomal subunit biogenesis.  
4.2.10 Analysing subcellular localisations of RPL11 phospho-mutants.  
Glycerol gradient analysis suggested that some RPL11 mutations affect ribosome 
biogenesis. Hence, I next performed immunofluorescence in the U2OS cells expressing 
RPL11 mutants in order to investigate whether RPL11 mutations affect the protein’s 
subcellular localisation.  
Tetracycline was applied to the stably transfected U2OS cell lines grown on glass 
coverslips for 48 hours in order to express FLAG-tagged RPL11 WT or mutant proteins. 
After fixing the cells, anti-FLAG antibody was used detect the FLAG-RPL11 proteins and 
DAPI staining was used to identify the nucleus. The signal was subsequently visualised 
with fluorescence microscopy. U2OS cells transfected with empty pcDNA5 plasmid 
were used as control. 
In the pcDNA5 control cells, no FLAG signal was detected. In the cells expressing WT 
RPL11, the FLAG signal was predominantly located in nucleoli and the cytoplasm (WT, 
Figure 4.12). This is consistent with previous observations performing 
immunofluorescence that RPL11 was predominantly located in the nucleoli and 
cytoplasm of HEK293 cells (Sloan et al., 2013a).  
In the U2OS cells expressing the S140A RPL11 mutant, the cytoplasmic levels of RPL11 
S140A were significantly reduced compared to control cells (S140A, Figure 4.12). This 
observation agrees with the gradient results which showed a decrease of mutant 
protein in mature ribosome (Figure 4.10B). In the cells expressing the S140D mutant, 
the FLAG-tagged protein localisation was largely similar to the WT protein, with a 
slightly stronger nucleolar FLAG signal (S140D, Figure 4.12).   
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Figure 4.12. Mutations in phospho-sites change the localisation of RPL11. 
The localisation of newly synthesised FLAG-RPL11 wild type (RPL11) or mutants (S51A, 
S51D, S140A, S140D, S29A, S29D, T73V and T73E) in U2OS cell lines was determined by 
immunofluorescence. Stably transfected U2OS cells were grown on coverslips and the 
expression of tagged protein was induced by tetracycline. After fixing the cells, 
immunofluorescence was performed using α-FLAG antibody (red/grayscale). DAPI 
staining was used to visualise nuclear material (blue). Nucleoli are indicated with arrows 
(white). Independent experiments were repeated twice and a representative result is 
presented. 
 110 
In cells expressing either the S51A or S51D RPL11 mutant, there was increased nuclear 
and nucleolar FLAG-specific signal compared to the WT protein (S51A and S51D, Figure 
4.12). Compared to the S51A mutant, RPL11 S51D was localised more predominantly in 
the nucleoplasm (Figure 4.12). The gradient result suggests that both these mutations 
block 5S RNP incorporation into the ribosome (Figure 4.9B). The increased nuclear 
FLAG-RPL11 levels observed in these cells agrees with the gradient results, since free 
5S RNP accumulates in nucleoplasm.  
In the cells expressing T73V or T73E mutant proteins, overall FLAG related 
fluorescence was noticeably weaker than for the WT protein (T73V and T73E, Figure 
4.12), which coincides with to the low cellular levels of FLAG tagged RPL11 previously 
observed (Figure 4.8). According to the gradient results, the T73E mutant does not 
associate well with the 5S RNP. Moreover, the FLAG signal in cells expressing T73V was 
distributed similar to the WT protein (T73V, Figure 4.12). Compared to the T73V 
protein, the FLAG-RPL11 T73E signal was noticeably increased in the nucleoli, but 
reduced in the cytoplasm (T73E, Figure 4.12).  
Compared to the WT protein, cells expressing the S29A and S29D RPL11 showed a 
complete absence of nucleolar FLAG signal (S29A, S29D; Figure 4.12). Furthermore, 
there were almost undetectable nuclear FLAG signals in the cells expressing the RPL11 
S29A mutant (Figure 4.12). The gradient results for these cells suggest that S29A 
causes free 5S RNP accumulation, whereas S29D results in the accumulation of pre-60S 
RNA. Neither of the immunofluorescence result relates well to the corresponding  
gradient results. 
In summary, although the reduced nucleolar FLAG signal in RPL11 S29A and S29D 
expressing cells were unexpected and difficult to explain, the immunofluorescence 
results from the rest of the mutant proteins provide additional evidence supporting 
the glycerol gradient results. The accumulated nucleolar signal of RPL11 S140A and 
S140D supports the gradient results which indicated that serine 140 is important for 
ribosome biogenesis. Furthermore, the increased nuclear RPL11 S51D signal concurs 
with the accumulated protein in ‘free’ gradient fractions, both findings support the 
hypothesis that this mutation inhibits the integration of RPL11 into 5S RNP. Finally, the 
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reduced cytoplasmic T73E signal also agree with the gradient results which indicate 
almost complete absence of FLAG tagged RPL11 protein in ribosomal fractions.  
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4.2.11 A relation between RPL11 mutant expression and p53 activation?  
When ribosomal defects occur, free 5S RNP accumulates and promotes p53 
stabilisation and activation via the inhibition of MDM2 (Sloan et al., 2013a). As a 
component of the 5S RNP, RPL11 had been associated with MDM2 interaction and p53 
signalling in a number of studies. Previously, Loren Gibson from the Watkins lab 
showed that mutations of phosphorylated tyrosine residues in ribosomal protein RPL5 
resulted in p53 stabilisation and activation via MDM2 (unpublished data). Given the 
importance of RPL11/MDM2 interactions to p53 regulatory signalling, it is conceivable 
that the phosphorylation of RPL11 could also play a vital role in regulating p53. I, 
therefore, investigated how overexpressing the RPL11 mutants described above affect 
p53 and p21 cellular levels.  
U2OS cells were treated with tetracycline for 48 hours in order to overexpress FLAG-
tagged RPL11 WT or mutant proteins. Whole cell lysates were separated by SDS-PAGE 
followed by detecting p53 and p21 protein levels using western blotting with specific 
antibodies. Protein signals were visualised using ECL detection. U2OS cells transfected 
with empty plasmid were included as controls and karyopherin protein levels were 
measured as loading control. To quantitate the signal p53 and p21 bands were 
normalised to the loading control and data were plotted in relation to the empty 
plasmid control. Since both T73 mutants did not reliably express, they are omitted 
from this analysis.  
When expressing RPL11 WT, S51D or S140A mutants in U2OS cells, there was a slight 
induction in p53 levels compared to the control (Figure 4.13B). Although the result is 
not statistically significant, expression of other RPL11 mutants also indicated p53 
stabilisation to various degrees. For example, there was a threefold increase in p53 
levels when expressing S29A or S29D mutants (Figure 4.13B). Expression of these 
mutant proteins also caused increased cellular p21 levels; again, the differences were 
not significant (Figure 4.13C).   
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Figure 4.13. Effect of RPL11 mutants on p53 and p21 protein levels. 
 (A) Western blot determining cellular p53 and p21 levels. U2OS cells stably 
expressing RPL11 WT or mutants (indicated above the panel) were induced for 48 
hours. Whole cell lysates were separated on SDS-PAGE and specific antibodies were 
used to determine protein levels (indicated on the left). U2OS cells transfected with 
empty plasmid were used as control. Karyopherin protein levels is used as a loading 
control. (B-C) Quantitation of p53 or p21 bands from (A). The mean value and 
standard error from three repeats is presented in related to the control (*p<0.05, 
***p<0.005).  
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4.3 Discussion and Future Work 
The 5S RNP is a crucial component for both ribosome biogenesis and the p53 
regulatory pathway in response to the nucleolar stress (Sloan et al., 2013a). In human 
cells, the 5S RNP is assembled in the nucleoplasm, where RPL5 stabilises the 5S rRNA, 
before RPL11 binds to the RPL5/5S rRNA dimeric complex to form the 5S RNP. The 5S 
RNP is then integrated into the pre-LSU in the nucleolus. After that, the pre-LSU 
undergoes further processing and the matured LSU is exported into the cytoplasm.  
When ribosome biogenesis is disrupted, the accumulated ‘free’ 5S RNP binds and 
inhibits MDM2 functions resulting in p53 stabilisation and activation. It has been 
reported that the zinc finger and acidic domain of MDM2 interacts with RPL11 (Zheng 
et al., 2015), and when MDM2 binds to the 5S RNP, the MDM2 binding interface on 
RPL11 is the same region that contacts the 28S rRNA in the ribosome (Khatter et al., 
2015). Since RPL11 has been reported to be phosphorylated at multiple serine and 
threonine residues, I aimed to establish the importance of RPL11 phosphorylation in 
relation to both ribosome biogenesis and p53 signalling in this chapter.  
I first identified the reported phosphorylated sites and analysed their location on 
RPL11 in relation to the 5S and 28S rRNAs (Figure 4.4). Since serine 29 of RPL11 is 
distant to either the 28S or the 5S rRNA, phosphorylation of this site is likely to be 
involved at later stages of ribosome biogenesis. Hence, I hypothesised that phospho-
mutants of this residue could affect the 5S RNP integration into the LSU or subsequent 
steps in LSU processing (Table 4.2).  
Because the sugar-phosphate backbone of RNAs is negatively charged, based on the 
observation that serine 51 and serine 140 of RPL11 are located close to the sugar-
phosphate backbone of the 28S and 5S rRNA in the ribosome structure (Figure 4.4), I 
predicted that the phospho-mimic mutation of these residues could inhibit RPL11 
association with the rRNAs (Table 4.2).   
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Number of reports Location Site Mutant Predicted effects 
6 
contacts 
RPs in LSU 
S29 
A 
affects the 5S RNP integration into 
LSU 
D 
3 
contacts 
28S 
backbone  
S51 
A 
Phospho-mimic inhibits 28S binding 
D 
1 
contacts 
nitrogenous 
bases in 5S  
T73 
V 
affects 5S binding and 5S RNP 
assembly 
E 
2 
contacts 5S 
backbone 
S140 
A 
Phospho-mimic inhibits 5S binding 
D 
Table 4.2. Summary of the predicted effects of the introduced point mutations on 
RPL11 protein function based on the location analysis of the reported 
phosphorylated amino acid residues.  
 
Finally, the structure analysis showed that threonine 73 of RPL11 is located close to the 
nitrogenous bases in the 5S rRNA of the ribosome. Therefore, I hypothesised that 
mutating this residue could affect the binding between RPL11 and the 5S rRNA, which 
could further affect the assembly of the whole 5S RNP (Table 4.2).  
4.3.1 Threonine 73 in RPL11 could be important for RPL11 binding to 5S 
RNP components 
I have first observed that in U2OS cells, the over-expressed T73E mutants of RPL11 
distributed significantly less in the ribosomal complexes compared to the WT 
counterpart (Table 4.3). These results suggest that the RPL11 T73E mutant may be 
integrated into ribosome less efficiently than the WT counterpart.  
Using immunofluorescence, I also showed that the T73E RPL11 mutant becomes 
accumulated in the nucleus and reduced in the cytoplasm (Figure 4.12). Because the 5S 
RNP is integrated into the pre-LSU in the nucleus, and mature ribosomes are mainly 
located in the cytoplasm, this result supports the speculation that T73E inhibits the 
integration of 5S RNP into the ribosome.   
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Site 
Mutant 
(protein level) 
Distribution (gradient result) 
Localisation (IF result) Free Ribosomal 
S29 
A ⬆ n.c. 
undetectable nucleolus, 
⬇ nucleus 
D ⬇ ⬆ 
undetectable nucleolus, 
⬇ nucleus 
S51 
A ⬆ ⬇ 
⬆ nucleolus, 
⬆ nucleus 
D (⬇) ⬆ ⬇ 
⬆ nucleolus, 
⬆ nucleus 
T73 
V (⬇) ⬆ ⬇ n.c. 
E (⬇) ⬆ ⬇ 
⬆ nucleolus, 
⬇ cytoplasm 
S140 
A n.c. ⬆ pre-ribosome ⬇ cytoplasm 
D (⬇) n.c. ⬆ pre-ribosome n.c.  
Table 4.3. Summary of the gradient and IF results for over-expressed RPL11 mutant 
proteins in U2OS cells. (n.c. no change; ⬆ increased levels; ⬇ reduced levels)  
 
Based on the structural analysis showing that threonine 73 in RPL11 locates close to 
the nitrogenous bases of the 5S rRNA in the ribosome, I predicted that mutations of 
this residue interfere with the binding between RPL11 and the 5S rRNA and could 
further affect the 5S RNP assembly (Table 4.2). My results support this hypothesis, as 
the negatively charged glutamic acid substituting the serine 73 residue likely abolishes 
the RPL11 binding to the 5S rRNA. It inhibits the RPL11 mutant from being assembled 
into the 5S RNP in the first place, before the 5S RNP can be integrated into the 
ribosome.   
Furthermore, my results suggest that threonine 73 could be an important residue for 
RPL11 binding to the 5S rRNA. Previously Horn et al. reported that a mutation of the 
arginine 75 residue (R75Q), adjacent to threonine 73, inhibits the interaction between 
RPL11 and RPL5, by blocking RPL11 binding to the 5S rRNA (Horn and Vousden, 2008). 
Since my result showed that T73E mutant inhibits 5S RNP integration into the 
ribosome, it is possible that threonine 73, like arginine 75, provides essential 
interactions between RPL11 and the 5S rRNA.  
I have also demonstrated that both FLAG-tagged T73 RPL11 mutants are less stable 
than WT and other mutants when over-expressed (Figure 4.5). This could also be the 
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result of mutants not being assembled into the 5S RNP, since it has been shown that 
RPL11 protein is produced in excess and the unbound molecules are degraded by the 
proteasome (Lam et al., 2007). A recent study also has demonstrated that RPL11 
incorporation into the 5S RNP is a rate limiting step during LSU production (Sloan et al., 
2013a). Taken together, it is likely that those T73 mutants which cannot bind to the 5S 
rRNA are turned over rapidly in the cell, resulting in less stable protein as observed in 
my results.  
Since T73E is designed to mimic a phosphorylated threonine, it is possible that the 
phosphorylation of threonine 73 in RPL11 influences RPL11 turn-over in U2OS cells. 
Because RPL11 is produced in excess and those proteins unbound to the RPL5/5S rRNA 
complex are turned over, the low cellular levels of the T73E RPL11 mutant suggest that 
threonine 73 phosphorylation could target RPL11 for degradation. This could also 
explain why only one proteomic study reporting the phosphorylation of this residue 
has been published (Table 4.2), as a transient phosphorylation event on ‘free’ RPL11 
with a low abundance (less than 10% free in U2OS cells) would be technically difficult 
to observe.  
In fact, this work has not directly established a phosphorylation event at threonine 73 
in the free RPL11 proteins, to confirm this will require additional investigations in the 
future, such as utilising kinase inhibitor (see Chapter 5 for detail). As a conclusion, my 
work suggests that threonine 73 in RPL11 could be important for RPL11 binding to the 
5S rRNA.   
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4.3.2 Serine 51 phosphorylation in RPL11 could inhibit 5S RNP integration 
into the large subunit  
In RPL11 serine 51 is located on the RPL11-MDM2/28S rRNA interface and when RPL11 
interacts with the 28S rRNA in the ribosome, the sidechain of serine 51 is in close 
proximity to the sugar-phosphate backbone of the 28S rRNA (Figure 4.4). Because the 
sugar-phosphate backbone of RNA is negatively charged, I therefore predicted that the 
phospho-mimic mutant of this residue (S51D) inhibits RPL11 binding to the 28S rRNA 
(Table 4.2).   
My glycerol gradient results suggest that the 5S RNP containing the S51A or S51D 
RPL11 mutant is not incorporated into the ribosome. The S51D mutant is barely 
detectable in ribosomal complexes, indicating that the S51D mutation in RPL11 
severely affects the 5S RNP incorporation into the ribosome (Figure 4.9). This 
assumption is supported by the immunofluorescence data which showed reduced 
S51D mutant levels in cytoplasm, suggesting there were few mature ribosomes 
containing the mutant RPL11 (Figure 4.12).  
As a phospho-mimic mutation of S51D, the negatively charged aspartic acid sidechain 
of the mutant likely disrupts the association between RPL11 and the sugar-phosphate 
backbone of the 28S rRNA. My observations presented in the results section supports 
this hypothesis. In contrast, as a phospho-null mutant, S51A is supposed to have a 
lesser effect on RPL11 binding to the 28S rRNA, because the similarity between alanine 
and a serine residues. In deed when over-expressing S51A in U2OS cells, the mutant 
did cause less free 5S RNP accumulation than the RPL11 S51D mutant (Figure 4.12).  
Therefore, phosphorylation of serine 51 is likely to block the RPL11 binding to 28S 
rRNA, which could constitute an important step in controlling 5S RNP integration into 
the LSU. Consequently, to integrate the 5S RNP into the LSU, dephosphorylation could 
be needed. Nonetheless further investigation is required to confirm this speculation 
(See Chapter 5 for detail). In conclusion, my work suggests that serine 51 
phosphorylation in RPL11 could inhibit 5S RNP integration into the large subunit.   
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4.3.3 Phosphorylation of serine 140 in RPL11 could be important for LSU 
maturation  
It was shown by structural analysis that the sidechain of serine 140 locates close to the 
sugar-phosphate backbone of the 5S rRNA in the ribosome. I therefore predicted that 
mutations of this residue may affect RPL11 binding to the 5S rRNA, which may 
subsequently affect the 5S RNP assembly (Table 4.2).  
Although the structural analysis leads to the prediction that mutations of this residue 
may affect RPL11 binding to the 5S rRNA, the IP experiments performed demonstrated 
otherwise. They showed that S140A and S140D mutants associate with the 5S and 5.8S 
rRNAs at comparable levels to the WT (Figure 4.6). Interestingly, the gradient 
centrifugation result suggested that these mutants may instead affect ribosome 
maturation.  
Using glycerol gradient analysis, I showed that both of S140A and S140D RPL11 
mutants accumulated in fractions containing pre-ribosomes. Compared to the WT 
protein, there was a notable reduction of RPL11 S140A in the mature ribosomes (Table 
4.3, Figure 4.10). This suggests that while both mutants affect LSU maturation, the 
phospho-null mutation RPL11 S140A causes a more severe defect. The subsequent IF 
results showed that RPL11 S140A accumulated in the nucleus and that there was a 
significant reduction of cytoplasmic RPL11 S140A levels, which was not seen for the 
S140D mutant (Figure 4.12). Since the mature ribosomes are exported from the 
nucleus into the cytoplasm, the IF data support the gradient results and further 
suggest that the S140A mutation give rise to more severe LSU maturation defects than 
the S140D mutant.  
Because a serine to alanine mutation creates a residue which is not a substrate for 
protein kinases, my results imply that phosphorylation of serine 140 residue is needed 
for the LSU maturation. In the mature ribosome structure (PDB ID: EMD-2938; Khatter 
et al., 2015), serine 140 contacts the sugar-phosphate backbone of 5S rRNA in the LSU 
(Figure 4.4). Since a phosphorylated serine 140 residue is likely to disrupt the RPL11 5S 
rRNA interaction, it is likely that the phosphorylation on this residue is a transient 
event during LSU maturation.  
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Furthermore, yeast studies have demonstrated that after integration into the large 
subunit, 5S RNP undergoes a 180-degree rotation during LSU maturation (Leidig et al., 
2014). Up to now this remodelling event has not been fully documented in human, 
however the rotation is believed to initiate a cascade of large subunit protein 
maturation events, leading to the final conformation of the mature LSU (Baßler et al., 
2014; Nicolas et al., 2016). Therefore, it is possible that a transient phosphorylation on 
serine 140 is involved to this process, allowing the 5S RNP to adopt the final 
conformation within the CP region of the mature LSU, followed by dephosphorylation 
of the residue to stabilise RPL11 binding to the 5S rRNA after LSU maturation. In 
conclusion, phosphorylation of serine 140 in RPL11 could be important for LSU 
maturation, and further studies are needed to characterise the involvement of this 
modification in LSU maturation (See Chapter 5 for detail).  
4.3.4 Phosphorylation of serine 29 in RPL11 could be involved in the 5S 
RNP integration into the ribosome  
The structural analysis showed that S29 of RPL11 is not interacting with either 5S or 
5.8S rRNA (Figure 4.4). After 5S RNP assemby, S29 is located to the CP region of the 
large subunit during the late stages of the ribosome biogenesis. Since this process 
involves different ribosome biogenesis factors, S29 could regulate interactions with 
these biogenesis factors. I therefore predicted that the phospho-mutants for this 
residue could affect the 5S RNP integration into the LSU and the LSU maturation 
process (Table 4.2).  
My results first showed that the RPL11 S29D mutant is barely detectable in the ‘free’ 
fractions (Figure 4.11). Given that the cellular protein levels of both mutants are 
comparable to WT (Figure 4.5), it is unlikely that the absent S29D RPL11 mutant 
protein in the ‘free’ fractions are due to protein instability. It rather suggests that the 
5S RNP containing S29D RPL11 is integrated into the pre-LSU more efficiently than the 
WT protein. Interestingly RPL11 S29D mutant protein also accumulated in fractions 
containing pre-ribosome material, whereas the S29A mutant was distributed similar to 
the WT protein (Figure 4.11). Taken together, my results suggest that the S29D mutant 
may result in more efficient 5S RNP integration into the ribosome, however this 
mutation also slows down the following ribosome maturation process.  
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My results suggest that the phosphorylation of serine 29 could enhance 5S RNP 
incorporation into the ribosome. However, this phosphorylation may slow down the 
ribosome maturation process. Since ribosome biogenesis is a complicated process 
involving a large number of co-factors at different stages of the processes, a 
phosphorylated serine 29 residue in RPL11 could provide binding surface for ribosome 
biogenesis factors which yet to be identified in further investigations (See Chapter 5).  
My IF results further showed a notable reduction of RPL11 S29A and S29D mutant 
proteins localised in the nucleus of cells (Table 4.3, Figure 4.12). More surprisingly, 
these mutant proteins were not detected in the nucleolus as the WT protein (Table 
4.3, Figure 4.12). The reduction in both mutant protein levels in the nucleus could 
mean more efficient nuclear export of mature ribosomes containing the mutant RPL11, 
however this hypothesis does not concur with the gradient result. Furthermore, the 
lack of nucleolar signal of the mutant proteins is difficult to explain as the gradient 
analysis showed the RPL11 S29D mutant retained in the pre-ribosomes. It is possible 
that mutation of serine 29 causes a structural change in RPL11, which blocks antibody 
access to the FLAG epitope after RPL11 integration into the pre-LSU, resulting in the 
loss of signal. Because ribosome maturation takes place in the nucleoli and the process 
involves multiple protein co-factors, it is conceivable that the RPL11 mutations block 
certain interactions between the ribosome and protein co-factors, resulting in reduced 
FLAG-tag detection in IF. In conclusion, phosphorylation of RPL11 at S29 could favour 
5S RNP integration into the ribosome, and become dephosphorylated during later 
steps of LSU maturation.  
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4.3.5 Result summary and proposed model  
Based on the conclusions drawn from my results, I propose a model summarising the 
roles that the phosphorylated residues play during ribosome biogenesis.  
Accordingly, during the 5S RNP assembly, RPL11 binds to and stabilises the RPL5/5S 
rRNA intermediate complex in nucleoplasm. It has been shown that RPL11 protein is 
produced in excess and the RPL11 integration into the 5S RNP is tightly regulated (Lam 
et al., 2007) (Sloan et al., 2013a). Unbound RPL11 is targeted for degradation which is 
mediated by the phosphorylation on threonine 73 residue.  
After the assembly of the 5S RNP, it is integrated into the large ribosome subunit 
precursor in the nucleolus. During this process, the phosphorylation of serine 29 in 
RPL11 promotes 5S RNP integration into the ribosome, by providing an interface for 
the binding of ribosome biogenesis factors. At the same time, serine 51 in RPL11 is 
dephosphorylated to allow the RPL11 binding to the sugar-phosphate backbone of the 
28S rRNA.  
During the large ribosomal subunit maturation, 5S RNP undergoes a 180-degree 
rotation to adopt the final conformation in the mature ribosome, likely to trigger the 
continuation of the ribosomal protein maturation process (Nicolas et al., 2016). In this 
process, serine 140 in RPL11 is transiently phosphorylated to allow 5S RNP to adopt 
the conformational changes. After that this residue is dephosphorylated to allow the 
stable binding between RPL11 and the sugar-phosphate backbone of the 5S rRNA 
again.  
Finally, once the maturation of large ribosomal subunit completes, serine 29 
dephosphorylation is required to allow the export of the mature large ribosomal 
subunit to the cytoplasm.  
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4.3.6 Future work 
In this work I provided evidence suggesting that phosphorylation takes place at serine 
29 and 51 residues of RPL11. Furthermore, my work also implies that during LSU 
maturation, it is possible that a transient phosphorylation takes place at the serine 140 
residue. However, further investigations are required to confirm these conclusions.  
Preliminary data from the Watkins lab showed that, using Phos-tag™ SDS-PAGE, stably 
phosphorylated RPL11 was not detected in whole cell lysates of U2OS cells (Justine 
Lee, personal communication). This suggests that the reported phosphorylation of 
RPL11 found by Mass-spectrometry-based phosphoproteomic analysis could be a 
  
Figure 4.14. Proposed model of the phosphorylation events in RPL11 during 
different stages of large ribosomal subunit biogenesis. 
The phosphorylation event is indicated using Ⓟ. The dephosphorylation event is 
indicated as Ⓟ.  
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transient phosphorylation event. Therefore, kinase or phosphatase inhibitor 
compounds could be used prior to the future analysis to either block phosphorylation 
or stabilise the phosphorylated residues in the cell. Alternatively, methods to more 
accurately separate and enrich free and ribosomal complexes may also be needed to 
be developed in order to differentiate the phosphorylation status in free or ribosomal 
5S RNP. After that, mass spectrometry could be used to identify the different 
phosphorylation status in pre-ribosomal complexes.  
In human cells, the process of 5S RNP integration into the LSU, including the 5S RNP 
remodelling event which was described in yeast, is still not fully understood. It is 
known that ribosome biogenesis factors BXDC1 and RRS1 are required for the 
assembly of the CP region in the LSU (Sloan et al., 2013a; Nicolas et al., 2016). 
Therefore, further investigations into how these reported phosphorylation steps are 
related to the different factors could yield insight into the 5S RNP integration and 
remodelling process in humans. To characterise this, the association and interaction 
between RPL11 phospho-mutant protein and BXDC1 or RRS1 could be tested by using 
immunoprecipitation or immunofluorescence in U2OS cell lines.  
In this work I also attempted to characterise how RPL11 mutant expression affects p53 
activation in U2OS cells and due to time constraints the results remained inconclusive 
(Section 4.2.11). It has been proposed that proteins involved in 5S RNP production, 
localisation and integration into the ribosome could be important in regulating p53, 
indirectly via 5S RNP (Sloan et al., 2013a). The results I presented in this work on RPL11 
serine 51 and 29 (Section 4.2.11), implied a potential involvement of these residues in 
5S RNP integration into the ribosome. Hence, further investigations are needed to 
establish how phosphorylation of RPL11 serine 51 and 29 tie into p53 regulation via 
the 5S RNP-MDM2 pathway. Since serine 51 is proposed to locate at the RPL11/MDM2 
binding interface, co-immunoprecipitation could be used to validate the association 
between MDM2 and the RPL11 S51 mutants. In addition, recent studies suggested that 
RPL11 and RPL5 couple nucleolar structural integrity and p53-dependent nucleolar 
stress (Nicolas et al., 2016). My results showed that the serine 29 mutant of RPL11 
affects nucleolar localisation of the protein (Figure 4.12), and its over-expression also 
causes increased cellular p53 levels (Figure 4.13). Together, these results are 
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compatible with a connection between serine 29 in RPL11 and p53 signalling, though 
more repetitions of experiments are required to be conclusive.  
Furthermore, it remains unclear that how much RPL11 mutant protein in U2OS cells is 
required to reach the threshold of significant p53 activation. Therefore, in future 
investigations, the concentration of tetracycline used to induce the expression of 
mutant protein in the U2OS cell lines should be reviewed. Alternatively, the potential 
of using CRISPR-Cas9 genome editing technique to create phospho-mutations in the 
RPL11 gene in the cells could also be explored in future investigations.  
Finally, other documented phosphorylated residues in RPL11, such as threonine 44 and 
47, should also be characterised for their involvement in ribosome biogenesis and p53 
signalling in future studies.  
The findings in this work have led to better understanding of the role of RPL11 
phosphorylation in ribosome biogenesis. This work also raised unanswered questions 
about the involvement of RPL11 phosphorylation in the 5S RNP-regulated p53 
signalling, which deserved attention in future investigations (Chapter 5).  
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Chapter 5. Final Discussion  
5.1 Final Discussion  
The 5S RNP is made up of three components, ribosomal protein RPL5, RPL11 and the 
5S rRNA. Structurally it is relatively simple compared to the rest of the ribosome. 
However its uniqueness does not only refer to being a core component of the 
ribosome, as it is required for a functional ribosome, but it is also able to regulate p53 
through interacting with MDM2.  
In this work, I aimed to investigate the role of 5S RNP in ribosome biogenesis and 5S 
RNP-mediated p53 signalling. This work first characterised protein factors suspected to 
be involved in the 5S RNP-mediated p53 signalling pathway. It demonstrated the 
important role of splicing factor SRSF1 in this pathway, while showing that protein 
factors HEXIM1, Mybbp1a and NML are not essential in p53 activation through the 5S 
RNP (Chapter 3). This work also provided experimental evidences suggesting the 
phosphorylation of serine and threonine residues of ribosomal protein RPL11, a 5S RNP 
component, could be involved in various stages of ribosome biogenesis such as the 5S 
RNP assembly and its integration into the ribosome as well as large ribosomal subunit 
maturation (Chapter 4). Results presented in this work provide valuable insights into 
the complex relationship between ribosome biogenesis and p53 signalling connected 
via the 5S RNP. This work hence points to future research directions to further the 
understanding of  the molecular basis of diseases like ribosomopathies and cancer.   
5.1.1 The 5S RNP assembly   
In humans the newly transcribed 5S rRNA is stabilised by binding to ribosomal proteins 
in the nucleoplasm, before recruiting RPL11 in the nucleolus forming the stable 5S 
RNP. The results presented in this work, as discussed in the previous chapter, may 
suggest that threonine 73 is important for RPL11 binding to the 5S rRNA during 5S RNP 
assembly (Section 4.3.1). It has been previously reported that in RPL11, mutation of 
the arginine 75 (R75Q), adjacent to threonine 73, inhibits the interaction between 
RPL11 and the 5S rRNA (Horn and Vousden, 2008). Indeed, structural analysis showed 
that both of residues in RPL11, arginine 75 and threonine 73, are located close to the 
nitrogenous bases of the 5S rRNA (Section 4.2.2). Taken together the data presented in 
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this work strongly suggest that residues in this region of RPL11 play crucial roles in 
stabilizing the 5S rRNA during 5S RNP assembly.  
Furthermore, it is believed that ribosomal proteins are produced in excess to 
accommodate the rapid process of biogenesis, and those ribosomal proteins unbound 
to pre-ribosomes are targeted for proteasome mediated degradation (Lam et al., 
2007). Moreover, the recruitment of RPL11 into the 5S RNP is a rate limiting step for 5S 
RNP integration into the ribosome (Sloan et al., 2013a). However it remains unclear 
which factors control the RPL11 availability that regulates 5S RNP synthesis. 
Phosphorylation of threonine 73 in RPL11 has been identified by high-resolution Mass-
spectrometry-based phosphoproteomic analysis (Mertins et al., 2016) and suggested 
to affect RPL11-5S rRNA interaction.  
Results in this work showed that expressing RPL11 protein mimicking the 
phosphorylated threonine 73 in human cells, prevents 5S RNP assembly, likely by 
blocking the 5S rRNA binding which results in RPL11 degradation (Section 4.3.1). 
Hence, evidence presented in this work may suggest that phosphorylation of threonine 
73could be an important signal controlling the turnover of RPL11 and regulating RPL11 
availability in 5S RNP assembly.  
Data presented in this work may also provide a better understanding of the role that 
splicing factor SRSF1 plays in 5S RNP assembly (Section 3.3.2). Previously in the 
Watkins Lab, SRSF1 was shown to interact with both RPL5 and the 5S rRNA in U2OS 
cells (Loren Gibson, unpublished data), which was consistent with the result 
demonstrated by Fregoso et al. (2013) in BJ-TT cells. Gibson’s work also showed that 
SRSF1 is important for regulating the cellular localisation of RPL5 and RPL11. Hence 
Loren Gibson proposed a chaperone role for SRSF1 facilitating the recruitment of 
RPL11 to the RPL5/5S rRNA subcomplex (unpublished data).  
This work demonstrated that recombinant SRSF1 interacts with RPL5 and RPL11 in 
vitro (Chapter 3). The binding between SRSF1 and RPL11 provided important evidence 
which is complementary to Gibson’s work. Furthermore, this work suggested that 
RPL11 exhibits a higher binding affinity to SRSF1 than RPL5. Since RPL11 is likely to be 
produced in excess and the molecules unbound to the 5S RNP are turned over by 
degradation, it is possible that SRSF1 binding to RPL11 may block the modification on 
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RPL11 targeting it for degradation (such as threonine 73 phosphorylation, see above). 
Hence the high binding affinity between SRSF1 and RPL11 may ensure RPL11 
availability during 5S RNP assembly. The data presented in this work not only support 
the proposed ‘chaperone model’ from Loren Gibson’s work, it also suggests a direct 
role that SRSF1 may play in recruiting RPL11 to the 5S RNP precursor.  
In summary, data presented in this work could explain how the 5S RNP assembly is 
tightly regulated by protein factors such as SRSF1 and/or phosphorylation of the 
ribosomal protein RPL11.  
5.1.2 The ribosome integration of 5S RNP and the large ribosomal subunit 
maturation  
After its assembly, the 5S RNP is recruited, as one single complex, into the central 
protuberance region of the large ribosomal subunit. Structural analysis showed that 
RPL11 is located closely to the 28S rRNA in the mature large ribosomal subunit. 
Furthermore, the 5S RNP is an essential component for producing a mature ribosome, 
and its recruitment is thought to take place during the later stages of large subunit 
maturation. This work also aimed to establish how phosphorylation of RPL11 residues 
is related to ribosome biogenesis. Although multiple phosphorylated residues in RPL11 
had been identified in proteomic studies (Section 4.2.1), it remains unclear whether 
these modifications are important in the 5S RNP integration into the large ribosomal 
subunit.  
The data presented in this work may suggest that phosphorylation of serine 51 of 
RPL11 blocks the 5S RNP integration into the large ribosomal subunit, possibly by 
blocking the binding between RPL11 and the 28S rRNA located within the large 
ribosomal subunit precursor (Section 4.3.2). Indeed, previously the Watkins Lab 
showed that the helix 83-85 of the 28S rRNA interacts with RPL11 in vitro (Gibson, 
unpublished data). Taken together, this work showed the importance of RPL11/28S 
rRNA interaction in 5S RNP integration into the large ribosomal subunit. Moreover, 
since the 28S rRNA binding site and the interface that interacts with MDM2 are co-
localised in RPL11 (Zheng et al., 2015), the finding in this work could also be exploited 
in developing new therapeutic strategies for the treatment of ribosomopathies in the 
future (see below). The data presented in this work further showed that 
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phosphorylating serine 29 of RPL11 favours the 5S RNP integration into the large 
ribosomal subunit. Interestingly, results also showed that dephosphorylation of this 
residue could be required for large subunit maturation (Section 4.3.4), suggesting that 
this residue is transiently phosphorylated during large subunit maturation.  
The findings discussed above were related to the human ribosome structure 
demonstrating that serine 29 of RPL11 does contact neither the 5S rRNA nor 28S rRNAs 
(Section 4.2.2). This suggested that phosphorylation of this residue may not provide a 
binding surface for the protein-rRNA association. It is, in turn, more likely that serine 
29 phosphorylation provides a binding surface for other ribosome biogenesis factors 
during large ribosomal subunit maturation.  
Moreover, data presented in this work may also suggest a transient phosphorylation of 
serine 140 in RPL11 (Section 4.3.3), as phosphorylating the residue is required for large 
subunit maturation. In support of this hypothesis, the structural analysis predicted that 
a phosphate group could abolish the binding between RPL11 and the 5S rRNA.  
As mentioned in the introduction chapter, the current understanding of the 5S RNP 
recruitment into the large ribosomal subunit is primarily based on studies in yeast, 
while in humans this process is not yet fully understood (Section 1.2.6). In yeast, the CP 
region of the large subunit undergoes a conformational change in which the 5S RNP 
rotates 180 degrees during the final stages of large ribosomal subunit maturation. In 
contrast, there is still little known about the 5S RNP remodelling event in humans and 
whether phosphorylation of RPL11 is involved in this process. The data presented in 
this work could mean that during the 5S RNP remodelling event, the transiently 
phosphorylated residues in RPL11 provide binding interfaces which are needed by 
specific ribosome biogenesis factors during the complicated process of large subunit 
maturation. However, future investigations are needed to elucidate the relationship 
between RPL11 phosphorylation and the 5S RNP remodelling in humans. In summary, 
data presented in this work may reveal a highly sophisticated network of 
phosphorylation events in RPL11 which regulate large ribosomal maturation. 
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5.1.3 The 5S RNP-p53 pathway  
When ribosome biogenesis is blocked, non-ribosomal 5S RNP accumulates in the 
nucleoplasm where it binds to MDM2. In human cells, MDM2 is responsible for 
maintaining p53 at low levels by ubiquitinating it for protease degradation. 5S RNP 
binding to MDM2 inhibits its function thus resulting in p53 stabilization and increased 
expression of the p53-regulated genes.  
Previously Fregoso et al. (2013) showed that the splicing factor SRSF1 is needed for 
p53 activation by RPL5 and the study suggested that SRSF1, RPL5 and MDM2 function 
as a complex to stabilise and activate p53. Accordingly, it was demonstrated that all 
three 5S RNP components are required for ribosomal stress-induced p53 activation 
(Donati et al., 2013; Sloan et al., 2013a). Recently, Loren Gibson from the Watkins Lab 
attempted to elucidate if SRSF1 and 5S RNP function as a single complex. Gibson’s 
work demonstrated that SRSF1 binds to the 5S rRNA and its depletion causes abnormal 
nuclear re-localization of RPL5 and RPL11 in human cells, suggesting that SRSF1 indeed 
plays an essential role in the 5S RNP-p53 pathway (unpublished data). However it 
remains unclear whether SRSF1 directly regulates p53 via the 5S RNP. SRSF1 is known 
to be a highly phosphorylated protein and protein phosphorylation directly controls 
protein functions. Hence in this work, the splicing inhibitor compound SPRIN430 
specifically targeting SRPK, a kinase phosphorylating the RS domain in SRSF1, was 
utilised to investigate if SRSF1 function is required for p53 activation.  
The data presented in this work demonstrated that the Actinomycin D-induced p53 
activation reduces by SPRIN430 at a dose dependent manner (Section 3.2.10), 
suggesting that SRSF1 phosphorylation is indeed required for p53 activation in 
response to ribosomal stress. Furthermore, results from this work also showed that 
SRSF1 reduces p53 levels (Section 3.2.11) suggesting that SRSF1 phosphorylation is 
required for stabilising p53. Previous studies also showed that in SRSF1, SRPK-
mediated RS domain phosphorylation is important for the nuclear localisation of the 
protein (Lai et al., 2001; Cazalla et al., 2002; Ghosh and Adams, 2011). Therefore data 
presented in this work may imply that the nuclear localisation of SRSF1, as a result of 
the RS domain phosphorylation, is crucial in 5S RNP-p53 signalling. This may also 
suggest that the physical interaction between SRSF1 and the 5S RNP in the nucleus is 
required for stabilising p53 in response to ribosomal stress. However it requires further 
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investigation, such as immunofluorescence, to elucidate how nuclear SRSF1 level 
reduction correlates to RPL5 and RPL11 localisation when cells are treated with 
SPRIN430.  
Besides investigating protein factors such as SRSF1, this work also aimed to investigate 
how RPL11 phosphorylation is involved in the 5S RNP-p53 signalling (Chapter 4). 
Phosphorylation is one of many post translational modifications found in proteins, and 
it is widely regarded that phosphorylation controls protein functions and signalling 
pathways. As demonstrated previously (Chapter 4), several phosphorylated residues 
(serine 51, threonine 73 and serine 140) in RPL11 were found located at the RPL11-
MDM2 binding surface through structural analysis. Hence it was predicted that RPL11 
phosphorylation is involved in the 5S RNP-p53 signalling by affecting its interaction 
with MDM2.  
Result presented in this work demonstrated that a mutation mimicking 
phosphorylated RPL11 at its serine 140 residue results in a significant approximately 
twofold increase in p53 levels in U2OS cells (Section 4.2.11). However, despite the 
observed difference being statistical significant, arguably other factors than RPL11 
S140 phosphorylation must contribute to the tenfold p53 induction in response to 
Actinomycin D treatment. Therefore, future investigations are required to understand 
how RPL11 phosphorylation ties to p53 levels, for example, titrating the RPL11 mutant 
expression level in cells to account for dosage effects.  
This work also characterised protein factors HEXIM1, Mybbp1a and NML, which were 
predicted to be involved in the 5S RNP-p53 pathway based on previous publications 
(Chapter 3). However results presented in this work showed that in this experimental 
context they are not required for the Actinomycin D-induced p53 activation via the 5S 
RNP, as discussed in Chapter 3 (Section 3.3.1).  
5.2 Future Directions and Preliminary Data 
5.2.1 Future Directions 
In summary, findings presented in this work highlight the complex nature of different 
components, such as protein factors (SRSF1) and RPL11 phosphorylation, in regulating 
ribosome biogenesis and the 5S RNP-p53 pathway. Moreover, this work also points to 
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future research directions that could be explored to find new therapeutic strategies 
treating diseases like ribosomopathies and cancer.  
Ribosomopathies are a group of diseases caused by genetic mutations in ribosomal 
proteins and/or ribosome biogenesis factors. For most of these diseases the patients 
have an increased risk of developing cancers such as Myelodysplastic syndromes and 
acute myeloid leukaemia (Section 1.4, Chapter 1). Furthermore, there are a few better 
studied ribosomopathies, such as Diamond Blackfan Anemia, Treacher Collins 
syndrome and 5q-syndrome, which show elevated p53 levels (Table 1.1). Especially for 
Diamond Blackfan Anemia, the essential role of 5S RNP in regulating p53 levels has 
been documented (Jaako et al., 2015). Moreover, the 5S RNP links ribosomal 
biogenesis and nucleolar stress to p53 regulation (Sloan et al., 2013a). This work 
investigated roles that 5S RNP play in ribosome biogenesis and p53 regulation. Since 
ribosome biogenesis and p53 signalling are tied to each other, future research in both 
aspects are equally important.  
Results from this work suggested that phosphorylating threonine 73 of RPL11 may 
control the turnover of the protein. Although kinases regulating this modification are 
not yet identified, they could be therapeutic targets to deplete the RPL11 availability in 
the cell. This strategy could be exploited to reduce free 5S RNP levels since 5S RNP 
assembly requires recruiting RPL11. This tactics may also be used in combination with 
anticancer treatments, since ribosome production is a common target for anticancer 
drugs.  
Data presented in this work may also suggest that phosphorylating serine 29 of RPL11 
favours the 5S RNP integration into the large ribosomal subunit. If kinases and 
phosphatases modifying this residue were identified in the future, new therapeutic 
strategies could be developed deliberately driving 5S RNP integration into ribosomes. 
This could, in theory, restore functional ribosomes and lower the non-ribosomal 5S 
RNP levels in terms of treatments for ribosomopathies. In order to identify kinases that 
are responsible for phosphorylating RPL11, in the future, selective kinase inhibitors 
could be applied to human cells and their effects on ribosome biogenesis could be 
used to evaluate their involvement in modifying the protein (Section 5.2.2).  
 133 
The most interesting evidence highlighted in this work, by comparing recently 
published structures, is that the MDM2 binding interface in RPL11 co-localises with the 
region associating with the 28S rRNA in the ribosome (Figure. 4.2.). It provides 
structural evidence of 5S RNP coupling ribosome biogenesis to the p53 signalling 
regulation. This work started with proposing that phosphorylation of residues at this 
binding surface in RPL11 is important to both ribosome biogenesis and regulation of 
p53 signalling. Data presented in this work indeed suggested that phosphorylating 
serine 51 of RPL11 blocks 5S RNP integration into the ribosome (Section 4.3.2). 
However further investigations are needed to elucidate the role of RPL11 
phosphorylation in RPL11-MDM2 binding, such as utilising kinase and phosphatase 
inhibitors in the future studies (Section 5.2.2).  
Research in this direction could potentially be beneficial in developing new therapeutic 
strategies not only for ribosomopathies, but also cancer treatment in the future. As an 
example, by exploiting the ability of RPL11 to bind to 28S rRNA, short rRNA oligos 
mimicking the sequence of 28S rRNA could potentially be introduced to cancer cells. In 
theory these oligos could block the 5S RNP-MDM2 interaction to restore the MDM2 
role in negatively regulating p53 levels in cells. As mentioned, previously Loren Gibson 
from the Watkins Lab demonstrated that a short helix from the 28S rRNA is able to 
bind to RPL11 in vitro. Therefore, it would be interesting to investigate further to find 
out whether this helix is stable in human cells and if its association to RPL11 inhibits 
the RPL11-MDM2 association.  
5.2.2 Identify kinase phosphorylating RPL5 (Preliminary data)  
During the cause of this PhD project, I also attempted to identify kinase that are 
involved in RPL5 phosphorylation, however due to time constraints only preliminary 
data was obtained. Previously Loren Gibson from the Watkins Lab demonstrated that 
mimicking the phosphorylation at tyrosine 30 of RPL5 stabilises and activates p53, 
likely by inhibiting the 5S RNP integration into the ribosome (data unpublished).  
It was observed that in U2OS cells, from my preliminary results, when expressing 
phosphorylated mimics of RPL5 at tyrosine 30, the p21 gene expression were 
upregulated detected using RT-qPCR. This observation was expected and consistent 
with Loren Gibson’s previous finding.  
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Furthermore, the approach of utilising kinase inhibitor in human tissue cultures was 
also used to identify kinases involved in the 5S RNP-p53 signalling regulation. One 
collaborator of the Watkins Lab, using kinase inhibitor screening, highlighted several 
kinase inhibitor candidates which were associated with p53 regulation. The effects of 
these candidates on the 5S RNP-mediated p53 activation were subsequently 
characterised using human cells. Due to confidential terms from the collaborator, 
name and result details of these tested kinase inhibitors will be remained undisclosed 
in this work. Preliminary data demonstrated that four kinase inhibitors have inhibiting 
effects on ribosomal stress-induced p53 activation in a dose dependent manner. 
Furthermore, preliminary data also showed that three of them inhibit p53 activation 
specifically through 5S RNP.  
These preliminary results may suggest that phosphorylation of RPL5 is important for 
the 5S RNP-mediated p53 regulation. However, further studies are needed to generate 
conclusive data and to confirm this hypothesis. As an example, RT-qPCR could also be 
further in use to gain data of more p53-regulated genes, other than p21, to further 
confirm how mimicking RPL5 phosphorylation affects p53 activity.  
On the other hand, more works are needed to association between kinase inhibitor 
and RPL5 phosphorylation. Previously Loren Gibson demonstrated that three stable 
forms of phosphorylated RPL5 are separated and detected from U2OS cells using the 
PhosTag™ SDS-PAGE (data unpublished). Hence future investigation could focus on 
whether kinase inhibitors treatment changes the RPL5 phosphorylation status by 
analysing the protein band intensity detected by the PhosTag™ SDS-PAGE. This could 
potentially further narrow down the kinase responsible for phosphorylating RPL5.  
Finally, because the 5S RNP contains RPL5 and RPL11, and they are both needed in p53 
regulation, same strategy could also be used to identify kinase phosphorylating RPL11. 
To tackle this, kinase inhibitors could be applied to human cells and their involvement 
in phosphorylating RPL11 / RPL5 could be analysed by on 5S RNP assembly and the 5S 
RNP integration into ribosome.  
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5.3 Conclusions  
This PhD thesis has investigated the important role of the 5S RNP in both ribosome 
biogenesis and the 5S RNP-mediated p53 signalling. It has investigated factors involved 
in 5S RNP assembly, the 5S RNP-p53 signalling and the ribosomal large subunit 
maturation. In relation to the 5S RNP assembly, this work has demonstrated that 
RPL11 T73 phosphorylation could be involved in recruiting RPL11 to the 5S RNP. It also 
extended evidence suggesting SRSF1 acts as a chaperone during the 5S RNP assembly.  
In relation to 5S RNP-mediated p53 signalling, this thesis demonstrated that SRSF1 is a 
potential regulator for 5S RNP-p53 signalling, while HEXIM1, Mybbp1a and NML are 
not required in this pathway, illustrating the complex nature of regulating the 5S RNP-
p53 signalling pathway. Furthermore, this work also provides evidence suggesting 
RPL11 phosphorylation is involved in large ribosomal subunit biogenesis. Finally, 
further investigations will be needed to gain a more comprehensive understanding of 
how protein phosphorylation and protein co-factors contribute to ribosome biogenesis 
and the regulation of 5S RNP-p53 signalling. Future research may also yield valuable 
insights in developing new therapeutic strategies treating ribosomopathies and other 
diseases.  
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